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I. Summary 
Studies have shown that T cells can serve as carriers to deliver cytotoxic drugs to tumors. How-
ever, these drugs also impair physiological T cell functions. 
The subject of this thesis was to identify therapeutics for T cell-mediated drug delivery, which do 
not affect natural cytotoxicity and viability after uptake in order to synergize the tumoricidal 
properties of T cells with the drug effect. By redirecting drug-loaded human T cells to cancer 
cells via bispecific antibodies, the feasibility of this approach was tested. 
Assuming that encapsulation of cytotoxic drugs would protect carrier cells, various polyester na-
noparticles, containing the chemotherapeutic idarubicin (IDA-NPs), were examined. Moreover, 
differently glycosylated polylysine derivatives were tested as a potential drug encapsulation ma-
terial. Photosensitizers (PS) exhibit cytotoxicity only upon light irradiation. Hence, the suitability 
of the PS 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin (mTHPP) as payload was studied. 
Polylysine derivatives were non-toxic and interacted to different extent with T cells. IDA-NPs 
failed to preserve the viability of carrier cells. In contrast, mTHPP was delivered to target cells 
and did not impair carrier cell functions when kept in the dark. Upon illumination, retargeted 
mTHPP-loaded T cells were more efficient in killing cancer cells than unloaded cells. Hence, the 
use of light-sensitive drugs provides new perspectives for cell-mediated drug delivery. 
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II. Zusammenfassung 
Studien haben gezeigt, daß T-Zellen (TZ) als Träger von Zytostatika (ZS) dienen können, um 
diese zu Tumoren zu transportieren. Dadurch werden jedoch auch physiologische TZ-Funktionen 
beeinträchtigt. 
Ziel dieser Arbeit war es, Therapeutika für die TZ-vermittelte Medikamentenabgabe zu finden, 
die diese Funktionen nicht beeinträchtigen, um die tumoriziden Eigenschaften von TZ mit der 
Wirkung der ZS synergistisch kombinieren zu können. Indem mit ZS beladene humane TZ mit-
tels bispezifischer Antikörper zu Krebszellen dirigiert wurden, wurde die Machbarkeit des Kon-
zepts überprüft. 
Unter der Annahme, daß eine Verkapselung von ZS die Trägerzellen schützt, wurden verschiede-
ne Polyester-Nanopartikel, die alle das ZS Idarubicin enthielten (IDA-NP), untersucht. Ferner 
wurde evaluiert, ob glykosylierte Polylysinderivate (PD) als Verkapselungsmaterial geeignet sein 
könnten. Photosensibilisatoren (PS) sind nur zytotoxisch, wenn sie mit Licht bestrahlt werden. 
Daher wurde überprüft, ob der PS mTHPP als Medikamentenfracht geeignet ist. 
PD waren nicht toxisch und interagierten unterschiedlich spezifisch mit TZ. IDA-NP reduzierten 
die TZ-Vitalität signifikant. Im Gegensatz dazu wurde mTHPP an Zielzellen abgegeben. Unter 
Lichtausschluß beeinträchtigte es zudem nicht die Funktionen von TZ. Nach der Bestrahlung 
konnten beladene TZ Krebszellen effizienter abtöten als nicht beladene TZ. Somit eröffnet die 
Verwendung von lichtaktivierbaren ZS neue Perspektiven für die zell-vermittelte Arzneimittelab-
gabe. 
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1. Introduction 
 
1.1 Envisioned T cell-mediated drug delivery concept for cancer therapy 
The motivation of the presented thesis was to explore the feasibility of using living human 
T lymphocytes (see section 1.3) as vehicles to deliver cytotoxic drugs (section 1.4) to tumor cells. 
The purpose of this targeted delivery concept is to improve the selectivity and efficacy of cancer 
treatment and to reduce adverse effects normally provoked by systemically applied chemothera-
peutics. The natural cytotoxicity of tumor-specific effector T lymphocytes has been exploited in 
adoptive cell transfer (ACT) to treat neoplasms. Clinical studies have demonstrated the curative 
potential of ACT [1]. However, durable complete responses are often limited to a fraction of pa-
tients [2]. Therefore, the T cell-based drug delivery approach aims to combine the cytotoxicity of 
cell-delivered pharmaceuticals with the cell-mediated cytotoxicity to improve the curative poten-
tial of ACT. 
The first step of the envisioned therapy concept is the isolation of polyclonal peripheral blood 
T lymphocytes of patients. Here, polyclonal means that each cell possess a different target anti-
gen specificity. Most of these lymphocytes are “dormant”, because they have not yet encountered 
their particular antigen (naïve cells) or are antigen-experienced but inactive memory cells [3]. Na-
ïve and memory T cells exhibit no immediate effector function such as cytotoxicity. Therefore, 
the next step is ex vivo activation of T lymphocytes. Consequently, T cells proliferate, expand 
and acquire effector functions (see section 1.3). Due to expansion, a sufficient number of carriers 
for treatment is gained [4]. Furthermore, the cell size within the non-activated population of 
T lymphocytes is smaller than that within the population of activated T cells (see chapter 2, Fig-
ure S2.1). Hence, it is likely that activated T lymphocytes have a greater capacity for drug uptake. 
In order to investigate the proposed immunotherapy approach, T cells isolated from blood of 
healthy donors and targets of defined cancer cell lines were used in the presented work. In con-
trast to naturally activated and clonally expanded T lymphocytes, in vitro stimulated polyclonal 
T cells are not specific for particular tumor cells. An option to recruit unspecific T lymphocytes 
to cancers cells is the use of bispecific antibodies (bsAbs) [5]. It should be pointed out that Man-
druzzato et al. already suggested the use of bsAbs in the context of cell-mediated drug delivery 
[6]. However, the group never published any related results. 
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Bispecific antibodies (bsAb) are engineered molecules, which in contrast to normal antibodies 
(monospecific but bivalent) possess dual specificity for two different antigens (bispecific but 
monovalent). One antigen-binding site of bsAb recognizes a surface marker, such as a tumor-
associated antigen (TAA), on the target cell. In T lymphocyte-based therapies, the other moiety 
binds specifically to a component of CD3, a signaling complex associated to T cells receptors 
(TCRs) located on the plasma membrane. Normally, effector functions of activated 
T lymphocytes are initiated after TCRs recognize their antigen-ligands presented by major histo-
compatibility complex (MHC) molecules expressed on the surface of target cells [3]. However, 
bsAbs induce the cytolytic activity of T lymphocytes in a non-MHC-restricted manner [7]. There-
fore, by bypassing TCRs using bsAbs, polyclonal T cells become specific just for one TAA. The-
oretically, all CD3-positive subsets of T cells (see section 1.3) present in the peripheral blood of 
cancer patients can be exploited as carrier cells. The bsAb HEA125×OKT3 used in the presented 
work (kindly provided by Gerhard Moldenhauer, Department of Translational Immunology, 
German Cancer Research Center, Heidelberg, Germany), redirects T lymphocytes to EpCAM 
(Epithelial Cell Adhesion Molecule, CD326) over-expressing epithelial tumor cells derived from 
human carcinomas (Figure 1.1). The therapeutic potential of HEA125×OKT3 was already 
demonstrated in cell culture and animal experiments as well as in a clinical trial involving ovarian 
carcinoma patients [8-10]. 
 
 
 
 
 
 
 
 
 
 
After activation and expansion, T cells are loaded with an anticancer drug-formulation transform-
ing them into drug carriers aptly termed as “pharmacytes” by Huang and colleagues [11]. Before 
commencing the cancer treatment, residual free drug is removed. Then, loaded T cells are mixed 
with bispecific antibodies. Upon arriving at cancer sites, bsAbs bind T lymphocytes to target cells 
Figure 1.1. Schematic of the bispecific anti-
body HEA125×OKT3. Cells of the murine
hybridoma cell lines OKT3, specific for human
CD3, and HEA125, specific for human CD326
(EpCAM), were fused using the hybrid-
hybridoma technique [10]. While OKT3 cells
express type G2a immunoglubolins (IgG2a),
HEA125 cells produce IgG1 molecules. 
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and trigger effector functions (T cell effect). At the same time, carrier cells release the drug, ide-
ally in a continuous manner at the tumor site [12]. Here, the payload can exert its cytotoxic func-
tion (drug effect). The process is schematically illustrated in Figure 1.2. 
 
 
 
Fig. 1.2. Illustration of the envisioned T cell-mediated drug delivery concept (see text). In this thesis, the approach 
was pursued until step 4. Then pharmacytes and bsAb were applied to cancer target cells cultivated in vitro. In the 
center, the proposed mode of action is shown: ① T lymphocytes are cross-linked through bsAbs to cancer cells. ② 
After reactivation T cells exert effector functions. In addition, while bound to cancer cells the therapeutic is trans-
ferred by pharmacytes. ③ T cells with cytotoxic effector function (CTLs) will kill target cells by inducing apoptosis, 
while T cells with helper function (Ths) can also serve as carrier cells. All drawings except the center and the bsAb 
schema were kindly provided by Alice Borth. 
 
It was proposed that ideal carrier cells should meet the following requirements: 1) Access to pa-
tients’ cell population should be simple and preferably non-invasive. 2) Sufficient amounts of 
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cells should be easily generated by ex vivo expansion and the respective procedure should not be 
deleterious for cell properties. 3) Re-implantation of modified cells should be effortlessness. 4) 
Cells should possess tropism for (diseased) sites of interest [13]. T lymphocytes meet those re-
quirements, because they can easily be isolated from peripheral blood of patients. Moreover, 
commercial available T cell expansion kits facilitate the generation of large cell numbers. Possi-
ble minor reduction of cell viability at the beginning of expansion phase is manageable by remov-
ing dead cells from the culture. Reinfusion of manipulated T lymphocytes into patients’ blood 
stream poses no obstacle. Furthermore, T cells are recruited to and infiltrate solid tumors [14], 
which is also reflected by the fact that tumors can evolve multiple strategies to evade 
T lymphocyte-mediated immune responses [15]. 
Usually, the immune system is able to specifically recognize and destroy cancer cells [16]. This 
process is termed “immune surveillance” and was first suggested in the 1950s by Sir Frank 
MacFarlane Burnet and Lewis Thomas [3, 17]. As already indicated, in tumor-bearing patients this 
surveillance has failed and natural host defenses are curbed, because cancers have developed 
immune evasion strategies (reviewed in [18, 19]). Nevertheless, the main natural process for detec-
tion and eradication of cancers remains the cellular mediated immunity [13]. Consequently, adop-
tive cell therapies have emerged, in which patient-derived immune cells such as T lymphocytes [1] 
or natural killer (NK) cells [20] are isolated, manipulated to (re)-gain anticancer functions and 
transferred back into hosts. As compared to NK cells, T lymphocytes exhibit a greater capacity 
for proliferation, survival, and elimination of large neoplastic masses [20]. Accordingly, T cells 
have been a major focus of research. Using these lymphocytes in ACT has been proven to be 
effective in clinical trials involving hematological malignancies [21, 22], metastatic melanoma [2] 
and other types of neoplastic diseases [23]. In these trials, tumor-reactive autologous (the donor is 
also the recipient) tumor-infiltrating lymphocytes (TILs) or patient-derived genetically engi-
neered T cells were used for ACT. Transduced T lymphocytes have been redirected towards tu-
mor-associated antigens through genetic modification with T cell receptor or chimeric antigen 
receptor (CAR) genes [24]. As mentioned before, the utilization of bispecific antibodies is another 
option to target T lymphocytes to sites of malignancies. In addition to fulfilling the aforemen-
tioned requirements, the curative potential of T cells in ACT is another reason for choosing them 
as cellular drug vehicle in this thesis. Several studies have also attempted to use this type of cells 
as drug vehicle (see section 1.2.1). However, cell-mediated drug delivery is not restricted to 
T lymphocytes as described in the subsequent section. 
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1.2 Cell-mediated drug delivery 
In recent years, drug delivery systems (DDS) have been comprehensively investigated as an op-
tion to enhance the therapeutic efficacy of drugs by improving pharmacokinetics (drug absorp-
tion, distribution, metabolism, and excretion (ADME)) and pharmacodynamics (drug efficacy 
and toxicity). Extensive research efforts have been made to design carriers for therapeutics with 
improved drug solubility, prolonged circulating time, limited biodistribution, specific targeting, 
controlled drug release, and reduced toxicity and immunogenicity [25]. A plethora of drug delivery 
devices such as antibodies [26], fibers [27], films [28], hydrogels [29], liposomes [30], nanoparticles [31, 
32], micelles [33], polymers [34, 35], and several modifications thereof have been studied. However, 
only few DDS such as liposomal formulations of the anticancer drugs doxorubicin (Caelyx®, 
Doxil®, and Myocet®), daunorubicin (DaunoXome®) and vincristine (Marqibo®), an albumin 
conjugated nanoparticle formulation of the antineoplastic drug paclitaxel (Abraxane®), and anti-
body-drug conjugates for cancer treatment (Kadcyla® and Adcetris®) have reached the market [36-
38]. The major problems of most drug delivery systems are low clinical efficacy due to rapid 
clearance from patients’ blood stream by phagocytic cells of the reticuloendothelial system (RES) 
[39] and still insufficient targeting to the diseased site. For instance, over 95% of the systematical-
ly administered dose of a nanoparticulate system accumulates not at the target site but in the liver, 
lungs, spleen and kidneys [40]. As reported in several review articles, cell-mediated drug delivery 
has emerged to overcome these obstacles and to serve as an alternative for the treatment of severe 
diseases such as cancer, infectious diseases, and inflammatory and neurological disorders [12, 13, 25, 
37, 41-43]. 
In contrast to the relatively simple structural organization of vehicles for drugs, cells are complex 
biological systems, which can exhibit unique natural properties such as the ability to actively 
home to pathological sites, a quality even “active targeted” DDS do not possess [40]. In addition, 
homing includes crossing barriers such as the blood-brain or blood-tumor barrier. Furthermore, 
autologous cells are generally not immunogenic and some immune cells show natural killing or 
phagocytic functions, which can additionally be exploited to fight diseases like cancer. By conju-
gating drugs with cells, thereby transforming them into “Trojan Horses”, therapeutics are protect-
ed from the hepatic metabolism and the RES, which prolongs the drug half-life. Local drug deliv-
ery, slowed drug release, and decreased drug toxicity are further advantages of a cell-based ap-
proach. Therefore, pharmacytes are considered as a novel class of therapeutics and drug carriers 
[12, 25, 37, 41, 42]. 
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In principle, three options are available to “upgrade” carrier cells with therapeutics: conjugations 
of therapeutics to carriers via membrane surface engineering, loading of therapeutics into cells, 
and transfection of carrier cells with nucleic acids, the translated products of which have thera-
peutic properties. Chemical processes such as covalent conjugation, biotinylation, and click 
chemistry (e.g. azide-alkyne Huisgen cycloaddition [44]) are possible options to bind therapeutics 
to cell membranes. Hypotonic hemolysis (of erythrocytes) and electroporation are physical meth-
ods, which facilitate uptake of therapeutics by cells. In addition, adsorption via electrostatic or 
hydrophobic interactions is used to attach therapeutics to cell membranes. Biological pathways 
such as endocytosis and ligand-receptor interactions can mediate cellular uptake and binding of 
therapeutics. Furthermore, gene modification enables carrier cells to express therapeutic proteins 
(Fig. 1.3) [25, 41]. 
 
Fig. 1.3. Approaches used in cell-mediated drug delivery for encapsulation/conjugation of therapeutics into/to carrier 
cells. Adapted with permission from [25]. Copyright 2015 American Chemical Society. 
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So far, the cell-mediated drug delivery concept has been evaluated in the context of cancer, infec-
tious diseases, and inflammatory and neurological disorders. Subsequent studies have demon-
strated positive therapeutic effects by using cellular drug vehicles such as erythrocytes [45-54], fi-
broblasts [55, 56], encapsulated or inactivated cancer cells [57-59], mesenchymal [60-62] and neural [63-
68] progenitor/stem cells, myoblasts [69], Sertoli cells [70] and leukocytes such as dendritic cells [71], 
monocytes/macrophages [72-79], lymphocytes [80], lymphokine-activated killer (LAK) cells [6, 81, 82], 
NK cells [83], and T lymphocytes [11, 84-91]. Members of following therapeutic classes were used as 
payloads for the aforementioned cellular carriers: derivatives of alkaloids [11], anthracyclines [6, 46, 
57, 58, 74, 76, 81, 83], antimetabolites [45, 47, 72], antimicrobials [48, 51, 79], cytokines [90], enzymes [52-54, 77], 
immunomodulators [91], immunosuppressors [49, 50, 70, 71], nanoparticulate gold [75] and iron/iron 
oxide [73], photosensitizers [47], plant toxins [82, 84], radioactive isotopes [80], and viruses [62, 68, 89]. 
Expressed therapeutic proteins have included angiogenic growth factors [56, 67], antibodies [59], 
cytokines [60, 61], enzymes [55, 65, 78], immunotoxins [85-88], and neurotrophic factors [63, 64, 66, 69]. 
The use of vectors to produce gene-modified carrier cells raises safety concerns. The integration 
of newly introduced DNA into the genome could transform genetically engineered cells into ab-
errant cells, because of dysregulation of proto-oncogenes. This could give rise to new malignan-
cies [24]. In addition, therapeutic-producing cells could be hazardous if they remain active in the 
patient after the cure of the disease [92]. Moreover, clinical gene therapy implicates considerable 
regulatory and cost barriers [90]. Therefore, a non-genetic engineering approach using endocytic 
pathways of T lymphocytes was preferred and pursued in this thesis.  
 
1.2.1 T lymphocyte-mediated drug delivery for cancer treatment 
The National Cancer Institute at the National Institutes of Health (USA) lists more than 100 dif-
ferent types of cancer [93], which illustrates the complexity of neoplastic diseases. However, 
Hanahan and Weinberg proposed a number of following hallmarks [94], which define an organiz-
ing principle underlying the multistep development of malignant tumors. According to the somat-
ic mutation theory (SMT), cancer is initiated by DNA mutations caused by inherited predisposi-
tion, genotoxic carcinogens or spontaneous mutations occurring during stem cell divisions [95]. By 
accumulating of these mutations, normal cells evolve and acquire traits that enable them to be-
come malignant. In normal tissues, proliferation of cells is strictly regulated by growth-promoting 
signals. Aberrant cells are able to deregulate these mitogenic signals and sustain proliferative 
signaling to multiply uncontrolled. In addition, abnormal cells have acquired the capability to 
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evade growth suppressors, which negatively regulate normal cell proliferation. Furthermore, 
those cells are able to resist cell death. Growing neoplastic tissue needs nutrients and oxygen. 
Moreover, metabolic waste and CO2 have to be removed. Therefore, during tumorigenesis, cells 
need to acquire the trait to induce angiogenesis for blood supply. The ability to invade into 
neighboring tissues and metastasize via lymphatics and blood stream to distant locations, distin-
guishes benign from malignant tumors. Hanahan and Weinberg have additionally proposed two 
emerging hallmarks. Apparently, to fuel uncontrolled cell growth and division, adjustments of 
energy metabolism are required. Therefore, a reprogrammed energy metabolism is another quali-
ty of cancer cells. As mentioned before, according to the immune surveillance theory [16], the 
immune system keeps neoplasms in check. However, permanent selection of cell variants re-
sistant to immune effectors (immunoediting) and an immune suppressive tumor-environment [18] 
gives rise to cells, which are able to evade immune destruction [94].  
Despite the many advances in surgery, chemo- and radiation therapy, cancer is still a leading 
cause of death. All types of malignant neoplasms combined (excluding non-melanoma skin can-
cer) were responsible for 8.2 million deaths worldwide in 2012 [96]. Therefore, other modalities of 
cancer treatment are the subject of intensive research. Feasibility studies of lymphocyte-based 
drug delivery were commenced 31 years ago. A paper published in 1984 reports that murine 
spleen cells, a mixture of cell types also containing T lymphocytes, could serve as donor cells in 
order to transfer the plant toxin ricin to murine recipient spleen cells in vitro [97]. Those transfer 
studies were conducted in the presence of phytohaemagglutinin (PHA), a polyclonal mitogen that 
only activates T cells [3, 98]. Although not stated, McIntosh et al. started to explore a potential can-
cer therapy modality, which was pursued in a subsequent biodistribution study [99]. Therein, the 
group clearly aimed at exploiting the ability of ricin-loaded lymphocytes to home to lymphatic 
tissues in order to target associated malignancies. To this end, Sparshott et al. used ricin-loaded 
thoracic duct lymphocytes (TDLs, including T cells) to deliver the toxin to the spleen, lymph 
nodes and Peyer’s patches of healthy rats. TLDs were also used to deposit a radioactive isotope 
of indium (In-114m) to spleen and lymph nodes of rats to fight tumors of lymphoid origin [80]. 
Repeated injections of In-114m loaded TDL delayed the lethal onset of lymphocytic leukemia. 
However, this treatment did not lead to permanent remission and after injections were stopped the 
rats died. Likewise, ricin-loaded Moloney-murine sarcoma virus specific T cells exerted a tempo-
rary therapeutic effect in tumor-bearing mice. However, the tumor started to proliferate again 
after 6 days. In order to prolong the period of tumor growth inhibition, the number of adoptively 
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transferred ricin-loaded cytotoxic T cells was increased. As consequence, the recipient animals 
died very quickly, because of ricin toxicity [84]. A second study reports that ricin-loaded lympho-
kine-activated killer cells were more successful in reducing lung metastases in mice than unload-
ed LAK cells [82]. The LAK cell phenomenon is mediated mainly by NK cells but also by T cells 
[100]. The selection of ricin as payload for carrier cells had several drawbacks. First, after adoptive 
transfer of ricin-loaded lymphocytes, cells became stuck in the tissues and were not able to re-
enter the blood stream in same way as normal recirculating lymphocytes. In addition, they also 
failed to migrate from blood to lymph. Second, the difference between therapeutic and toxic con-
centration of ricin was very narrow. Most importantly, as early as 3 hours after ricin loading the 
cytolytic activity of lymphocytes against target cells was seriously impaired [82, 84, 99]. Due to the 
high systemic toxicity, Mandruzzato et al. substituted ricin for an antineoplastic anthracycline [6]. 
The authors achieved a striking reduction of lung metastases in mice using adoptively transferred 
and 4’-deoxy-4’-iododoxorubicin (IDX) loaded LAK cells. However, cytotoxic activity of carrier 
cells was again gravely inhibited. Furthermore, since LAK cells had redistributed to liver and 
spleen considerable levels of IDX were found in these organs of the mice. Other investigators 
have also pursued similar strategies: Steinfeld and colleagues encapsulated the anticancer drug 
doxorubicin, reversible attached to nanoparticles, into human T cells to synergize chemotherapy 
and adoptive T cell immunotherapy [101]. Mortensen et al. aimed at delivering boron carbide na-
noparticles via loaded human T cells to render tumor tissue susceptible for boron neutron capture 
therapy [102]. Iida and colleagues proposed a magnetically mediated immunotherapy using human 
T cells loaded with magnetite (Fe3O4) nanoparticles [103]. Kennedy et al. tested whether human 
T lymphocytes are able to deliver gold nanoparticles into murine tumors for photothermal therapy 
[104]. However, none of these studies demonstrated any therapeutic effects in vitro as well as in 
vivo. 
In the aforementioned studies, therapeutics were loaded into carrier cells. Stephan and colleagues 
used a cell membrane-modification approach. By covalent coupling of cytokine or small-
molecule drug containing nanoparticles onto the plasma membrane surface, they provided a sus-
tained “pseudoautocrine” stimulation to carrier cells, which caused an increased T cell expansion, 
longevity and an enhanced tumor elimination after in vivo transfer. The authors were able to 
augment the therapeutic potential of T cells without impairing cell functions [90, 91]. However, the 
strategy applied by Stephan and colleagues differs from the one pursued in this thesis in that the 
payload is attached to the outside of carrier cells. Furthermore, in those studies non-cytotoxic 
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drugs were used, which acted on carrier cells and not directly on target cells. Recently, the group 
has substituted these non-toxic payloads for the cytotoxic topoisomerase I poison SN-38 [11], 
which is the active metabolite of the anticancer drug irinotecan (a semisynthetic analog of the 
alkaloid camptothecin). In this study by Huang et al., SN-38-loaded lipid nanocapsules were at-
tached to the surface of ex vivo expanded polyclonal T lymphocytes. Within a therapeutic win-
dow, T cells were resistant to SN-38 while lymphoma target cells were not. In contrast to control 
mice, animals treated with SN-38 nanocapsules bound to T cells showed a significant reduction 
of tumor burden. However, the intrinsic cytolytic activity of T cells was not exploited in this 
study, which is part of the approach pursued in this thesis. 
As already noted, most of the previously mentioned studies revealed major drawbacks of the cell-
based drug delivery strategy that probably hampered clinical trials until now. When carrier cells 
were loaded with toxic pharmaceuticals, a rapid loss of physiological functions and a decline of 
cell viability were observed. In the work presented here, formulations of two different types of 
polymer-encapsulated therapeutics were investigated to overcome the obstacle of cell function 
loss. The first approach pursued the idea of incorporation of an “active” drug, an anthracycline 
(see section 1.4.1), into nanoparticulate systems in order to protect the living vehicles (chapter 3). 
For the second approach, a “stimulus-sensitive” drug represented by a photosensitizer (see sec-
tion 1.4.2), the mode of action of which is only triggered by light irradiation (chapter 3 and 4), 
was used. The immunological and physiological functions of T cells meant to be preserved are 
summarized in the next section. 
 
 
1.3 T lymphocytes 
T lymphocytes (or T cells) play a central role in the acquired (adaptive) immune response against 
pathogens such as bacteria, fungi, parasites and viruses. In addition, T cells have the potential to 
kill abnormal cells. They belong to the group of white blood cells also known as leukocytes, 
which originate in the bone marrow, a central (primary) lymphoid organ. Leukocytes are further 
divided into two main categories, the lymphoid and myeloid lineages. B cells, natural killer cells 
and T cells arise from common lymphoid progenitor cells and are therefore classified as lympho-
cytes. In contrast to other lymphocytes, T cells mature in the thymus, the other primary lymphoid 
organ located in the upper chest. Here, each thymocyte (a precursor T lymphocyte) generates a 
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unique T cell receptor, a heterodimer consisting of an α and a β polypeptide chain, through the 
rearrangement of TCR genes. Afterwards, TCRs are positively selected for the affinity to self-
peptide:MHC complexes (major histocompatibility complex restriction). MHC molecules are 
glycoproteins that present peptide antigens on cell-surfaces. T cells that recognize antigenic self-
peptides too strongly are negatively selected and deleted by apoptosis. After maturation, three 
subsets of T lymphocytes can be distinguished: conventional αβ T cells that express either CD4 
or CD8 co-receptor molecules on the cell membrane surface and CD4+ T cells that also express 
high levels of CD25. The latter population represents a thymic subset of regulatory T cells (natu-
ral Tregs). Conventional T cells leave the thymus and recirculate between blood and peripheral 
(secondary) lymphoid tissues such as lymph nodes and the spleen searching for their specific 
antigen (Ag) of pathogenic origin. They are also termed “naïve”, as long as they have not en-
countered their cognate antigen. The repertoire of unique TCRs enable mature T cells to recog-
nize a very broad range of peptides derived from non-self antigens. Upon recognition of their 
specific non-self-peptide:MHC complexes presented by antigen-presenting cells (APCs) such as 
dendritic cells (DCs) located in peripheral lymphoid tissues, naïve T cells are activated (primed). 
DCs are “sentinels”, which traffic from the blood into tissues. Here, while in an immature state 
they take up Ags and process them to peptides. Pathogenic antigens captured in the context of an 
inflammatory reaction provoked by infections or cancers drive DCs to leave the tissues and mi-
grate to draining lymphoid organs. Here, they mature to APCs and start to express specialized 
membrane surface molecules that enable them to prime T lymphocytes [3]. While the TCRs of 
CD4+ T cells bind to peptide:MHC class II complexes present on DCs, TCRs of CD8+ T cells 
are stimulated by peptide:MHC class I complexes. TCR ligation represents the first signal needed 
to activate naïve T cells. Via further receptor-ligand interactions within the “immunological syn-
apse”, for instance between CD28 expressed by the T cell and CD80/CD86 located on the den-
dritic cell, the same DC delivers a second “co-stimulatory” signal. This signal induces the secre-
tion of the cytokine interleukin-2 (IL-2) by the activated T lymphocyte to ensure its own survival 
by autocrine stimulation. Following a defined combination of cytokines expressed by the antigen-
presenting cell, the activated T cells are polarized. The combination of cytokines is determined 
by the type of inflammation (viral, microbial etc.) and represents the third signal (Fig.1.4) [105-107]. 
Because of their destructive nature (see below), CD8+ T cells require a stronger co-stimulation 
than CD4+ T cells. Although this requirement can be met by sufficiently activated DCs, often 
CD4+ T cells provide additional help to fully activate CTLs [108]. 
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Fig. 1.4. Full activation of T lymphocytes requires three signals. The first signal needed for activation is the recogni-
tion of antigenic peptides (Ag) bound to MHC molecules by TCRs of a naïve T cell and presented by an APC. Inter-
actions of co-stimulatory ligand-receptor complexes generate the second signal. The third signal is provided by cyto-
kines secreted by the APC. This process polarizes T lymphocytes to specialized effector cells. Adapted with permis-
sion from [105]. Copyright 2015 American Society for Clinical Investigation. 
 
Polarization by APC derived cytokines leads to differentiation into different cell lineages, such as 
the Th1, Th2, and Th17 subsets of CD4+ helper (h) or follicular helper (fh) lymphocytes, as well 
as induced regulatory CD4+ T cells (iTregs), type 1 regulatory cells (Tr1), and Th3 cells. Less 
defined subsets are Th9 and Th22 cells [109]. All subsets exhibit specialized effector functions. For 
instance, Th1 cells induce macrophage activation and the production of complement-fixing and 
opsonizing antibodies by B cells. Accordingly, they are involved in the clearance of intracellular 
bacteria, fungi, protozoal parasites and viruses. Th2 cells fight extracellular pathogens and worms 
(helminthes and nematodes) by inducing antibody class-switching in B cells and the recruitment 
of eosinophils to sites of infection. Th9 cells are considered to contribute to the eradication of 
parasitic infections. Th17 lymphocytes provide protection against extracellular bacteria and fungi 
by recruiting neutrophils. Tfh cells assist antibody production by secreting B cell-promoting cy-
tokines. Regulatory T cells are generally involved in maintaining self-tolerance and immune ho-
meostasis. The CD4+ T cell compartment seems to shows plasticity. An established subset is not 
necessarily committed to its effector function. For instance, Th17 cells can acquire a Th1 or Th2 
phenotype. Such flexibility could be beneficial for the host, because it allows an efficient way to 
fight the same pathogen under different conditions [3, 109-112]. Another example for plasticity are 
CD4+ T lymphocytes, which are post-thymically reprogrammed to gain a cytolytic capacity upon 
chronic antigen stimulation [113]. CD8+ T cells are largely pre-committed to differentiate into cy-
totoxic T lymphocytes (CTLs) upon activation. The most important ability of CTLs is to detect 
and kill infected or neoplastic cells by inducing apoptosis, mainly via the granule-dependent exo-
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cytosis pathway (Fig.1.5) [114]. The underlying mechanism is also responsible for the previously 
described T cell effect. Of note, there is growing evidence that CD8+ T lymphocytes also exhibit 
heterogeneity in differentiation and function [115]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon activation, one T cell can generate a large number of progeny (clonal expansion), that all 
bear the same specificity for one particular antigen. Notably, effector T cells do not require co-
stimulation anymore to mount an immunological attack [3]. Following antigen clearance, over 
95% of effector cells die by apoptosis (contraction). However, a small pool of T cells survives 
and differentiates into long-lived immunological memory cells, which also show heterogeneity 
[116]. Memory T lymphocytes provide a protective immunity based on a faster and stronger im-
mune response upon the re-exposure to a pathogenic antigen compared to naïve T cells [3, 117]. In 
addition to αβ T lymphocytes, other unconventional populations such as γδ T cells [118], mucosa-
associated invariant T (MAIT) cells [119], and natural killer T cells [120] responsible for different 
aspects of the immune response are described. 
Since T lymphocytes constitute an important part in the defense from pathogens, it is no surprise 
that they also affect tumors. Aberrant cells exhibit gene alterations, which in turn can give rise to 
altered self-antigens. These “neoantigens” can be presented bound to MHC class I molecules on 
the surface of tumor cells, which can be then recognized as non-self and killed by CTLs [121]. This 
Fig. 1.5. Granule-dependent exocytosis pathway. While screening cells,
cytotoxic CD8+ T lymphocytes initially bind to cells through nonspecif-
ic adhesion molecules such as LFA-1 and ICAM. Upon recognition of
non-self antigens presented by tumor or infected cells, the CTL becomes
polarized. It directs components of the killing machinery towards the
immunological synapse (IS) formed between CTL and target cell. The
microtubule-organizing center (MTOC) is reoriented by the cortical
actin cytoskeleton located at the contact site. MTOC in turn aligns the
Golgi apparatus (GA), which provides cytotoxic proteins encapsulated
into specialized lysosomes termed cytotoxic granules (CG). These gran-
ules migrate along microtubules in the direction of the plasma mem-
brane. Their content consists of perforin, granzymes and granulysin.
Upon release into the IS, the cytotoxic proteins act in concert to induce
apoptosis within the target cell. Adapted with permission from [3]. Copy-
right 2012 Garland Science/Taylor & Francis Group. 
1. INTRODUCTION 
 
16 
process is analogous to the events occurring after immunogenic cell death upon insult with thera-
peutics shown in Figure 1.10B (section 1.4.2.2). Here however, the first step of this “cancer-
immunity cycle” [121], namely the capturing of neoantigens by DCs and subsequent activation of 
CTLs is initiated by the spontaneous death of cancer cells, for instance induced by hypoxic con-
ditions in the tumor core. Because of their antitumor properties, it is obvious to use CTLs as drug 
carriers. However, in this thesis all peripheral blood T cells were converted into pharmacytes. 
The rationale behind this approach is the specificity of the bispecific antibody, which cross-links 
CD3+ T cells to target cells. Since all mature CD4+ and CD8+ T lymphocytes express CD3 [3], 
all these cells could be exploited as drug carrier cells. This includes also those CD4+ T cells, 
which exert a cytotoxic phenotype in combination with bsAb [10]. Furthermore, there is evidence 
that CD4+ T cells could augment the response to adoptive T cell transfer when co-administered 
with CD8+ T cells in vivo [122, 123]. However, the role of the CD4+ T cell compartment in tumor 
immunity is complex and it is a key modulator of the anticancer immune response. 
CD4+ T lymphocytes can contribute either to tumor regression or to progression. The presence of 
Th1 cells in the tumor correlates generally with a good prognosis for the patient. Depending on 
the cancer type, the infiltration of Th2 cells, Th17 cells or Tregs can comprise a good or poor 
prognosis or can have no influence at all [14]. Furthermore, Th9 cells can contribute to an anti-
cancer immune response via cytokine secretion [124]. 
 
 
1.4 Drugs used as payload for T cells and their mechanisms of actions 
In this thesis, formulations of two different kinds of drugs were used as payload for human 
T lymphocytes. While the anthracycline idarubicin (IDA) was encapsulated into polymeric nano-
particulate systems, the model photosensitizer 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin 
(mTHPP) was applied complexed with the polyelectrolyte poly(styrene sulfonate) sodium salt 
(PSS). IDA exhibits direct cytotoxicity of its own and is therefore considered as an active phar-
maceutical. In contrast, mTHPP exemplifies a passive or inducible therapeutic, because light (and 
molecular oxygen) are needed to trigger the cytotoxic activity of this photosensitizer. 
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1.4.1 Anthracycline based chemotherapy 
Anthracyclines, a class of antibiotic-based compounds with similar chemical structures, such as 
daunorubicin, doxorubicin, epirubicin, and idarubicin (Fig. 1.6), belong to the most effective an-
ticancer drugs in current clinical practice [125, 126]. As noted previously, this class of therapeutics 
has already been used in cell-mediated drug delivery (see section 1.2). 
 
 
 
 
Fig. 1.6. Chemical structures of selected anthracyclines. 
 
Daunorubicin (daunomycin, DAU) and doxorubicin (adriamycin, DOX) were the first anthracy-
clines isolated from the bacterium Streptomyces peucetius [127, 128] and the variant Streptomyces 
peucetius var. caesius, respectively, in the 1960s [129]. The range of the antineoplastic activity of 
anthracyclines is very broad. Solid tumors and leukemia such as acute myelogenous leukemia, 
breast cancer, hepatocellular carcinoma, Hodgkins’ disease, non-Hodgkins’ lymphoma, multiple 
myeloma, sarcoma, and small cell lung cancer, among others are treated with these agents [130].  
 
1.4.1.1 Mechanisms of anthracycline-based tumor destruction 
The molecular mechanisms responsible for antitumor activity of anthracyclines are not yet com-
pletely elucidated. Several mechanisms of action have been proposed and are controversially de-
bated: 1) production of free radicals causing DNA damage and lipid peroxidation; 2) direct ef-
fects on cell membranes; 3) DNA binding and alkylation; 4) DNA cross-linking; 5) interference 
with DNA unwinding or strand separation and helicase activity; 6) intercalation into DNA lead-
ing to inhibition of DNA, RNA and protein synthesis; 7) inhibition of type IIA topoisomerase 
 R1 R2 R3 R4 
Daunorubicin OCH3 H OH H 
Doxorubicin OCH3 H OH OH 
Epirubicin OCH3 OH H OH 
Idarubicin H H OH H 
Daunosamine-moiety 
Tetracyclic quinoid aglycone adriamycinone-
moiety D      C      B     A 
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(Top) mediated DNA religation generating and accumulating DNA double-strand breaks that 
consequently cause apoptosis. However, poisoning of Tops is considered a crucial part of the 
cell-killing activity of anthracyclines at clinically relevant concentrations [125, 131, 132]. Many cellu-
lar processes involving the genetic material such as transcription, replication, recombination, mi-
totic segregation and genomic compaction, affect and stress the topology of DNA. Topoisomer-
ases are enzymes that break and join DNA strands to manage and control the topological state of 
mitochondrial [133] and genomic DNA [134]. All vertebrates express two isoforms, Top2α and β, of 
type IIA topoisomerase. Human neoplastic tissues overexpress Top2α; therefore, this enzyme is 
an ideal target for chemotherapeutics [135]. Anthracyclines act by stabilizing the enzyme-DNA 
adduct in which DNA chains are cleaved and covalently linked to tyrosine residues of topoiso-
merase II [136]. Figure 1.7 illustrates the proposed catalytic cycle of type IIA topoisomerases [135] 
and the poisoning of this cycle by doxorubicin as an example for anthracyclines. In addition, the 
shown docking models present two calculated configurations of Top2-DNA-DOX ternary com-
plexes, in which the broken DNA ends are kept physically apart so that strand resealing is 
blocked [137, 138]. 
Tumors form complex tissues encompassing tumor microenvironment and neovasculature, con-
sisting of non-aberrant multiple distinct cell types such as bone marrow-derived vascular progeni-
tor cells, endothelial cells, fibroblasts, myofibroblasts, mesenchymal stem cells, pericytes, and 
various types of immune cells [94]. The latter cells are often not able to induce a potent antitumor 
immune response, due to the presence of immunosuppression signals and the lack of suitable 
immunostimulatory signals. However, anthracyclines such as DOX and IDA can cause an immu-
nogenic apoptosis of cancer cells. In contrast to physiological apoptosis, which is considered a 
non-immunogenic or even tolerogenic cell death pathway [139], this so-called immunogenic cell 
death (ICD) is accompanied by the emission of immunostimulatory damage-associated molecular 
patterns (DAMPs) [140]. Hence, the clinical efficacy of those anthracyclines is related not only to 
their intrinsic toxicity but also to their ability to induce ICD, which evokes a robust antitumor 
immune response [141]. 
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Fig. 1.7. Proposed catalytic cycle and poisoning of type IIA topoisomerases. Top2 enzymes are homodimers forming 
a molecular clamp at the N-terminal region (N-gate) that also contains ATPase domains. In addition, a DNA cleav-
age core is sandwiched between the N-terminal domains and a C-gate at the C-terminal region. State 1 and 2: 
N‐gate is open and the DNA cleavage core (blue and green domains) is in equilibrium between open and closed 
form. State 3: Upon binding of a duplex DNA G‐segment (gate) by the cleavage core, the two ATPase domains 
undergo a conformational change that partly closes the N‐gate. In this state, the N-gate is enabled to capture a duplex 
DNA T‐segment (transport). State 4: Upon binding of two ATP-molecules, the N‐gate closes, thereby entrapping 
the T-segment and triggering the unlocking of the DNA‐gate by generating a double‐strand break with 4‐base pair 
overhangs within the G-segment (center figure and docking model B). Each strand end is covalently bound to the 
active site tyrosine residue located within a WHD domain (green). State 5: Transport of T‐segment from N-gate 
through opened DNA‐gate to the C-gate is facilitated by hydrolysis of one of the bound ATP-molecules. State 6: 
Upon closure of the DNA‐gate, the cleaved G‐segment is religated again. This induces the opening of the C-gate, the 
release of the T‐segment and resetting of the enzyme. 
Progression to state 6 is inhibited by intercalation of anthracyclines into the DNA of the already cut G-segment. 
Docking model A (yeast Top2) and B (human Top2β) show two possible intercalation sites for a doxorubicin mole-
cule. Docking model A: Blue ribbons highlight the backbones of DNA strands. The DNA break is located between 
+1 and -1 nucleotide. Yellow lines indicate hydrogen bonds between DOX and amino acid residues of one WHD 
domain. Adopted with permission from [137]. Copyright 2004 American Chemical Society. Docking model B: Only 
one DOX molecule is located within the cleavage core. Adopted with permission from [138]. Copyright 2013 Nucleic 
Acids Research. Catalytic cycle: Adapted with permission from [135]. Copyright 2013 Annual Reviews. 
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In addition to adverse effects that are usually common to all chemotherapeutics such as gastroin-
testinal toxicity, myelosupression, and alopecia, cumulative dose-dependent chronic cardiomyo-
pathy occasionally followed by congestive heart failure also limits the clinical use of anthracy-
clines [132]. Recently, Zhang et al. suggested that type IIA topoisomerase Top2β is the key media-
tor for doxorubicin-induced cardiotoxicity [142]. The search for novel anthracyclines with im-
proved therapeutic indexes, particularly with regard to cardiotoxicity, resulted in a vast number of 
analogs. However, only few of them have attained clinical approval. Among them, epirubicin and 
idarubicin are useful alternatives to doxorubicin or daunorubicin, respectively [125].  
 
1.4.1.2 Idarubicin 
In this thesis, the second-generation semisynthetic anthracycline idarubicin (IDA) was used as 
drug payload for carrier cells, because of its improved therapeutic index and high lipophilicity. 
Mandruzzato and colleagues compared doxorubicin and 4’-deoxy-4’-iododoxorubicin (IDX) in 
the context of LAK cell-mediated drug delivery [81]. DOX-loaded LAK cells did not affect the 
growth of lung metastases compared to untreated mice. However, treatment with IDX-loaded 
LAK cells lead to a significant reduction of metastases. The authors attributed the difference in 
treatment outcome to the higher lipophilicity of IDX compared to DOX, which could have facili-
tated a more effective drug transfer from carrier cells to tumor cells. IDA was first purified in 
1976 [143] and is a structural analog of daunorubicin but lacks the 4-methoxy group in ring D 
(Fig. 1.6). This modification alters IDA to a much more lipophilic compound compared to doxo-
rubicin, epirubicin (EPI) and daunorubicin [144]. Thus, like IDX the use of IDA could be advanta-
geous for cell-mediated drug transfer. 
In contrast to DAU, which is mainly used for the treatment of acute lymphoblastic or myelo-
blastic leukemia, IDA is given to patients suffering from acute myelogenous leukemia, multiple 
myeloma, non-Hodgkin’s lymphoma, and breast cancer [125, 145]. The wider antineoplastic activity 
of IDA is probably also due to the increased lipophilicity leading to enhanced cellular internaliza-
tion and improved stabilization of the ternary topoisomerase IIα-DNA-IDA complex [125]. Fur-
thermore, idarubicin exhibits greater cytotoxicity than DAU, DOX, and EPI against tumor cells 
in vitro [146]. In addition, IDA is more effective than DOX and DAU in killing tumor cells show-
ing a multidrug resistance phenotype. This is important to note, because the clinical utility of an-
thracyclines can be limited due to evolving chemoresistant tumor cell populations [147]. Conver-
sion of keto-anthracyclines, such as DAU, DOX, and EPI to their 13-hydroxy metabolites via 
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carbonyl-reducing enzymes is regarded as a drug-inactivation pathway. Indeed, the correspond-
ing alcohol metabolites daunorubicinol, doxorubicinol, and epirubicinol exhibit relatively lower 
anticancer activity. However, even after carbonyl-reducing the principal circulating metabolite of 
IDA, idarubicinol (IDOL), is still as cytotoxic as the parent drug. Furthermore, IDOL shows a 
high plasma concentration and a long in vivo half-life. Therefore, in contrast to alcohol metabo-
lites of other anthracycline, IDOL contributes to the clinical efficacy of the parent drug [146-148]. 
Idarubicin is more hematotoxic than doxorubicin [149]. However, it is considered less cardiotoxic 
than other anthracyclines [150].  
Encapsulation of anthracyclines into liposomes has been proven to be a successful strategy to 
reduce the cardiotoxicity of these compounds due to altered tissue distribution and pharmacoki-
netics [151]. Another option to minimize adverse effects is a targeted approach in which the drug is 
selectively transported to the disease site. T cell-based drug delivery could be such an approach.  
 
1.4.2 Photodynamic therapy 
Photodynamic therapy (PDT) is typically a minimally invasive therapeutic modality [152], alt-
hough intraoperative PDT can have a heavy impact on patients [153]. PDT requires the simultane-
ous presence of three components at the disease site: molecular oxygen, an either topically or 
systemically administered photosensitizer (PS), and light of a specific wavelength matched to an 
absorbance peak of the respective PS [152]. It is important to note, that none of these components 
are in general cytotoxic. 
As referenced by several reviews [152, 154, 155], German medical student Oscar Raab discovered 
PDT in 1900 by demonstrating the cytotoxic effect of the combination of light and the PS acri-
dine orange on infusoria, a mixture of aquatic microorganisms [156]. Since then, PDT has been 
applied in areas as diverse as cardiology [157, 158], cosmetics [159], dentistry [160], dermatology [161], 
and ophthalmology [162, 163]. Moreover, PDT shows potential for antibacterial, antifungal, antipro-
tozoal, and antiviral medical treatments [164]. Notably, PDT is a clinically approved therapeutic 
modality successfully used for the treatment of neoplastic diseases [165]. For the first time, photo-
dynamic therapy was approved by the Canadian health agency for the prophylactic treatment of 
bladder cancer, using porfimer sodium (Photofrin) as a PS in 1993 [166]. Subsequently, worldwide 
approval for PDT was obtained to treat several types of neoplasm such as bile duct, bladder, 
brain, esophagus, lung, pancreatic, ophthalmic, ovarian, and skin cancer [165]. In addition, pallia-
tive photodynamic therapy of head and neck cancer was approved in Europe in 2001 [155]. 
1. INTRODUCTION 
 
22 
Several advantages render photodynamic therapy as an attractive alternative for cancer treatment. 
PDT shows intrinsic dual selectivity based on the localization of the photosensitizer in the tumor 
tissue and on the light, which is directly focused on the malignant lesion. The required spatio-
temporal presence of PS and light facilitates highly localized tissue damage and reduced off-
target toxicities [167]. In addition, PDT does not lead to cumulative toxicity in patients like an-
thracyclines (see section 1.4.1.1), and in contrast to chemotherapy and radiation, there is no 
known maximum cumulative dose [168]. Therefore, PDT could be a modality to contain neoplastic 
diseases even if a complete cure is not achievable. However, tumor selectivity after systemic ap-
plication of classical photosensitizers is limited and healthy tissues also accumulate PS [169]. The 
general distribution of PS leads to adverse effects, like prolonged eye and skin photosensitivity. 
To circumvent these obstacles, several tumor-targeting PDT strategies are under investigation 
[170]. The use of cellular vehicles to transport PS molecules directly to the target site, as evaluated 
in chapter 3 and 4 of this work, could be an option to reduce these adverse effects. As noted pre-
viously, oxygen is a major component of PDT. However, tumors often contain hypoxic regions. 
In addition, oxygen deficits can also arise if oxygen consumption during PDT occurs at a faster 
rate than oxygen replenishment. An option to counteract the lack of oxygen in tumors is the ad-
ministration of carbogen and nicotinamide to patients, which can improve PDT-tumor response 
[171]. 
 
1.4.2.1 Basic Photochemistry 
The cytotoxicity exhibited by photodynamic therapy is based on a photosensitizing process 
commencing with the absorption of a photon by the photosensitizer. Most organic molecules 
have an electronic singlet ground state, which is characterized by paired electrons being in an 
energetically most favorable molecular orbital (highest occupied molecular orbital, HOMO). Ab-
sorption promotes the PS from its electronic ground singlet state S0 (1PS) to an excited electronic 
singlet state S1 (1PS*) by transferring one of the paired electrons to an orbital of higher energy 
(lowest unoccupied molecular orbital, LUMO) (Fig. 1.8). The short-lived (nanoseconds) activat-
ed species usually relaxes back to the ground state. This deactivation process can occur by photon 
radiation and/or radiationless transformation of excitation energy into heat (internal conversion). 
De-excitation via a radiation pathway involving transitions of an electron between states of the 
same spin multiplicity (singlet-to-singlet or triplet-to-triplet transitions) is referred to as fluores-
cence. The excited singlet PS can also relax radiationlessy, accompanied by an electron spin con-
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version, to a more stable excited electronic triplet state T1 (3PS*) by the process known as inter-
system crossing. In the triplet state, the PS has a lower energy, because the two electrons are now 
unpaired and have parallel spins. The triplet state of the excited photosensitizer is longer-lived (> 
microseconds), because relaxation to the electronic ground state S0 requires another spin conver-
sion to be consistent with the Pauli exclusion principle. However, spin conversion is less proba-
ble and therefore electronic energy is “trapped” in the triplet state. As consequence of this, de-
excitation from T1 to S0 by light emission, known as phosphorescence, is rather slow. Further-
more, the lifetime of this species is long enough to initiate photoreactions of type I (see next sec-
tion). In addition, the excited triplet PS can decay radiationlessy via intersystem crossing. In the 
presence of molecular oxygen, transfer of electronic energy to an oxygen molecule mediated by 
bimolecular collision can accompany this transition. While the PS molecule is relaxing back to its 
electronic ground singlet state, the oxygen molecule is elevated from its ground triplet state T0 
(3O2) to the first excited singlet state S1 (1O2). This species is known as singlet oxygen and its 
formation is referred to as a type II process [165, 172-175]. 
 
 
 
Fig. 1.8. Relevant valence electrons in molecular orbitals (upper panel) participating in electronic transitions illus-
trated in the simplified Jablonski diagram (lower panel) are shown. Vibrational and rotational energy levels of elec-
tronic states were omitted. Electronic transitions are described in the text. 
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1.4.2.2 Mechanisms of PDT-mediated cytotoxicity and tumor destruction 
In biological systems like cells, type I processes are characterized by electron and hydrogen ab-
straction from biomolecules, located in the cellular microenvironment, by the excited triplet pho-
tosensitizer (Fig. 1.9) [165, 176]. Biomolecules usually participating in those reactions are NADPH, 
guanine in nucleic acids, and tryptophan and tyrosine in proteins [173]. Furthermore, type I pro-
cesses generate reactive oxygen species (ROS) such as superoxide anion radicals (O2-•), hydroxyl 
radicals (OH•), hydroperoxyl radicals (HO2•), and hydrogen peroxide (H2O2•) (Fig. 1.9), which in 
turn directly attack other biomolecules. Although singlet oxygen (1O2), produced via the type II 
mechanism, is believed to be mainly responsible for the cytotoxic effects elicited by PDT, photo-
sensitizers often induce reactions of both photochemical types [173].  
 
 
 
Biomolecules such as proteins, lipids and nucleic acids are prone to oxidatively generated dam-
age leading to cell death. Photo-induced modifications of proteins can cause unfolding, confor-
mational changes, aggregation, fragmentation, and inactivation, which in turn lead to alteration of 
protein functions essential for cell signaling, redox homeostasis, and proteolytic pathways [177]. 
Lipid peroxidation mediated by photogenerated singlet oxygen and other ROS leads to lipid de-
composition and gives rise to radicals, which initiate free-radical chain reactions resulting in lipid 
bilayer breakdown of biomembranes. Typical targets for lipid peroxidation are unsaturated fatty 
acids and glycolipids, phospholipids, and cholesterol [173, 176]. Oxidatively generated DNA dam-
age in cells is characterized by single nucleobase lesions, single and double strand breaks, in-
trastrand base cross-links, DNA interstrand cross-links, DNA-protein cross-links, and nucleobase 
Fig. 1.9. Relevant type I reactions initiated 
by photon (hν) absorption of a PS elevating 
it to an excited triplet state PS*. The activat-
ed PS can react with molecular triplet oxy-
gen (O2) and biomolecules. In some reac-
tions PS is restored. Reactive oxygen spe-
cies such as superoxide anion radicals (O2-
•), hydroxyl radicals (OH•), hydroperoxyl 
radicals (HO2•), and hydrogen peroxide 
(H2O2) are also photogenerated and contrib-
ute to oxidatively-derived damage to cells. 
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adducts with lipid peroxidation breakdown products [178]. DNA insults caused by PDT can be 
genotoxic and mutagenic [168]. However, there is no data available yet, which show that PDT di-
rectly induces cancerogenesis in vivo. Hence, several authors consider the risk that PDT can give 
rise to secondary tumors as low [166, 168, 173]. 
Three distinct processes, elicited by PDT-derived oxidatively generated damage, have been rec-
ognized to contribute to tumor destruction: 1) direct cellular damage, 2) indirectly through shut-
down of tumor-associated vasculature, and 3) by initiating an immune response against cancer 
cells (Fig. 1.10A) [155]. Direct cellular damage can be further divided into three different cell 
death pathways: 1) apoptosis, 2) necrosis, and 3) autophagy-associated cell death [165]. The life-
time of 1O2 in a single life rat neuron or HeLA cell was determined to be approximately 3 µs [179]. 
Based on this result and on values for the intracellular oxygen diffusion coefficient, it was esti-
mated that the spatial domain of 1O2 reactivity within HeLa cells has a spherical radius of around 
100 nm [180]. Therefore, the loci of subcellular damage due to PDT is determined mainly by the 
localization of the respective PS. In vitro data suggest that photosensitizers accumulating in mito-
chondria induce apoptosis while those targeting the plasma membrane are more likely to mediate 
necrosis. However, tumor destruction in vivo is expected to result from a mixture of apoptotic and 
necrotic cell death [181]. Autophagy promotes cell survival at low levels of photodamage. Yet, it 
can become a cell-death pathway, when cells attempt to recycle damaged biomolecules and orga-
nelles beyond their capacity for recovery. Furthermore, in cells with compromised apoptosis, 
autophagy is probably responsible for cell death. However, the exact role of autophagy in PDT-
mediated cell death has still to be elucidated [182, 183]. Damage to tumor-associated vasculature can 
provoke thrombosis and hemorrhage in tumor blood vessels. As consequence of the ischemic 
condition, tumor cell death occurs because of lack of oxygen (hypoxia) and nutrients, which fa-
cilitates long-term tumor control [184, 185]. Like anthracycline-based chemotherapy, photodynamic 
therapy can act as an inducer of immunogenic cell death [186], which is accompanied by the re-
lease of immunostimulatory signals (see section 1.4.1.1). Accordingly, PDT can evoke an inva-
sion of immune cells into the tumor tissue (Fig. 1.10B), which contributes to its destruction and 
enables the immune system to recognize malignant metastases [184, 187]. Several factors such as the 
nature of the applied photosensitizer, its localization within the neoplastic tissue during irradia-
tion, the light exposure dose, the type of tumor, and the tumor microenvironment determine the 
relative contribution of each process to tumor eradication [155]. 
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1.4.2.3 Photosensitizers and PSS/mTHPP complex 
Photosensitizing compounds can generally distinguished into porphyrins and non-porphyrins [188]. 
Well-known porphyrins are chlorophylls as well as the heme cofactors of hemoglobin, myoglo-
bin, and cytochromes. Indeed, a mixture of photosensitizing molecules termed hematoporphyrin, 
later used in PDT, was isolated from hemoglobin by Scherer in 1841 [189]. Porphyrins are a class 
of heterocyclic macrocycle organic compounds, based on modified tetrapyrroles. In contrast, the 
class of non-porphyrin-based PS, encompassing amongst others hypericin, chalcogenopyrylium 
and phenothiazinium dyes, as well as cyanines, cannot be derived from a common parent chemi-
cal structure. Porphyrin-based PS are further subdivided into first, second, or third generation 
photosensitizers. Hematoporphyrin derivatives (HpD) such as the clinically approved Photofrin 
belong to first generation photosensitizers. However, drawbacks such as prolonged skin photo-
sensitization and suboptimal tissue penetration led to the development of the next generation of 
Fig. 1.10. Three modes of PDT-mediated tumor destruction 
and simplified illustration of PDT-induced activation of the 
immune system. (A) Oxidative stress caused by PDT is cyto-
toxic ① and vasculotoxic ②. In addition, leukocytes such as 
dendritic cells and neutrophils are attracted to the inflamma-
tion site triggered by PDT ③. (B) After PDT-mediated tumor 
cell death, cell debris is phagocytosed by immature dendritic 
cells (DCs). DCs mature upon stimulation by inflammatory 
cytokines and home to tumor-draining lymph nodes where 
they present antigens to naïve T cells. After priming, clonally 
expanded effector T cells migrate, attracted by chemokines, to 
the malignant lesion in order to kill further aberrant cells. 
Adapted with permission from [187]. Copyright 2006 Nature 
Reviews / Cancer. 
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photosensitizers. Second generation PS such as clinically approved Foscan, Metvix or NPe6 ab-
sorb light of longer wavelengths (ensuring deeper tissue penetration [165]) and/or cause signifi-
cantly less skin photosensitization compared with first generation PS. The ideal characteristics of 
a photosensitizer are shown in table 1.1. However, no clinically approved PS can be regarded as 
ideal so far. The search for agents fulfilling the chemical, physical and biological requirements of 
an optimal photosensitizer is the focus of current research. Candidates could be found among 
third generation photosensitizers, encompassing second generation PS, which are rendered more 
tumor tissue selective by conjugation to antibodies, liposomes, and nanoparticles [170, 188]. PS-
loaded tumoritropic cells, as investigated in this thesis, could meet some requirements, especially 
increased selectivity but reduced toxicity, for an ideal photosensitizer. 
 
Table 1.1. Requirements for an ideal photosensitizer. Adapted with permission from [188]. Copyright 2009 John Wiley 
& Sons, Inc. 
Activation Significant absorption of wavelengths between 700 and 850 nm for maximum light penetration through tissue with minimum light scattering. 
ADME Optimal absorption, distribution, metabolism and excretion (ADME) proper-ties for relevant indication. 
Cost and availability Inexpensive and commercially available in order to promote extensive utiliza-tion of treatment. 
Mutagenicity ⁄ carcinogenicity Neither mutagenic nor carcinogenic effects should result from the photosensi-tizer 
Purity Should be a single pure substance of known composition that is stable at room temperature. 
Quantum yield High single oxygen quantum yield for photochemical event, which is usually the production of singlet oxygen and other ROS. 
Selectivity Accumulation within tumor tissue is favorable. 
Toxicity 
Minimal toxicity in the absence of light and only cytotoxic in the presence of 
light of defined wavelengths. Photosensitizer should not yield toxic metabo-
lites. 
 
In this work, the porphyrin-based photosensitizer 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin 
(mTHPP, Fig. 1.11) was used. mTHPP is the parent porphyrin of 5,10,15,20-tetrakis(3-
hydroxyphenyl)chlorin (mTHPC, Fig. 1.11), which is a corresponding dihydroporphyrin [190]. 
mTHPC is the active pharmaceutical ingredient of Foscan, which is approved for the use in sys-
temic cancer treatment. Foscan-PDT has been proven an effective measure in the treatment of 
cancer types related to chest, gastrointestinal tract, gynecological tissues, skin, and head and neck 
[153]. mTHPC appears to be one of the most potent photosensitizers. However, a major drawback 
of Foscan is still the prolonged skin photosensitivity that can last for several weeks post-
treatment [188]. 
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The reduction of one of the double bounds of tetrapyrrole (red oval in Fig. 1.11) causes a greater 
absorption of red light by mTHPC compared to mTHPP [191]. The molar extinction coefficients of 
mTHPP and mTHPC are 3400 M-1×cm-1 at a wavelength of 644 nm and 29600 M-1×cm-1 at a 
wavelength of 650 nm, respectively [190]. For PS with lower molar extinction coefficients a great-
er concentration of the PS or intensity of light are required to achieve adequate tumor eradication 
[188]. Therefore, red light-activated mTHPP is less cytotoxic than its derivative Foscan [192]. Nev-
ertheless, the precursor has been frequently applied as model photosensitizer in basic research on 
photodynamic therapy (PDT) [153]. Likewise, a water-soluble formulation of mTHPP complexed 
with poly(styrene sulfonate) sodium salt (PSS) was used as a model in the present work, in order 
to evaluate whether polymeric photosensitizer preparations are suitable drug formulations for 
cell-mediated drug delivery (PSS/mTHPP, Fig. 1.11). mTHPP itself is practically insoluble in 
water. Originally, the negatively charged complex was designed as a layer material for a delivery 
system of water-insoluble drugs. PSS was chosen for its water solubility and its benzene rings 
that can interact with benzene rings of mTHPP. Reum and co-workers showed that within the 
complex one mTHPP molecule is noncovalently attached to around 11 monomer units of the 
polyelectrolyte PSS. Thus, the complexation efficiency is around 2 mTHPP molecules per poly-
mer [193]. Noncovalent bonding is preferred in terms of drug efficiency and singlet oxygen quan-
tum yield [194]. 
 
 
Fig. 1.11. Chemical structures of mTHPP, mTHPC (Foscan, Temopofrin), and PSS-complexed mTHPP. mTHPC is a 
derivative of mTHPP and lacks a double bond (red oval). 
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1.5 Aim of this thesis 
One main objective of the thesis presented here was to identify anticancer drug formulations for 
human T lymphocyte-mediated drug delivery, which preserve loaded carrier cells from premature 
cell death. To this end, two different types of polymer-encapsulated therapeutics were investigat-
ed. The first approach pursued the idea of incorporation of an “active” drug into nanoparticulate 
systems in order to protect the living vehicles. In this regard, interactions between T cells and 
glycosylated polylysine polymers were studied in order to estimate which kind of polypeptide 
could be suitable as material for drug encapsulation (chapter 2). In addition, the protective effect 
on carrier cells of poly(lactic-co-glycolic-acid) nanoparticles (NPs), newly developed maleate-
based polyester NPs and gold shell-coated polyester-based NPs, all enclosing the cytotoxic 
chemotherapeutic agent idarubicin, was examined (chapter 3). For the second approach, a “pas-
sive” drug represented by the photosensitizer 5,10,15,20-tetrakis (3-hydroxyphenyl)porphyrin 
(mTHPP) was used, the mode of action of which is only triggered by light irradiation (chapter 3 
and 4). The tolerance of T lymphocytes for loading with a water-soluble formulation of this drug 
was tested. Classical pharmaceuticals applied in chemotherapy lack high specificity for tumor 
sites. The living cell-mediated drug deliver concept aims to improve the selectivity and efficacy 
of cancer treatment to reduce adverse effects by using tumor-specific T cells as transport vehi-
cles. In the study presented here, tumor specificity was provided by bispecific antibodies, which 
cross-link T cells and cancer cells thereby triggering cytotoxic effector T cells to kill target cells. 
The T cell-based drug delivery approach aims to combine the cytotoxicity of cell-delivered 
pharmaceuticals with the cell-mediated cytotoxicity to improve the curative potential of adoptive 
cell therapy. Hence, the second main objective of this thesis was to prove the feasibility of this 
concept in vitro. Particularly, the question of whether this combination is synergistic or additive 
was addressed. 
 
Within the scope of the presented thesis the following research questions were investigated: 
 
1) What requirements do glycosylated polylysine polymers fulfill to be a potential ma-
terial for drug encapsulation in T cell-mediated drug delivery? 
The purpose of the encapsulation material is to protect the carrier cells against the toxicity 
of the drug. Therefore, it was tested whether the polylysine polymers are themselves toxic 
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for T lymphocytes. Furthermore, polymers were conjugated with sugar-based ligands. 
Therefore, it was tested whether these ligands facilitate the uptake of glycosylated polyly-
sine polymers by T cells. 
 
2) What formulations facilitates drug uptake by T cells? 
The prerequisite for cell-based drug delivery is that the “Trojan horse” (the carrier) take 
up “greek soldiers” (drug molecules). Therefore, internalization of therapeutics by 
T lymphocytes was monitored. 
 
3) To what extent do drug formulations harm the living vehicles? 
Polyester-encapsulated idarubicin and complexed mTHPP must not harm loaded T cells 
to prevent impairment of physiological functions. Hence, the effect of the payload (asso-
ciated materials and pharmaceutics) on cell viability and cytolytic activity was studied. 
 
4) Are pharmaceuticals released from carrier cells and transferred to target cells? 
For the T cell-based drug delivery approach to function is it mandatory that the therapeu-
tics are released or transferred to the target cells, where they can exhibit their cytotoxic 
potential. This question was tackled by tracking drug uptake by target cells over time. 
 
5) Is the amount of released/transferred drug sufficient to kill tumor cells? 
Drug delivery by loaded carrier cells is only feasible, when the anticancer drug is not 
trapped within the vehicles. To elucidate this question the viability of target cells was de-
termined after the challenge with drug loaded T lymphocytes. 
 
6) Is the combination of drug and cell cytotoxicity additive or synergistic in vitro? 
This was the most important question addressed in this thesis. In case the use of loaded 
T cells would only achieve an additive killing effect, the loading process would not be 
needed. It would have the same effect as the administration of the free drug formulation in 
combination with empty bsAb-retargeted T cells. Consequently, the T cell-mediated drug 
delivery approach would presumably be unfeasible. 
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1.6 Statement of contributions 
Chapter 2, 3, and 4 of this thesis contain parts, which were published in scientific journals. Sec-
tion 1.5 explains, how each chapter is related to each other. The results described in each chapter 
are discussed and brought into context in chapter 5.  
In the following, the author of the thesis state his contributions to these chapters. 
 
Parts of chapter 2 were published in: 
Stöhr T., Blaudszun A.-R., Steinfeld U. and Wenz G. 
Synthesis of glycosylated peptides by NCA polymerization for recognition of human T-cells. 
Polymer Chemistry; 2011, 2: 2239-48 
 
The second author contributed the following points to the chapter: 
- Design, performance, and interpretation of all shown experiments. 
- Writing of the chapter. 
T. Stöhr provided the glycosylated peptides. 
 
 
Parts of chapter 3 were published in: 
Blaudszun A.-R., Lian Q., Schnabel M., Loretz B., Steinfeld U., Lee H.-H., Wenz G., Lehr C.-
M., Schneider M., Philippi A. 
Polyester-idarubicin nanoparticles and a polymer-photosensitizer complex as potential drug 
formulations for cell-mediated drug delivery. 
International Journal of Pharmaceutics; 2014, 474: 70-79 
 
The first author contributed the following points to the chapter: 
- Design, performance, and interpretation of all shown experiments except generation and charac-
terization of nanoparticles as well as synthesis and characterization of poly(diethylene glycol-
maleate-co-sebacate)ester (MPE). 
- Writing of the chapter. 
Q. Lian provided and characterized the nanoparticles. 
M. Schnabel characterized MPE. M. Schneider provided PSS/mTHPP. 
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Parts of chapter 4 were published in: 
Blaudszun A.-R., Moldenhauer G., Schneider M., Philippi A. 
A photosensitizer delivered by bispecific antibody retargeted human T lymphocytes enhances 
cytotoxicity against carcinoma cells upon light irradiation 
Journal of Controlled Release; 2015, 197: 58-68 
 
The first author contributed the following points to the chapter: 
- Design, performance, and interpretation of all shown experiments. 
- Writing of the chapter. 
G. Moldenhauer provided the bispecific antibody. 
M. Schneider provided PSS/mTHPP. 
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2. Interactions of statistical glycosylated copolypeptides with hu-
man T lymphocytes 
Parts of this chapter were published in: 
 
Stöhr T., Blaudszun A.-R., Steinfeld U. and Wenz G. (2011) 
Synthesis of glycosylated peptides by NCA polymerization for recognition of human T-cells. 
Polymer Chemistry; 2: 2239-48 
 
 
2.1 Abstract 
There is evidence to suggest that targeted drug delivery increases the efficacy of chemotherapies. 
A wide variety of nanoparticulate systems composed of different materials such as inorganic 
compounds, lipids and polymers as artificial drug vehicles are used in approaches to accumulate 
therapeutics at the disease site. However, the concept has limitations such as recognition of drug 
carriers by the immune system and removal from the host by phagocytic cells of the reticuloendo-
thelial system before they can reach their target site. Given the diverse restrictions of classical 
drug delivery systems, alternative more efficient drug targeting strategies are being investigated. 
Among them, cell-mediated transport of therapeutics has emerged as a new drug delivery con-
cept. In order to protect cellular drug carriers against highly toxic pharmaceuticals, encapsulation 
of active drugs into protective nanoparticles has been proposed. 
We plan to use human T lymphocytes as carriers for anticancer therapeutics. In the present study, 
we investigated interactions of potential compounds for polymeric nanoparticulate systems with 
ex vivo activated human T cells. Tested compounds comprised neutral O-glycosylated polylysine 
derivatives with attached diethylene glycol chains. To target cells, carbohydrate ligands such as 
β-D-galactopyranose, β-D-glucopyranose and α-D-mannopyranose were bound to the backbone 
of these statistical copolypeptides. Indeed, human T lymphocytes specifically took up galactosyl-
ated and mannosylated peptides at 37 °C but not at 4 °C. In addition, T cell viability was pre-
served for polymer concentrations of up to 0.33 mg/mL. Therefore, glycosylated polylysine de-
rivatives are potentially useful for selective staining of cells or targeted drug delivery. 
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2.2 Introduction 
Targeted drug delivery has emerged as a therapeutic concept to increase the effectiveness and 
specificity of chemotherapies. Most approaches use artificial drug carriers such as liposomes, 
polymeric, metallic, viral and many other varieties of nanoparticles (NPs) or nanoparticulate sys-
tems to concentrate therapeutics at the pathological site. Often, these classical drug vehicles are 
functionalized with monoclonal antibodies (mAb), cell-specific ligands (e.g. folate or transferrin), 
peptides or aptamers to further enhance the targeting effect [195, 196]. Numerous studies have 
demonstrated the benefits of targeted drug delivery, but they also revealed serious limitations of 
this concept. These restrictions include the recognition of particulate drug carriers as “foreign” by 
the immune system and removal from the bloodstream by phagocytic cells of the reticuloendothe-
lial system before they reach the target site. Therefore, comparably high drug doses are still re-
quired to bring therapeutically effective drug amounts to pathological sites. Consequently, the 
adverse effects of many targeted drug delivery approaches are still severe. Toxic effects of carrier 
materials, chemical instability and inadequate tissue distribution are further problems of various 
drug delivery systems [39]. 
Given the diverse limitations of classical drug delivery systems, alternative more efficient drug 
targeting strategies are being investigated. Cell-mediated transport of therapeutics has emerged as 
a new drug delivery concept (reviewed in [12, 42]). Several mammalian cell types, such as immune 
and stem cells, have a number of natural properties, which make them ideal candidates for the 
development of novel drug targeting strategies. Unlike many artificial drug carriers, defense and 
stem cells can actively trace and infiltrate diseased sites (homing ability) and migrate across im-
permeable barriers, such as the blood-brain or the blood-tumor barrier [42, 197, 198]. These intrinsic 
abilities can be utilized to transport pharmaceuticals specifically to the target site. Furthermore, 
various types of immune cells like cytotoxic T lymphocytes and natural killer cells or mono-
cytes/macrophages and neutrophils possess a natural killing function such as cytotoxic [199] or 
phagocytic activity [200], respectively, that can additionally be exploited to fight diseases. The 
biocompatibility of cellular drug carriers and diminished drug immunogenicity represents a fur-
ther advantage of cell-based drug delivery strategies [12]. 
We aim to use human T lymphocytes as tumoritropic vehicles for antineoplastic therapeutics to 
fight malignancies. In studies pursuing a similar approach, cell-delivered drugs included ricin [82, 
84] and a doxorubicin derivative [81]. The efficacy of those delivered drugs was clearly shown. 
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However, the emerging strategy also revealed a major drawback. Carrier cells loaded with highly 
toxic pharmaceuticals showed a rapid loss of physiological functions and a decline in cell viabil-
ity. To preserve cellular drug carriers from toxic effects of delivered therapeutics, incorporation 
of active drugs in protective nanoparticles has been proposed [12]. Ideal encapsulation materials 
are non-toxic and biodegradable and do not alter the physiological functions of loaded cells. 
Moreover, they show high drug encapsulation efficiencies and allow sustained release of en-
closed pharmaceuticals inside the carrier cells. Given that many natural and synthetic polymers 
meet these requirements [201, 202], polymeric nanoparticles have recently attracted the attention of 
research groups working on cell-mediated drug delivery [203, 204]. 
Recognition between different cells, between viruses and cells, and between tissues and cells is 
controlled by the cooperativity of rather weak ligand-receptor interactions. Among others, carbo-
hydrates like glucose, mannose, galactose, and lactose as well as complex oligosaccharides are 
well-known ligands for biological receptors expressed on cell membranes [205, 206]. Binding inter-
actions between carbohydrate ligands and receptor proteins are indeed highly specific, but gener-
ally rather weak compared to other biological interactions [207]. Therefore, molecular recognition 
between biological entities requires the interplay of more than one receptor-ligand interaction. 
Cooperativity of binding can also be used in artificial systems to improve binding affinities. In 
the so-called “multivalency approach,” many ligands are connected to an inert polymer backbone 
to reach manifold binding [208]. Therefore, many carbohydrate ligands have been attached to pol-
ymers [209, 210], carbon nanotubes [211], and cyclic scaffolds, e.g., cyclodextrins [212-214] or spherical 
molecules such as dendrimers [215]. The resulting so-called “glycoclusters” or “neoglycoconju-
gates” indeed showed improved binding to multivalent receptors, e.g., lectins [216-219], in vitro and 
to cells in vivo [220], and are potentially useful for targeted delivery [221]. Despite the successes of 
the multivalency approach, some drawbacks still obstruct broad application. Firstly, glycoclusters 
are often not biodegradable because mostly synthetic scaffolds are used in their synthesis. Sec-
ondly, polymers and high molecular weight glycoclusters tend to bind non-specifically to biolog-
ical surfaces, i.e., by Coulomb interactions between oppositely charged species.  
In the present study, we investigated interactions of potential compounds for polymeric nanopar-
ticles with ex vivo activated human T cells. Tested compounds comprised neutral O-glycosylated 
polylysine derivatives with attached diethylene glycol chains. Nanoparticulate systems based on a 
variety of polypeptides derivatives were already produced for drug delivery (reviewed in [32]). 
Polypeptides have hydrolysable bonds and are therefore biodegradable by proteolytic enzymes 
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(proteases) [32]. Thus, glycosylated polylysine polymers meet at least one requirement (biodegra-
dation) for an ideal encapsulation material. The use of oligo(ethylene glycol) side chains mini-
mizes unspecific binding to cell surfaces [222] and to biomolecules such as serum proteins applied 
in cell culture like bovine serum albumin (BSA) [223]. The α-helical synthetic polypeptides [224] 
were used as a backbone for attachment of carbohydrate ligands such as β-D-galactopyranose 
(galactose), β-D-glucopyranose (glucose) and α-D-mannopyranose (mannose). To analyse and 
visualize interactions with biological systems like cells, fluorescein isothiocyanate (FITC) was 
coupled to free ε-NH2 groups of lysine repeating units as well (compare Figure 2.1). 
 
 
 
 
 
Figure 2.1. Chemical structure of the O-glycosylated (y units) polylysine derivative with attached fluorescein (z 
units) and diethylene glycol chain (x units). R = functionalized lysine repeating units, R1 = galactose, glucose or 
mannose. 
 
T lymphocytes express a variety of glycoprotein-binding receptors on the cell surface such as L-
selectin (CD62L) [225] which belongs to a subclass of the calcium-dependent (C-type) lectin fami-
ly, galectins, a family of β-galactoside-binding lectins [226] and mannose-6-phosphate receptors 
(P-type lectins) [227, 228]. In addition, T cells express membrane transporters of the SLC2 (GLUT) 
family [229] which show affinity to saccharides such as galactose, glucose and mannose [230]. Thus, 
the introduced glycosylated polymers could be used to target T cells. To estimate which kind of 
glycosylated polylysine polymer could be suitable as material for drug encapsulating NPs, pre-
2-[2-(2-Methoxyethoxy)ethoxy]acetamide-moiety 
Fluorescein-thiourea-moiety 
Pyranosyl-oxapentyl-thiourea-moiety 
Polylysine-backbone 
R1 
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liminary studies to evaluate the cytotoxicity and binding/uptake capacity of polymers were per-
formed. To this end, T cell viability after incubation with polymers, binding and internalization of 
glycopeptides were studied using an XTT based in vitro toxicology assay, flow cytometry and 
fluorescence microscopy, respectively. We demonstrate that T cell viability was preserved for 
polymer concentrations of up to 0.33 mg/mL. Furthermore, although all glycosylated polylysine 
derivatives were taken up by T lymphocytes, the preference for internalisation of particular pol-
ymers was clearly evident. 
 
2.3 Materials and methods 
Synthesis (section 2.3.1) of glycosylated peptides was not conducted by the author of this thesis. 
 
2.3.1 Synthesis and handling of glycosylated peptides by N-carboxyanhydride polymeriza-
tion 
O-glycosylated polylysine (PL) polymers were synthesized as previously described [231]. In brief, 
peracetylated sugars (glucose, mannose and galactose) were attached via a thiourea linker to the 
3-amino group of α-BOC-lysine and α-Z-lysine. After transformation to the N-carboxyanhydride 
(NCA), the product was copolymerized with both PEGylated lysine-NCA and ε-TFA-lysine-
NCA by both tertiary amine and nickel complex catalysts. After deprotection fluorescein isothio-
cyanate (FITC) was coupled to the free ε-NH2 groups of the lysine repeating units. The glucosyl-
ated polylysine (PL-Glu), the mannosylated polymer (PL-Man), and the galactosylated polymer 
(PL-Gal) as well as the unsubstituted polypeptide (PL) were dissolved in autoclaved purified wa-
ter obtained from an Elix3 (UV) water purification system (Merck Millipore, Darmstadt, Germa-
ny) as stock solutions with a concentration of 2 mg/mL. Stock solutions were stored protected 
from light at -20 °C. 
 
2.3.2 Fluorescence spectrometry of polymers 
Thomas Stöhr (Organic Macromolecular Chemistry, Saarland University, Germany) kindly pro-
vided polypeptides PL-Gal, PL-Glu, PL-Man, and PL. These polymers were diluted in cell cul-
ture medium without phenol red (RPMI 1640 (PAN Biotech, Aidenbach, Germany) supplement-
ed with 10% (v/v) heat-inactivated FBS (PAN Biotech), 100 U/mL penicillin and 0.1 mg/mL 
streptomycin (Sigma-Aldrich, Steinheim, Germany) (stock c(PL) = 20 µg/mL, pH = 7.5). Fluo-
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rescence intensities of samples (V = 100 µL) at indicated concentrations were measured in a 
black 96-well microplate (Greiner Bio-One, Frickenhausen, Germany) with a Modulus Micro-
plate Multimode Reader (Promega, Mannheim, Germany) at an excitation wavelength of 490 nm 
and emission wavelengths of 510-570 nm at 25 °C. Aliquots of 100 µL of pure cell culture medi-
um served as blanks. Fluorescence intensities of blanks were subtracted from the intensities of 
polypeptides. 
 
2.3.3 Isolation and activation of human T lymphocytes 
Buffy coat blood of healthy donors was obtained from a local blood center (Blutspendezentrale 
Saar-Pfalz gGmbH, Saarbrücken, Germany) after informed consent according to the declaration 
of Helsinki. CD3+ T cells were enriched by using a RosetteSep Kit (StemCell Technologies, 
Grenoble, France) according to the manufacturer’s instructions. Briefly, 0.5 mL RosetteSep anti-
body cocktail was added to 20 mL buffy coat blood and incubated at 25 °C for 20 min while gen-
tly shaking. Cells were isolated by centrifugation using a Pancoll human density gradient (PAN 
Biotech). Remaining erythrocytes were lysed with 2 mL of an ammonium chloride-based lysing 
buffer (BD Pharm Lyse, BD Biosciences, Heidelberg, Germany). Afterwards, enriched cells were 
resuspended in cell culture medium (supplemented RPMI 1640). Purity of isolated 
T lymphocytes was consistently higher than 90% when analyzed by flow cytometry (FACSCali-
bur, BD Biosciences) with antibodies against human CD3 (Bio-Rad AbD Serotec, Puchheim, 
Germany). Prior to experimental use, T lymphocytes were stimulated for at least 3 days using 
particles functionalized with antibodies against human CD2, CD3, and CD28 (MACS T Cell Ac-
tivation/Expansion Kit, Miltenyi Biotec, Bergisch Gladbach, Germany). Expansion of T cells was 
achieved by adding 20 U/mL of recombinant human Interleukin-2 (IL-2, PAN Biotech), and fresh 
culture medium every 3 to 4 days. 
 
2.3.4 In vitro toxicology assay 
T lymphocytes were harvested from cultures and counted using an automated cell counter (CASY 
Model TT, OMNI Life Science, Bremen, Germany). Subsequently, cells were inoculated at a 
concentration of 2.5×105 cells/well in 100 µL fresh cell culture medium (supplemented RPMI 
1640 without phenol red (PAN Biotech), containing 20 U/mL of IL-2) into 96-well microtiter 
plates. Triplicates of culture wells were subjected to 20 µL of stock solutions of polylysine PL-
Man, PL-Glu, PL-Gal, and PL and incubated at 37 °C in a humidified atmosphere with 5% CO2. 
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Likewise, negative control cells were treated with 20 µL of phosphate buffered saline (PBS, Life 
Technologies, Darmstadt, Germany). Additionally, triplicate blanks contained only culture medi-
um with polypeptides or PBS. Prior to use, 5 mg of a mixture of 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide, XTT, and 1% phenazine 
methosulfate (PMS) (TOX-2, Sigma-Aldrich) were reconstituted with 5 mL of RPMI 1640 medi-
um without phenol red. After 18, 42 and 66 h, 24 µL of XTT-PMS solution was applied to the 
cultures, which were further incubated for 6 h. Subsequently, samples were homogenized to 
completely disperse the XTT formazan. Finally, the absorbance was measured at 450 nm with a 
reference wavelength of 690 nm using an absorbance microplate reader (Spectra Rainbow Ther-
mo, Tecan, Crailsheim, Germany). After subtracting blank values, all viability data obtained were 
normalized to the viability of the negative controls (PBS) which were set to 100%. 
 
2.3.5 Flow cytometric analysis of polypeptide uptake by T lymphocytes 
T cells were inoculated at a concentration of 5×105 cells per tube in 100 µL of fresh cell culture 
medium. Duplicates of T lymphocytes were subjected to 20 µg (10 µL of solution) of PL-Man, 
PL-Glu, PL-Gal and PL and incubated at 4 °C or 37 °C for 2, 4 or 8 h. Likewise, control cells 
were treated with 10 µL of PBS. Cells were washed twice with 1 mL of ice-cold PBS (300 × g 
and 4 °C for 10 min, centrifuge 5415 R, Eppendorf, Hamburg, Germany), resuspended in 500 µL 
of ice-cold PBS and kept on ice until analysis by flow cytometry. Fluorescence intensity of 
10,000 events per sample was measured by using a FACSCalibur cytometer (BD Biosciences) 
and CellQuest Pro software (version 5.1.1, BD Biosciences). Fluorescence intensities of gated 
T cell populations are represented by histograms. Furthermore, geometric means (GMFI) 
calculated by CellQuest Pro for cells incubated with each polymer were normalized to the 
fluorescence intensities of the polymers determined at a concentration of 0.02 mg/mL using the 
following equation: 
 
nGMFIPol ൌ ሺGMFIPol-GMFIBlankሻ × FIPL-GalFIPol  
 
nGMFIPol: normalized GMFI of T cells incubated with the respective polymer 
GMFIPol: GMFI of T cells incubated with the respective polymer 
GMFIBlank: GMFI of T lymphocytes 
FIPL-Gal: Fluorescence intensity of PL-Gal at 0.02 mg/mL 
FIPol: Fluorescence intensity of the respective polymer at 0.02 mg/mL 
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2.3.5.1 Flow cytometric analysis of PL-Glu uptake by T cells in the absence of glucose 
The culture medium used is supplemented with glucose as nutrient for cells (2 mg/mL according 
to data sheet provided by Pan Biotech). To verify whether medium related glucose is interfering 
with interactions between glucosylated polymers and T cells, the aforementioned experiment was 
performed using glucosylated polymers and a medium devoid of glucose (PBS containing 
1% (v/v) BSA). 
 
2.3.5.2 PL-Gal uptake by naïve/memory and activated T lymphocytes 
Non-actived T cells consists of naïve and memory subsets (see section 1.1). However, in the 
following naïve and memory T cells are also referred to as non-activated T cells. We were 
interested in whether there is a difference between non-activated and activated T cells in 
binding/uptake of glycosylated polymers. Thus the previously described experiment was 
accordingly perforemd with freshly isolated non-activated T lymphocytes and galactosylated 
polylysine. 
 
2.3.5.3 Inhibition of PL-Gal uptake with lactose 
We also investigated whether PL-Gal uptake by T cells can be inhibited with β-D-
galactopyranosyl-(1→4)-D-glucose (lactose). To this end, lactose monohydrate (Carl Roth, 
Karlsruhe, Germany) was dissolved in PBS to produce a stock solution with a concentration of 
120.11 mg/mL. T lymphocytes were inoculated at a concentration of 5×105 cells per tube in 
90 µL of cell culture medium. Duplicates of T cells were subjected to 90 µL of lactose stock 
solution and incubated at 37 °C for 30 min. Likewise, control cells were treated with 90 µL of 
PBS. Afterwards, 40 µg (20 µl of solution) was added and T cells were incubated at 37 °C for 
indicated periods (final concentration of lactose was then 0.15 mol/L). Finally, samples were 
processed as described in section 2.3.5. 
 
2.3.6 Fluorescence microscopy of polypeptide treated T cells 
For fluorescence microscopy, samples containing 2×106 T cells in 800 µL of cell culture medium 
and 0.1 mg/mL of polypeptides were incubated protected from light at 4 °C or 37 °C for 6 h. 
Subsequently, T cells were washed twice with 1 mL of ice-cold PBS (300 × g and 4 °C for 
10 min, centrifuge 5415 R, Eppendorf, Germany). For fixation, sedimented cells were resuspend-
ed in 400 µL of PBS containing 4% (w/v) formaldehyde (paraformaldehyde, Sigma-Aldrich) and 
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were incubated protected from light at 25 °C for 10 min. Afterwards, cells were washed twice 
with 1 mL of ice-cold PBS.  
For experiments including cell membrane staining, samples containing 3×106 T cells resuspended 
in 1 mL of cell culture medium and 0.1 mg/mL of PL-Gal were incubated protected from light at 
37 °C for 6 h. After washing, T lymphocytes were stained in serum-free culture medium contain-
ing 2.5 µL/mL DiD (Vybrant cell-labeling solution (1 mM), Life Technologies) at 37 °C for 
10 min. Afterwards, labeled cells were washed three times with warm cell culture medium 
(300 × g for 10 min, centrifuge 5415 D, Eppendorf, Germany) and were fixed as described above. 
Washing buffer was discarded and T cells were resuspended in 20 µL of polyvinyl alcohol-based 
anti-fading mounting medium consisting of 25 mg/mL 1,4-diazabicyclo-[2,2,2]-octane (DABCO, 
Carl Roth), 9.1% (w/w) Mowiol 4-88 (Carl Roth), 22.7% (w/w) glycerol (Merck Millipore), 
1 µg/mL 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI, Sigma-Aldrich) and 0.1 M Tris-
HCl pH 8.5 (Sigma-Aldrich). The mounting medium was allowed to harden overnight and kept 
protected from light at 4 °C. Fluorescence microscopy was performed using an IX71 inverted 
microscope (Olympus, Hamburg, Germany) equipped with U-MNU2, U-MWIBA2 and U-
N41033 filters. DNA-intercalating DAPI was excited at wavelengths of 360-370 nm. Polypep-
tides were excited at wavelengths of 460-490 nm and DiD at wavelengths of 625-655 nm. Fluo-
rescence, emitted by DAPI-DNA-complexes at wavelengths above 420 nm, by polypeptides at 
515-550 nm or by DiD at 662.5-737.5 nm, was imaged through a 60× PlanApo N oil-immersion 
objective (Olympus) with a numerical aperture of 1.42 by a digital camera (F-View II, Olympus) 
attached to the microscope. Immersion oil Immersol 518N (Carl Zeiss Microscopy GmbH, Göt-
tingen, Germany) was used. The camera was controlled by cellp imaging software (version 2.8, 
Olympus). All images were digitalized using the same conditions (automatic gain disabled and 
fixed exposure times) to compare the fluorescence intensities of polypeptides, whereas the imag-
ing of DAPI-stained cell nuclei and DiD-labeled cell membranes was automatically adjusted by 
cellp (Olympus soft imaging solutions). Merged images were generated via cellp imaging soft-
ware. 
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2.4 Results 
2.4.1 Fluorescence spectrometry of polypeptides 
It was desirable to attach fluorescent labels, such as fluorescein, to the glycopolypeptides to allow 
the detection of any interaction with biological systems. As illustrated in Figure 2.2, all FITC-
conjugated glycopolypeptides diluted in cell culture medium and the unsubstituted polypeptide 
exhibited a clear fluorescence signal at the greatest tested concentration. 
 
 
Table 2.1.  Fluorescence intensities (FI) of glycopolypeptides and the unsubstituted polymer at a concentration of 
0.02 mg/mL 
 
Polymer PL PL-Gal PL-Glu PL-Man
FI [arb. units] 27.6 13.3 8.9 3.5 
 
The order of fluorescence intensity (PL > PL-Gal > PL-Glu > PL-Man) is consistent with the 
order of polypeptide absorbance at a wavelength of around 480 nm determined by Thomas Stöhr 
[224]. Accordingly, the unsubstituted polypeptide PL exhibiting the greatest absorbance also 
showed the greatest fluorescence intensity. Obviously, more fluorescein-molecules were attached 
to unsubstituted polypeptides than to mannosylated polymers. Possible reasons for different 
amounts of conjugated fluorochrome could be an initially different number of ε-TFA protected 
lysine units added to the terpolymerization (compare [224, 231]) and/or an uncompleted labeling 
process. 
 
 
Figure 2.2. Fluorescence intensities in arbi-
trary units of glucosylated polylysine (PL-
Glu), mannosylated polymer (PL-Man), 
galactosylated polymer (PL-Gal) as well as 
the unsubstituted polypeptide (PL). One 
representative experiment is shown. Results 
are expressed as means of duplicate samples. 
Error bars indicate standard deviations (SD). 
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2.4.2 Analysis of T cell survival 
In vitro toxicity of glucosylated polylysine (PL-Glu), mannosylated polymer (PL-Man), galacto-
sylated polymer (PL-Gal) as well as the unsubstituted polypeptide (PL) was tested with ex vivo 
activated human T lymphocytes of two different donors using the XTT cell viability assay [232]. 
Fig. 2.3 clearly shows that cell viability remains preserved for polymer concentrations of up to 
0.33 mg/mL. From these observations, we conclude that all tested polymers are sufficiently bio-
compatible. 
 
 
 
2.4.3 Flow cytometric analysis of polylysine polymer uptake by T cells 
The interactions of polymers PL-Man, PL-Glu, PL-Gal as well as the unsubstituted polypeptide 
PL with ex vivo activated human T lymphocytes were investigated by flow cytometry (FCM). 
The fluorescence intensity distributions showed a pronounced shift to higher fluorescence intensi-
ties for the galactosylated polymer PL-Gal, especially for incubations at 37 °C as shown in 
Fig. 2.4D. 
 
Figure 2.3. Viabilities of human 
T lymphocytes after ■ 24 h, ■ 48 h and □ 
72 h of incubation with polylysine polymers 
(c = 0.33 mg/mL). Results are expressed as 
means of two independent experiments with 
2 different donors (n = 2). Error bars indi-
cate SD. 
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Figure 2.4. Fluorescence intensity distributions measured by FCM of T cell populations after incubation with poly-
mers at 4 °C (─2 h, ─8 h ) and 37 °C (─2 h, ─8 h ) for (A) the unsubstituted polypeptide PL (B) the mannosylated 
polypeptide PL-Man (C) the glucosylated polymer PL-Glu, and (D) the galactosylated polylysine PL-Gal. As con-
trols autofluorescence intensity distributions of T cells incubated at 4 °C (─8 h) and 37 °C (─8 h ) are shown as 
well. 
 
The uptake of each fluorescent polymers (Fig. 2.4) was quantified by calculating the geometric 
mean of fluorescence intensity (GMFI) over the cell populations. Moreover, these GMFI values 
were normalized to their respective fluorescence intensities taken from Table 2.1. While there 
was only little uptake of the fluorescent unsubstituted polymer PL and the glucose polymer PL-
Glu, the mannose polymer PL-Man and the galactose polymer PL-Gal were readily taken up, 
especially at 37 °C (Fig. 2.5). 
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Figure 2.5. Uptake of the glycosylated polymers PL-Gal, PL-Glu and PL-Man and the unsubstituted polymer PL 
by T cells at 4 °C (left panel) and 37 °C (right panel), as determined from the geometric mean of FCM fluorescence 
intensities (GMFI), normalized to the fluorescence intensity of the respective polymer at a concentration of 
0.02 mg/mL. One representative experiment is shown. Results are expressed as means of duplicate samples. Error 
bars indicate SD. 
 
2.4.3.1 Flow cytometric analysis of PL-Glu uptake by T cells in the absence of glucose 
Given that cell culture medium (supplemented RMPI 1640) in which interaction experiments 
were performed contained glucose as supplement (2 mg/mL according to data sheet provided by 
Pan Biotech), we verified whether medium related glucose interferes with the interaction between 
glucosylated polymers and T cells. To this end, T lymphocytes were incubated with PL-Glu in 
medium devoid of glucose (PBS + 1% BSA) at 4 °C and 37 °C for indicated periods of time. In-
terestingly, incubation in BSA supplemented phosphate buffered saline decreased uptake of PL-
Glu by T cells as shown in Fig. 2.6. Obviously, the selected glucose free-medium was not suita-
ble to answer the question whether medium related glucose impairs interactions between T cells 
and glucosylated polylysine. 
 
 
Figure 2.6. Uptake of the glucosylated polymer PL-Glu by 
T cells at 4 °C and 37 °C, as determined from the geometric 
mean of FCM fluorescence intensities (GMFI), normalized to 
the fluorescence of PL-Glu at 0.02 mg/mL. T lymphocytes 
were incubated with PL-Glu either in cell culture medium or 
in PBS containing 1% BSA. Results are expressed as means 
of two different experiments conducted with two different 
donors (n = 2). Error bars indicate SD. 
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2.4.3.2 PL-Gal uptake by non-activated and activated T lymphocytes 
Upon activation of T cells, the expression of several cell-surface molecules, associated with acti-
vation, co-stimulation, and adhesion, changes [233]. In addition, T lymphocytes start to proliferate 
rapidly (clonal expansion) which requires an upregulating of metabolic pathways to provide the 
needed energy [234, 235]. This is accompanied by an increased expression of GLUT1 sugar trans-
porters [236]. Accordingly, the transition from non-activated cell phenotype to activated cell phe-
notype could change the amount and specificity of binding-motifs for glycosylated polymers on 
the cell-surface. To gather preliminary information about the nature of those binding motifs, we 
investigated whether there is a difference between both states of T cells in binding/uptake of gly-
cosylated polymers. To this end, non-activated and activated T lymphocytes were incubated with 
PL-Gal at 4 °C and 37 °C for the indicated periods of time. PL-Gal was chosen, because this gly-
cosylated polylysine yielded the greatest GMFI values (Fig. 2.5). 
As illustrated in Fig. 2.7, all GMFI values of activated T cell populations are greater than the val-
ues obtained from non-activated populations after incubation with PL-Gal. Interestingly, even 
activated T lymphocytes, which had been incubated at 4 °C, showed a greater fluorescence inten-
sity than non-activated T cells. We conclude that ex vivo activation of T lymphocytes could pos-
sibly induce the expression of binding motifs for galactosylated polymers. 
 
 
 
Figure 2.7. Uptake of the galactosylated polymer PL-Gal by non-activated or activated T cells at 4 °C and 37 °C, as 
determined from the geometric mean of FCM fluorescence intensities (GMFI), normalized by the fluorescence of 
PL-Gal. The diagram shown in the right panel represents a magnified version of the diagram shown in the left panel. 
Results are expressed as means of two different experiments conducted with two different donors (n = 2). Error bars 
indicate SD. 
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2.4.3.3 Inhibition of PL-Gal uptake with lactose 
We also tried to impair the uptake of PL-Gal by T cells with β-D-galactopyranosyl-(1→4)-D-
glucose (lactose). Lactose (lac) was chosen because it contains a galactopyranose ring like PL-
Gal (compare Fig. 2.1). As representatively shown in Fig. 2.8, the results are inconclusive. Con-
trol T cells, which had been incubated only with lactose, showed the usual autofluorescence. As 
expected, the longer the incubation period lasted the greater was the fluorescence intensity of cell 
populations treated with PL-Gal. However, there was no significant difference in GMFI values 
when lactose treated T cells were incubated with PL-Gal. In conclusion, under the chosen exper-
imental conditions lactose did not inhibit uptake of the galactosylated polymer. 
 
 
 
2.4.4 Fluorescence microscopy of polypeptide treated T lymphocytes 
Fluorescence microscopy studies of T cells incubated with solutions (c = 0.1 mg/mL) of poly-
mers PL as well as PL-Gal for 6 h, shown in Figure 2.9A, demonstrated that the galactosylated 
polymer exhibited significant interactions with ex vivo activated T lymphocytes. Almost all cells 
exhibited the green fluorescence of fluorescein. Furthermore, Figure 2.9B suggests that the PL-
Gal is not only adsorbed at cell walls, but is also internalized by T cells. Merged fluorescence 
images clearly show that green fluorescent cell compartments are encircled by red stained cell 
membranes. Hence, the sites of green fluorescence emission were mainly located within T cells. 
 
Figure 2.8. Uptake of the galactosylated polymer 
PL-Gal by activated T cells after treatment with 
0.15 M lactose at 37 °C. Results are expressed as 
means of two samples derived from one donor 
(n = 1). Error bars indicate SD. 
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Fig. 2.9. Imaging of T lymphocytes by fluorescence microscopy. (A) After 6 h of incubation at 4 °C (left panels) and 
37 °C (right panels) with unsubstituted polypeptide PL (upper panels) and galactosylated polymer PL-Gal (lower 
panels). Blue fluorescent cell nuclei were stained with DAPI before. The green color represents the emission of fluo-
rescein, attached to the polymers. (B) Cell membranes were detected using DiD (red fluorescence). Galactosylated 
polypeptides are located within T cells as shown in the merged image (lower left panel) composed of the green (mid-
dle left panel) and the red fluorescence picture (upper left panel). Locations of blue stained cell nuclei are illustrated 
in right hand panels. 
 
 
2.5 Discussion 
We aim to use human T cells as carriers for antineoplastic drugs to fight cancer. To prevent 
premature death of cellular carriers due to toxic effects of delivered therapeutics, encapsulation of 
active drugs into protective nanoparticles has been suggested [12]. The purpose of the present 
work was to investigate the interactions between ex vivo activated T lymphocytes and neutral O-
glycosylated polylysine derivatives that could serve as potential compounds for polymeric nano-
particulate systems. Non-toxicity and biodegradability are among the requirements for optimal 
encapsulation materials. Here, we demonstrated that polymer concentrations of up to 0.33 mg/mL 
did not impair T cell viability. In addition, glycosylated polylysine derivatives are biodegradable 
by hydrolytic processes occurring within cells (e.g. hydrolysis mediated by proteolytic enzymes) 
[32]. Hence, the tested polymers meet at least some requirements for an ideal encapsulation mate-
rial. 
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Moreover, polylysine derivatives were functionalized with monosaccharides such as galactose, 
glucose and mannose to target binding-motifs on cell-surfaces. Indeed, we have shown that all 
glycosylated polymers were internalized to a greater extent than the non-glycosylated polylysine 
by T lymphocytes. However, the preference for uptake of particular polymers was evident. While 
there was only limited uptake of the fluorescent unsubstituted polymer PL and a slightly in-
creased uptake of the glucose polymer PL-Glu, the mannose polymer PL-Man and the galactose 
polymer PL-Gal were readily internalized, especially at 37 °C.  
Interestingly, we have demonstrated that populations of activated T cells are more intensely fluo-
rescent than populations of naïve/memory T lymphocytes after incubation with PL-Gal at 4 °C or 
at 37 °C. At 4 °C galactosylated polymers have presumably only bound cell membranes, since 
endocytosis is an energy-dependent process and inhibited at low temperatures [237]. However, 
non-activated T cells are smaller than activated T lymphocytes (see Supplementary Information, 
Fig. S2.1). Consequently, the cell surface of activated cells is larger than the surface of non-
activated cells. Therefore, activated T cells could bind more PL-Gal than naïve/memory T cells, 
which could explain the slightly increased fluorescent GMFI value of activated cell populations 
determined by flow cytometry at 4 °C. Upon activation, metabolism of T cells is upregulated to 
fuel bioenergetic demands for clonal expansion and differentiation into effector cells [235]. Upreg-
ulating is reflected in the increased reduction of tetrazolium salts, because energy metabolism is 
generally considered to correlate with the conversion of tetrazolium salts to formazans by cells 
[238]. Indeed, the bioreductive activity of non-activated T cells determined by a colorimetric XTT 
assay is much weaker than the activity of activated T lymphocytes (Supplementary Information, 
Fig. S2.2). In addition, proliferation and differentiation of cells requires increased uptake of nu-
trients for the biosynthesis of lipids, nucleic acids, and proteins as well [235]. Consequently, it is 
conceivable that activated T cells exhibit greater endocytic activity than naïve/memory 
T lymphocytes. For instance, increased macropinocytosis in activated T cells could cause greater 
unspecific uptake of polymers, which could explain the increased fluorescent GMFI value of ac-
tivated cell populations compared to non-activated T cells at 37 °C. 
However, cell size and increased unspecific binding upon activation cannot explain the prefer-
ence for uptake of different glycosylated polylysine derivatives or the preference of T cells for 
the glycosylated polymers to the unsubstituted polymer. We conclude, that modification with 
sugars granted polymers a distinct specificity for activated T lymphocytes. 
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Activation could have led to a stronger expression of galactose binding-motifs than of mannose 
and glucose receptors incorporated into the cell membranes. These motifs could be related to L-
selectin, which is known to bind the galactose-containing tetrasaccharide sialyl Lewis X and ga-
lactose clusters [239, 240]. The glycoprotein L-selectin (CD62L) is expressed on the surface of 
T lymphocytes and plays a crucial role during T cell recirculation [225, 241]. By binding to its lig-
ands, CD62L initiates the extravasation of T lymphocytes into peripheral lymphoid tissues. How-
ever, during activation of T lymphocytes, CD62L is down-regulated [242], which is in contrast to 
our finding of activated T lymphocytes taking up polymer PL-Gal significantly. Consequently, L-
selectin might not be the desired receptor. Another receptor candidate could be among the mem-
bers of the galectin family. These mammal lectins exhibit affinity for -galactosides [243]. Galec-
tins can exist as dimers or even pentamers [226]. Therefore, extracellularly secreted galectins are 
able to form lattices with glycoprotein receptors on the cell surface. This process enables the cell 
to modulate various receptor functions [244]. Galactosylated polymers could bind multivalently to 
these extracellular galectin lattices. This hypothesis is supported by the experimental results of 
both galectin-1 and galectin-3 being upregulated upon T cell activation [245, 246]. Moreover, the 
multivalency of PL-Gal could be the reason, why lactose (concentrations up to 0.15 mol/mL) 
could not inhibit a presumably strong and irreversible interaction of the galactosylated polymer 
with the T lymphocytes. 
One binding-motif for mannosylated polypeptides could be the cation-independent mannose-6-
phosphate (M6P) receptor (CI-MPR), which is expressed on membrane surface of T cells as well 
[227]. CI-MPR facilitates endocytosis of CD26, a multifunctional cell surface glycoprotein, there-
by contributing to T cell activation. The phosphomonoester group participates in the interactions 
between M6P and CI-MPR [228]. However, amino acid-residues essential for high-affinity binding 
of Mannose-6-phosphate form potential hydrogen bonds to hydroxyl-groups at the 2, 3 and 4 po-
sitions of mannose. Hence, mannosylated polylysine derivatives could have bound to CI-MPR, 
although glycosylated polymers did not contain phosphomonoester groups. 
GLUTs (glucose transporters) show affinity for saccharides such as galactose, glucose and man-
nose [230]. Because of the size of those polylysine derivatives (MW = 38400 – 44500 g/mol [231]), 
we do not assume that single transporters are able to mediate the uptake of glycosylated poly-
mers. However, multivalent binding of polymers could induce clustering of transporters followed 
by endocytosis of those polymer-transporter complexes similar to antibody-antigen complexes 
[247] or artificial multivalent protein-receptor complexes [248]. Notably, the uptake of PL-Glu by 
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T cells was significantly decreased compared to that uptake of PL-Gal or PL-Man. This observa-
tion seems to be conflicting with the fact that activated T cells show an increased expression of 
GLUT1 transporter [236], which is specific for glucose, and also for galactose and mannose [230]. 
Either those transporters simply do not bind glycosylated polymers or cell-culture medium-
related glucose competed with PL-Glu (and PL-Gal or PL-Man) for binding sites. To exclude this 
possibility, uptake experiments in medium (PBS + 1% BSA) devoid of glucose were performed. 
However, the use of this medium had an opposing effect on the uptake and even less PL-Glu was 
internalized. Several reasons for this observation could come into consideration. Cell culture me-
dium, supplemented with 10% FBS, contains serum proteins, which can reduce unspecific ad-
sorption to microtube walls. Alternatively, the amount of bovine serum albumin (1%) in PBS 
could have been insufficient to prevent unspecific binding. Thus, in interaction experiments less 
polymer molecules could have been available for uptake by T cell, because to some extent poly-
mers could have been already adsorbed to laboratory plastic ware. However, in experiments 
4.8 µM (M (PL-Glu) = 37600 g/mol [231]) of glucosylated polymers were used. This concentration 
is at least 100 times greater than the concentration at which adsorption effects are being consid-
ered to produce false or inconsistent results [249]. On the other hand, keeping cells for a longer 
period in PBS decreases cell viability due to lack of nutrients. Consequently, the ability to endo-
cytose glucosylated polymers could have been impaired, which in turn would explain the de-
crease of GMFI values derived from T cell populations incubated in BSA supplemented PBS. It 
is important to note, that if glucose uptake is indeed impaired because of GLUTs inhibition, then 
the observed uptake of galactose and mannose is predominantly not mediated by GLUTs. Fur-
thermore, glycosylated polymers are not natural ligands for transporters. Barnett and colleagues 
showed that glucose interacts with the GLUT1 transporter probably via hydrogen bonding at the 
1, 3 and 4 positions of glucose [250, 251]. A potential hydrophobic interaction via the C-6 position 
was also suggested. Given that glucose is linked to polylysine derivatives via an oxapentyl-
thiourea-spacer at the C-1 hydroxyl-group, binding to GLUT1 transporters is perhaps not impos-
sible but seems to be unfavorable due to steric hindrance. 
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2.6 Conclusions 
Ex vivo activated human T lymphocytes tolerated exposure to glycopolypeptides concentrations 
of up to 0.33 mg/mL very well for at least three days. Furthermore, glycosylated polylysine de-
rivatives can be used to target T cells, because those cells have readily taken up the galactosylat-
ed and mannosylated polymers. In contrast, uptake of glucosylated or unsubstituted polypeptides 
was rather poor or insignificant, respectively. Obviously, activated T cells show a greater density 
of galactose-binding motifs than non-activated T lymphocytes. However, inhibition with lactose 
could not be demonstrated. The small amounts of glycosylated polylysine derivatives available 
for the present work have precluded an exhaustive analysis of polymer-binding site interactions. 
Consequently, the true target sites for glycosylated polymers remain to be elucidated. Neverthe-
less, the work reported herein highlights the potential use of statistical glycosylated copolypep-
tides in biomedical applications such as selective staining of cells or protective encapsulation 
material for targeted cell-mediated drug delivery. 
 
 
2.7 Supplementary Information 
2.7.1 Size of non-activated and activated T lymphocytes 
 
Fig. S2.1. Size distribution of T cell 
populations measured by an automated 
cell counter (CASY Model TT, OMNI 
Life Science). A red orientation line is 
laid over the 10 µm value of both histo-
grams indicating that naïve/memory 
T cells (mean Ø = 7.71 µm) are smaller 
than activated T cells (mean Ø = 
10.40 µm). 
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2.7.2 Reduction of XTT tetrazolium salt by T lymphocytes 
 
 
 
Fig. S2.2. Bioreductive activity of T cells obtained from two healthy donors represented as absorbance after incuba-
tion with XTT tetrazolium salt. Colorimetric XTT assay was performed as described in section 2.3.4. Freshly isolat-
ed naïve/memory T lymphocytes were used. Bioreductive activity of ex vivo activated T cells was determined four 
days after activation and is significantly increased compared to non-activated cells. Means of two different donors 
(n = 2) are shown. Error bars indicate standard deviations. 
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3. Interactions of polyester-idarubicin nanoparticles and poly-
mer-photosensitizer complexes with human T lymphocytes 
 
Parts of this chapter were published in: 
 
Blaudszun A.-R., Lian Q., Schnabel M., Loretz B., Steinfeld U., Lee H.-H., Wenz G., Lehr C.-
M., Schneider M., Philippi A. (2014) 
Polyester-idarubicin nanoparticles and a polymer-photosensitizer complex as potential drug 
formulations for cell-mediated drug delivery. 
International Journal of Pharmaceutics; 474: 70-79 
 
 
3.1 Abstract 
Cell-mediated transport of therapeutics has emerged as promising alternative to classical drug 
delivery approaches. To preserve viability and functions of carrier cells, encapsulation of active 
drugs in protective nanoparticles or the use of inducible therapeutics has been proposed. Here, we 
compared the effects of novel polymeric formulations of an active and a stimulus-sensitive anti-
cancer drug on human T lymphocytes to identify suitable drug preparations for cell-mediated 
drug delivery. For the first approach, the chemotherapeutic agent idarubicin (IDA) was encapsu-
lated in poly(lactic-co-glycolic-acid) (PLGA) and newly developed maleate-polyester (MPE) 
nanoparticles. PLGA- and MPE-encapsulated IDA was efficiently internalized by ex vivo activat-
ed human T lymphocytes; however, both encapsulations could not prevent premature T cell death 
resulting from IDA-uptake. In contrast, loading with a poly (styrene sulfonate) (PSS)-complex of 
the light-sensitive pharmaceutical 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin (mTHPP) did 
not affect T cell viability if upon loading the cells were kept in the dark. The photosensitizer was 
transferred from loaded T lymphocytes to co-cultivated carcinoma cells, and induced cancer cell 
death if co-cultures were exposed to light. Inducible drugs, such as photosensitizers, thus, may 
help to overcome the limitations of encapsulated active drugs and open up new perspectives for 
the use of cells as drug transporters in cancer therapy. 
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3.2 Introduction 
Cell-mediated transport of therapeutics has emerged as a new drug delivery concept in the past 
decade. Several mammalian cell types, including immune and stem cells, have a number of natu-
ral properties which make them ideal candidates for the development of novel drug delivery 
strategies. Unlike artificial drug carriers, defense and stem cells actively move towards sites of 
inflammation, injury, and cancer. This intrinsic homing ability and the capability of those cells to 
migrate across the blood–brain and the blood–tumor barrier can be utilized to transport pharma-
ceuticals specifically to diseased sites. Furthermore, some defense cells possess an intrinsic cyto-
toxic or phagocytic activity, that can additionally be exploited to fight diseases [12]. The drug tar-
geting capabilities of living cells were demonstrated in various pre-clinical studies. 
In a murine model of Parkinson’s disease, the homing ability of bone marrow-derived macro-
phages was exploited to transport catalase nanoparticles the blood-brain barrier to the target site 
[252]. For the treatment of experimentally induced tumors mainly lymphokine activated killer 
(LAK) cells, macrophages, mesenchymal stem cells, and erythrocytes were utilized as drug carri-
ers [12]. Delivered therapeutics include ricin [82, 84], doxorubicin and derivatives [6, 46], liposomal 5-
fluorouracil [72], nanoparticulate gold [104] as well as magnetic nanoparticles [73]. In addition, ge-
netically modified cells expressing immunotoxins, apoptosis-inducing proteins, and immuno-
modulating cytokines were tested in cell culture and animal experiments [13]. 
Although in most of the studies above the efficacy of cell-delivered drugs was clearly demon-
strated, some of them also revealed a major drawback of the emerging strategy: often, when car-
rier cells were loaded with highly toxic pharmaceuticals, a rapid loss of physiological functions 
and a decline in cell viability were observed [6, 82, 84]. To preserve cellular drug carriers from the 
toxic effects of delivered therapeutics, incorporation of active drugs in protective nanoparticles 
has been proposed [12]. Ideal encapsulation materials are non-toxic and biodegradable and do not 
alter the physiological functions of loaded cells. Moreover, they show high drug encapsulation 
efficiencies and allow sustained release of enclosed pharmaceuticals inside the carrier cells. Since 
many natural and synthetic polymers meet with these requirements [201], polymeric nanoparticles 
have recently attracted the attention of research groups working on cell-mediated drug delivery. 
As shown in two basic studies, uptake of fluorochrome-labeled polyelectrolyte-coated 
poly(lactic-co-glycolic acid) (PLGA) microparticles and amino functionalized polystyrene nano-
particles did not affect the physiological functions of monocytes-derived dendritic cells (DCs) 
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suggesting that these particles could serve as delivery systems for peptide antigens in DC-based 
vaccination strategies [203, 204]. In contrast, only few data exist on cellular drug vehicles loaded 
with polymeric anticancer drug formulations [101]. 
In the present study, we aimed to identify anticancer drug formulations for cell-mediated drug 
delivery which preserve loaded carrier cells from premature cell death. To this end, two different 
types of therapeutics, an active and an inducible drug, were encapsulated in polymers. For the 
first approach, the highly toxic chemotherapeutic agent idarubicin (IDA) was enclosed in PLGA 
and newly developed maleate-based polyester (MPE) nanoparticles (NPs). Both NP-preparations 
were subsequently introduced in activated polyclonal human T lymphocytes. Upon loading, 
T cell survival was characterized as a function of drug concentration and loading time. Further-
more, the protective effect of gold shell-coated MPE nanoparticles, referred to as AuSh NPs, was 
examined. For the second approach, T lymphocytes were loaded with a water-soluble 
poly(styrene sulfonate) (PSS)-complex of the light-sensitive anticancer drug 5,10,15,20-tetrakis 
(3-hydroxyphenyl)porphyrin (mTHPP) [193]. First, survival of polymer-photosensitizer-loaded 
T cells was analyzed. In a second step, mTHPP-transfer from T lymphocytes to co-cultivated 
carcinoma cells, and the phototoxic effect of T cell-delivered photosensitizer on tumor cells were 
studied. 
 
 
3.3 Materials and methods 
Methods described in section 3.3.1 to 3.3.3 and preparation of PSS/mTHPP were not conducted 
by the author of this thesis. 
 
3.3.1 Synthesis of poly(diethylene glycol-maleate-co-sebacate)ester (MPE) 
Poly(diethylene glycol-maleate-co-sebacate)ester (MPE) was prepared by melt condensation. In 
brief, 20 g (0.185 mol) of diethylene glycol, 5.405 g (0.0375 mol) of dimethyl maleate, 34.729 g 
(0.151 mol) of dimethyl sebacate and 1.5 g of p-toluene sulfonic acid (Sigma-Aldrich, Steinheim, 
Germany) were mixed in a plain glass flask with plain bottom and heated up to 170 °C for 1 day 
under stirring. After distilling off methanol produced during the reaction under reduced pressure 
(20 mbar), a viscous product was obtained by cooling to 25 °C. The product was dissolved in 
200 mL of tetrahydrofuran and precipitated in 1000 mL of methanol. The oily precipitate was 
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collected by centrifugation and dried under reduced pressure (2×10-2 mbar). Polymer characteri-
zation was performed as described in the Supplementary information (S3.7.3). 
 
3.3.2 Synthesis of PLGA-IDA, MPE-IDA, and AuSh-IDA nanoparticles 
Idarubicin (IDA) ethyl acetate (EA) solution was prepared by extracting IDA as free base from 
aqueous idarubicin hydrochloride solution (IDA•HCl, 1 mg/mL, Sigma-Aldrich) after adding 
triethylamine (1%). To prepare PLGA-IDA and MPE-IDA NPs, polyesters poly(D,L-lactide-co-
glycolide) 50:50 (Sigma Chemical Co., St. Louis, MO, USA) and MPE were first dissolved in 
ethyl acetate (Fluka Chemie, Buchs, Switzerland) mixed with IDA in a defined ratio (2:0.1, w/w, 
polymer:IDA). This organic phase was added gradually to an equal volume of polyvinyl alcohol 
in water (PVA, 2.5% aqueous solution, Sigma-Aldrich). The emulsion was then homogenized 
using an Ultra-Turrax T25 device (IKA-Werke, Staufen, Germany) at 13,500 rpm for 10 min. 
NPs were obtained by adding purified water dropwise under gentle stirring to obtain a final sus-
pension. Stirring was continued overnight at room temperature to remove the organic solvent. 
To prepare AuSh-IDA NPs, an equal volume of chloroauric acid (1 mg/mL, Sigma-Aldrich) was 
added to the solution containing MPE-IDA NPs. Hydroxylamine (50%, Sigma-Aldrich) as reduc-
tion agent was further added dropwise under gentle stirring for 10 min. Gold nanoshells were 
self-assembling on the surfaces of MPE-IDA NPs. 
 
3.3.3 Determination of colloidal characteristics, drug encapsulation efficiency, nanoparticle 
morphology and drug release kinetics 
Average particle size, size distribution, and zeta potential were determined in purified water (Mil-
liQ) using the Malvern Zetasizer Nano (Malvern Instruments, Malvern, UK). For each batch, 
three samples were measured (with 30 subruns for each sample) to determine the mean values. 
Drug encapsulation efficiencies (EE) and drug loading values were determined indirectly by fluo-
rescence spectrometry using an Infinite 200 PRO reader (Tecan, Crailsheim, Germany). The na-
noparticle supernatant was used for fluorescence measurements. From the fluorescence of the 
supernatant, the IDA amount not encapsulated was determined using respective calibration of 
IDA fluorescence. Knowing the amount of drug used for NP-preparation (in the beginning) and 
the amount determined in the supernatant allowed to calculate the encapsulated drug amount. 
The morphology of NPs was determined by scanning probe microscopy (SPM) with a Bioscope 
equipped with a Nanoscope IV controller from Digital Instruments (Veeco, Santa Barbara, CA, 
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USA). Samples were dried under a stream of compressed air after deposition on a freshly cleaved 
muscovite mica (Plano, Wetzlar, Germany) and investigated under ambient conditions in tapping 
mode using a scanning probe with a force constant of 40 N/m at a resonant frequency of around 
300 kHz (Anfatec, Oelsnitz, Germany). 
For determination of drug release kinetics, 1 mL aliquots of polyester-IDA NP suspensions were 
placed into a QuixSep Micro Dialyzer (Carl Roth, Karlsruhe, Germany). The capsules were then 
covered with dialysis membranes. The receptor compartments were filled with 100 mL of phos-
phate buffer solution (pH 7.4). Release studies were performed at 37 °C. At each selected time 
point, the buffered solution in the receptor compartment was taken for HPLC analysis and re-
placed with fresh buffer solution. The samples were analyzed using an HPLC apparatus consist-
ing of a Dionex Pump P680 (Dionex, Idstein, Germany) with a Hitachi Fluorescence detector L-
2480 (Hitachi, Darmstadt, Germany). The excitation and emission wavelengths used were 485 
and 542 nm, respectively. The column used was LiChroCART 125-4 RP-18 (Merck Millipore, 
Darmstadt, Germany). The mobile phase consisted of water, acetonitrile, triethylamine, and 
phosphoric acid (624:370:4:2, v/v). The settings were as follows: flow rate = 1 mL/min; tempera-
ture = 25 °C; injection volume = 50 µL. 
 
3.3.4 Preparation and handling of PSS/mTHPP 
The photosensitizer (PS)-complex PSS/mTHPP was kindly provided by Hagar Ibrahim Labouta 
(Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Germa-
ny) and prepared as previously described [193]. Lyophilized PS-complex was dissolved in auto-
claved purified water obtained from an Elix3 (UV) water purification system (Merck Millipore, 
Darmstadt, Germany) as a stock solution of 5 mg/mL (around 1 mg/mL drug) which was stored 
in the dark for up to 4 weeks at 4 °C. An LED lamp (SBAR I, TPL Vision, La Chevrolière, 
France) having a peak wavelength of 588 nm was used to handle the PS-complex and 
PSS/mTHPP-loaded T cells. Incubations were carried out in the dark to avoid premature activa-
tion of the photosensitizer. 
 
3.3.5 Cell culture 
Human T lymphocytes were isolated from day-fresh buffy coat preparations, activated and fur-
ther expanded as previously described [231]. Buffy coat products were obtained from healthy do-
nors of the Blutspendezentrale Saar-Pfalz (Saarbrücken, Germany) after informed consent ac-
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cording to the declaration of Helsinki. Prior to use, activation beads (T cell Activation/Expansion 
Kit human, Miltenyi Biotec, Bergisch Gladbach, Germany) were removed from T cell cultures by 
density gradient centrifugation using Pancoll (human, PAN Biotech, Aidenbach, Germany) as 
separating solution. 
The human ovary carcinoma cell line SKOV-3 (HTB-77, American Type Culture Collection, 
Manassas, VA, USA) was maintained in RPMI 1640 medium (PAN Biotech) supplemented with 
10% (v/v) heat-inactivated FBS (PAN Biotech), 100 U/mL penicillin, and 0.1 mg/mL Streptomy-
cin (Sigma-Aldrich). 
 
3.3.6 Loading of T lymphocytes with nanoparticles and PSS/mTHPP 
Qiong Lian (Biopharmaceutics and Pharmaceutical Technology, Saarland University, Germany) 
kindly provided nanoparticles. For loading with NPs and the PS-complex PSS/mTHPP, 
T lymphocytes were adjusted 4-6 days post stimulation in cell culture medium (supplemented 
RPMI 1640) to a concentration of 2.5×106 cells/mL using an automated cell counter (CASY 
Model TT, OMNI Life Science, Bremen, Germany). After addition of the indicated amounts of 
PLGA-IDA, MPE-IDA, AuSh-IDA NPs and PSS/mTHPP (suspended/dissolved in purified wa-
ter), T cells were incubated unless otherwise specified for 2 h in a humidified atmosphere at 
37 °C and 5% CO2. Moreover, by treating T lymphocytes under the same conditions with appro-
priate small quantities of sterile purified water unloaded (empty) control T cells were prepared. 
To remove non-internalized NPs and PS-complex, T cells were subsequently sedimented at 
300×g and 4 °C for 10 min (centrifuge 5810 R, Eppendorf, Hamburg, Germany) and washed 
three times with ice-cold cell culture medium. Then, T lymphocytes were either immediately pro-
cessed or adjusted in 20 U/mL interleukin-2 (IL-2, PAN Biotech) containing cell culture medium 
to a concentration of 2.5×106 cells/mL and further cultivated at 37°C/5% CO2 for the indicated 
periods of time. 
 
3.3.7 Analysis of particle and photosensitizer uptake by flow cytometry 
For flow cytometry-based examination of NP and PSS/mTHPP uptake, 5×105 unloaded and load-
ed T lymphocytes were resuspended in 400 µL of ice-cold flow cytometer (FCM) buffer (MACS 
Buffer containing 2 mM EDTA and 0.5% BSA (Miltenyi Biotec) supplemented with 0.1% NaN3 
(Sigma-Aldrich)) and analyzed in a FACS Calibur flow cytometer (BD Biosciences, Heidelberg, 
Germany). Fluorescence intensities of 10,000 events were measured with the FL2 (idarubicin) 
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and FL3 (mTHPP) detector using the CellQuest Pro software (BD Biosciences). Cell debris was 
eliminated from the analysis by using a threshold of 80/120, before T cell populations were gated 
and the geometric mean (GeoMean) of fluorescence intensities was determined using the FlowJo 
software (Tree Star, Inc., Ashland, OR, USA). Results represent means of duplicate measure-
ments with standard deviations (SD) indicated. 
 
3.3.8 Fluorescence microscopy (FM) and confocal laser scanning microscopy (CLSM) 
Intracellular uptake of IDA and PSS/mTHPP was confirmed by FM and CLSM. For FM analysis, 
3×106 loaded T lymphocytes were first fixed for 10 min using 4% (w/v) formaldehyde (para-
formaldehyde, Sigma-Aldrich) in phosphate buffered saline (PBS, Life Technologies, Darmstadt, 
Germany) and then embedded in 1 µg/mL 4’,6-diamidino-2-phenylindole dihydrochloride 
(DAPI, Sigma-Aldrich) containing FluorSave mounting medium (Merck Millipore). Images were 
captured with an F-View II CCD camera (Olympus, Hamburg, Germany) mounted on an inverted 
IX71 microscope (Olympus) equipped with a 60 oil-immersion objective (numerical aperture 
1.42, Olympus) and the CellP software (version 2.8, Olympus). Immersion oil Immersol 518N 
(Carl Zeiss Microscopy GmbH, Göttingen, Germany) was used. To visualize idarubicin and 
mTHPP uptake, a MWG2 filter (excitation wavelength: 510-550 nm, emission wavelength: > 
590 nm, Olympus) was used, whereas nuclei stained with DAPI were detected using a MNU2 
filter (excitation wavelength: 360-370 nm, emission wavelength: > 420 nm, Olympus).  
For CLSM analysis of PLGA-IDA NP-loaded T lymphocytes, cells were first fixed as previously 
described and then stained for 20 min at 37 °C with a membrane dye (5 µL/mL of Vybrant DiO 
cell-labeling solution (1 mM), Life Technologies). Embedded cells were analyzed with a ZEISS 
LSM 510 META confocal laser scanning microscope (Carl Zeiss, Jena, Germany) equipped with 
a helium-neon laser with an excitation wavelength of 543 nm and a 560 nm long pass filter for 
detection of internalized idarubicin. Cell membranes stained with DiO were visualized using an 
argon-ion laser with an excitation wavelength of 488 nm and a 500-530 nm band pass filter, 
while a pulsed NIR laser (Chameleon-XR, Coherent, Dieburg, Germany) with an excitation 
wavelength of 720 nm (2  360 nm) and a 390-465 nm band pass filter served to detect DAPI 
stained nuclear DNA using two-photon excitation microscopy. 
To visualize photosensitizer transfer from loaded T lymphocytes to co-cultivated cancer cells, 
40,000 SKOV-3 ovary carcinoma cells were seeded in a µClear black 96-well plate (Greiner Bio-
One, Frickenhausen, Germany), before PSS/mTHPP-loaded T cells were added to the tumor cells 
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in a ratio of 4:1. After a co-cultivation period of 27.5 h, cells were stained for 30 min with 
5 µg/mL Hoechst 33342 (10 mg/mL solution in water, Life Technologies). Then, co-cultures 
were washed three times with cell culture medium to remove excess T cells. Subsequently, live 
cell fluorescence microscopy was performed using an inverted Olympus IX71 microscope 
equipped with an F-View II camera (Olympus) as described above. 
 
3.3.9 Analysis of cell survival 
Survival of NP- and PS-complex-loaded T lymphocytes was determined using colorimetric XTT 
and WST-1 cell viability assays. For both tests, 2.5×105 loaded T cells resuspended in RPMI 
1640 medium w/o phenol red supplemented with 10% FBS, and antibiotics were transferred in 
triplicates to 96-well plates. Unloaded T cells were used as negative control, whereas 
T lymphocytes treated with Triton X-100 (Merck, Darmstadt, Germany) served as positive con-
trol. Blanks containing only medium and assay components were included, too. All samples were 
incubated unless otherwise specified at 37 °C until XTT (Sigma-Aldrich) and WST-1 (Roche 
Applied Science, Mannheim, Germany) assays were conducted according to the protocols pro-
vided by the manufacturers. XTT assays were started 6 h before the time points indicated by mix-
ing 100 µL T cell culture with 20 µL reconstituted XTT reagent, while for the WST-1 assay 
100 µL T cell culture were incubated for 1 h with 10 µL WST-1 solution. To analyze the viability 
of PSS/mTHPP-loaded T cells, part of the cultures was irradiated at the time points indicated for 
2 min with a tungsten halogen light (Haloline Eco, 400 W, 9000 lm, OSRAM, Muenchen, Ger-
many) which corresponds to a light dose (fluence) of 2.8 J/cm2 (300-780 nm), whereas the re-
maining samples were kept in the dark. For absorbance measurements, a Spectra Rainbow Ther-
mo microplate reader equipped with the Magellan software (Tecan, Crailsheim, Germany) was 
utilized. The measurement and reference wavelengths used were 450 and 690 nm, respectively. 
After subtracting the blanks all viability data obtained were normalized to the viability of the 
negative controls which were set to 100%. 
To analyze cancer cell survival in irradiated co-cultures of PSS/mTHPP-loaded T lymphocytes 
and SKOV-3 ovary carcinoma cells, triplicates of 40,000 tumor cells were seeded in 96-well 
plates. Upon addition of different quantities of unloaded and PS-complex-loaded T cells, the 
samples were further incubated at 37°C/5% CO2. In addition, positive (1% TX-100) and negative 
controls (untreated cancer cells) and blanks containing only loaded or unloaded T cells were pre-
pared. To activate the photosensitizer, part of the co-cultures was illuminated after 16 and 20 h 
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for 2 min with a tungsten halogen light as specified above. After a total co-cultivation time of 
23.5 h, all cultures were incubated for 30 min with WST-1 reagent (Roche Applied Science), 
before absorbance were measured at 450 nm as described in the previous section. For data analy-
sis, first T cells blanks were subtracted. Then, all viability data obtained were normalized to the 
viability of untreated SKOV-3 cells which was set to 100%. In summary, cancer cell survival in 
the individual co-cultures was calculated using the following equation: 
 
% Cancer cell survival = 100 × 
ሺA of co-culturesሻ	- (A of T cells alone)
(A of cancer cells alone)
 
 
(A = mean absorbance of samples – mean absorbance of background controls) 
 
 
3.4 Results 
Results described in section 3.4.1 and shown in Figure 3.1 as well as Fig. 3.4A, and Table 3.1 
were not obtained by the author of this thesis. 
 
3.4.1 Synthesis and characterization of MPE-IDA and PLGA-IDA nanoparticles 
In order to evaluate whether encapsulation of highly toxic antineoplastic agents in polymeric na-
noparticles prevents cellular drug carriers from premature cell death, a novel amphiphilic polyes-
ter composed of a hydrophilic monomer (diethylene glycol), a hydrophobic monomer (dimethyl 
sebacate), and dimethyl maleate units was synthesized by melt condensation. 
Poly(diethylene glycol-maleate-co-sebacate) ester (referred to as MPE, chemical structure depict-
ed in Fig. 3.1A) has a melting point of 29°C and a molecular weight of 16,000 g/mol determined 
by DSC and GPC, respectively (M. Schnabel, personal communication). While the double bonds 
provided by the maleate units allow functionalization, the specific combination of the hydrophilic 
and hydrophobic component enables encapsulation of selected pharmaceuticals. 
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Figure 3.1. Nanoparticle characterization. (A) Chemical structure of poly(diethylene glycol-maleate-co-
sebacate) ester used for preparation of MPE-IDA NPs by an emulsification-solvent evaporation-based technique. (B) 
Scanning probe microscopy (SPM) images of PLGA-IDA and MPE-IDA nanoparticles. (C) Drug release profiles of 
PLGA-IDA and MPE-IDA NPs in PBS buffer (pH 7.4), n = 3. 
 
In the present study, MPE was used to encapsulate the hydrophobic anthracycline idarubicin 
(IDA) serving simultaneously as active drug and fluorescent probe. In addition, reference nano-
particles (NPs) composed of IDA and the well-known biocompatible polyester poly(lactic-co-
glycolic-acid) (PLGA) were synthesized. Using the emulsification-solvent evaporation technique 
almost spherical PLGA-IDA and MPE-IDA nanoparticles were obtained as shown by scanning 
probe microscopy (SPM) (Fig. 1B). The average particle diameter ranged between 216 nm 
(PLGA-IDA NPs) and 227 nm (MPE-IDA NPs), with the PLGA-IDA preparation exhibiting a 
better size distribution (PDI, Table 3.1). In terms of encapsulation efficiency (EE) and drug load-
ing PLGA-IDA NPs (EE = 92.6%, drug loading = 2.26%) were also slightly superior to MPE-
IDA particles (EE = 81.4%, drug loading = 1.97%). 
 
Table 3.1. 
Physicochemical characteristics of PLGA-IDA and  
MPE-IDA nanoparticles (n = 2) 
PLGA-IDA MPE-IDA 
Size [nm] 
PDI 
Zeta potential [mV] 
EE [%] 
Drug loading [%] 
215.8 ± 9.6 
0.067 ± 0.001 
-20.57 ± 0.76 
92.6 ± 0.2 
2.26 
226.8 ± 7.1 
0.116 ± 0.001 
-1.88 ± 0.28 
81.4 ± 1.34 
1.97 
 
Abbreviations: PDI, polydispersity index; EE, encapsulation  
efficiency 
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However, MPE-IDA NPs displayed better drug release kinetics at physiological pH. While in 
PBS buffer (pH 7.4) PLGA-IDA NPs lost almost 50% of the encapsulated drug within the first 
48 h, MPE-IDA NPs showed only a minimal burst release of about 15% within 24 hours 
(Fig. 1C). Consequently, MPE-IDA nanoparticles should be better suited than the reference NPs 
to protect loaded cells against the toxic effect of encapsulated idarubicin. 
 
3.4.2 Uptake of PLGA- and MPE-encapsulated idarubicin by ex vivo activated human 
T lymphocytes 
To evaluate whether the newly prepared idarubicin loaded polyester NPs can serve as drug pay-
load in cell-mediated drug delivery, particle uptake by ex vivo activated, polyclonal human 
T lymphocytes was studied. In contrast to other carrier cells polyclonal T cells, possess a natural 
cytotoxic activity which can be exploited in combination with the delivered drug [12]. However, to 
take advantage of the natural cytotoxicity of polyclonal T lymphocytes, it is required to activate 
and expand those cells ex vivo. In this study, naïve/memory T cells isolated from the blood of 
healthy donors were incubated with anti-CD3, -CD28 and -CD2 antibodies coupled to magnetic 
beads in order to obtain the required amounts of activated cells. After an activation-expansion 
period of 4-6 days, drug-loaded T lymphocytes were prepared. To this end, 2.5×106 cells/mL 
were incubated at 37 °C for a total period of 4 h with different amounts of MPE-IDA and PLGA-
IDA reference NPs. At the time points indicated, incorporation of the red fluorescent drug was 
examined using both flow cytometry and fluorescence microscopy. 
When nanoparticle treated T cells were analyzed by flow cytometry, a significant dose- and time-
dependent increase of fluorescence intensities was observed strongly suggesting that drug uptake 
occurred. Interestingly, T lymphocytes incubated with MPE-IDA NPs (Fig. 3.2B) produced 
weaker fluorescence signals than reference NP-loaded cells (Fig. 3.2A) indicating that MPE-
encapsulated IDA was less efficiently internalized than the PLGA-enclosed drug. Furthermore, 
signals began to plateau after 2 h irrespective of the particle type and amount used. 
When PLGA- and MPE-IDA NP-loaded T lymphocytes were analyzed by fluorescence micros-
copy, drug uptake could be confirmed (Fig. 3.2C and 3.2D). To study IDA incorporation in more 
detail, T cells loaded with PLGA-IDA NPs were stained with the membrane dye DiO and addi-
tionally characterized by confocal laser scanning microscopy. The CLSM image displayed in 
Fig. 3.2E clearly shows that PLGA-encapsulated idarubicin was internalized by the cells. Fur-
thermore, a strong accumulation of the red fluorescent drug in the cytoplasm could be recog-
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nized, whereas only little idarubicin was detected in the nuclei. Taken together, intracellular up-
take of polyester-enclosed idarubicin by ex vivo stimulated T lymphocytes could be demonstrat-
ed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2. Uptake of PLGA- and MPE-encapsulated idarubicin (IDA) by activated, polyclonal human T lymphocytes. 
Drug incorporation was examined by flow cytometry (A, B). In each panel, one of two independently performed 
experiments is exemplarily shown. T lymphocytes loaded for 2 h with 4 µg/mL PLGA- and MPE-encapsulated IDA 
(red fluorescence) were additionally analyzed by fluorescence microscopy (C, D). The nuclear DNA of fixed and 
embedded cells was stained with DAPI (blue fluorescence). Overlay images of fluorescence and bright field images 
are shown. (E) Confocal laser scanning microscopy of T lymphocytes loaded for 2 h with PLGA-IDA NPs (4 µg/mL 
IDA). Cell membranes were detected using DiO (green fluorescence), whereas nuclei were stained with DAPI.  
 
3.4.3 Survival of PLGA-IDA and MPE-IDA NP-loaded T lymphocytes 
To examine whether polymeric drug encapsulations prevent loaded T lymphocytes from prema-
ture cell death, the viability of unloaded and loaded T cells was compared over a total period of 3 
days. To prepare loaded cells, ex vivo stimulated T lymphocytes were incubated for 2 h with 0.04, 
0.4 and 4 µg/mL PLGA- and MPE-encapsulated idarubicin. Upon three washing steps, the lym-
phocytes were put back into culture, before a colorimetric XTT cell viability assay was per-
formed at the time points indicated. To exclude toxic effects of the polymeric drug encapsula-
tions, T cells incubated with empty PLGA and MPE particles were analyzed too, whereas 
T lymphocytes exposed to 4 µg/mL free idarubicin served as positive control. 
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Figure 3.3A reveals that irrespective of the particle concentration used PLGA-IDA NPs were as 
toxic for activated T cells as 4 µg/mL free idarubicin. Already after 8 h NP-loaded T cells 
showed a clearly reduced viability which further declined to an average value of 12.5% after 
24 h. In contrast, the viability of T lymphocytes exposed to empty PLGA nanoparticles was not 
impaired. When T cells were incubated with 0.4 and 4 µg/mL MPE-encapsulated IDA, a dra-
matic loss of cell viability within 24 h was detected as well (Fig. 3.3B). However, in the presence 
of 0.04 µg/mL nanoparticle-enclosed drug a delayed decrease of T cell viability was observed. At 
the lowest IDA concentration, it took 52 h until the minimum viability rate was reached, and only 
12.5% viable T lymphocytes were left. Though, a significant protective effect of the maleate pol-
yester-based drug encapsulation cannot be deduced from this result, since MPE-encapsulated 
IDA was less efficiently internalized by activated T cells than PLGA-enclosed IDA as shown in 
Figure 3.2. Rather it appears that both particle preparations released the drug too early to prevent 
premature death of NP-loaded T lymphocytes. 
 
 
 
 
 
 
 
 
 
Fig. 3.3. Survival of PLGA-IDA (A) and MPE-IDA (B) NP-loaded T lymphocytes. After incubation with different 
amounts of PLGA- and MPE-encapsulated idarubicin, T cell viability was analyzed using a XTT colorimetric assay. 
T lymphocytes loaded with empty particles and free idarubicin served as negative and positive control, respectively. 
All viability data obtained were normalized to the viability of unloaded T cells. Results are expressed as means of 
two independent experiments with standard deviations (SD) indicated. 
 
3.4.4 Uptake and cytotoxicity of gold-coated MPE-IDA nanoparticles 
Coating of doxorubicin-loaded PLGA NPs with a gold layer enables NIR irradiation-dependent 
controlled drug release as demonstrated in several comprehensive studies [253, 254]. To verify in 
this work whether an additional gold layer would reduce premature drug release from idarubicin-
loaded polymeric nanoparticles, and thus, extend the life span of particle-loaded T cells, MPE-
IDA NPs were coated with a gold shell (AuSh) using a novel one-step deposition method. In par-
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allel, AuSh nanoparticles without drug payload were prepared. Both, AuSh-IDA and control NPs 
had comparable hydrodynamic diameters and zeta potentials as determined by Zetasizer Nano 
measurements (Fig. 3.4A). 
To characterize nanoparticle uptake by activated human T lymphocytes, 2.5×106 cells/mL were 
incubated at 37 °C for a total period of 3.5 h with 4 and 8 µg/mL AuSh NP-encapsulated idarubi-
cin. In addition, loading with the highest NP concentration (8 µg/mL IDA) was carried out at 
4 °C. In this way, endocytosis-mediated uptake, which only occurs at elevated temperatures could 
be distinguished from non-specific particle binding and drug diffusion processes that also may 
happen at 4 °C. When analyzed by flow-cytometry, again a dose- and time-dependent increase of 
fluorescence intensities could be observed (Fig. 3.4B). Moreover, the fluorescence intensities of 
the 37 °C samples were significantly higher than the 4 °C values; thus, particle uptake most prob-
ably occurred. The low GeoMean values, however, suggest that only small quantities of AuSh-
IDA NPs were incorporated by the lymphocytes. As for non-AuSh NPs, the highest uptake was 
reached after 2 h. Thereafter, fluorescence intensities of analyzed cells decreased. 
For analysis of cell viability, T lymphocytes were incubated for 48 h with different amounts of 
AuSh-IDA and control AuSh NPs. Since the gold coated particles did not remain in the superna-
tant during centrifugation, washing was omitted here. At the time points indicated, a colorimetric 
WST-1 cell viability assay was performed. Although only small amounts of IDA containing NPs 
(0.4 and 0.8 µg/mL IDA) were used for loading, strong toxic effects on T cells were detected 
(Fig. 3.4C). Within 24 h, viability rates declined to 20-30% and reached 13% after 48 h. At long-
er incubation times, the survival of control particle-loaded T lymphocytes was impaired as well. 
Since toxic effects of the new maleate-based polyester could be excluded (compare Fig. 3.3B), 
the observed loss of T cell viability was most probably due to the additional gold coating. But 
regardless of any possible negative impact of gold shells on T lymphocytes, no significant protec-
tive effect of the additional drug encapsulation could be determined. 
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 AuSh-IDA NPs AuSh NPs 
Size [nm] 234.2  1.9 231.1  0.8 
Zeta potential [mV] -16.8  0.71 -15.3  0.70 
 
 
 
 
 
 
 
 
 
Fig. 3.4. Intracellular uptake and protective effect of AuSh-IDA nanoparticles. (A) Average hydrodynamic diameter 
and zeta potential of newly prepared gold shell-coated MPE-IDA nanoparticles (AuSh-IDA NPs) and AuSh-coated 
MPE NPs without drug content (AuSh NPs), n = 2. (B) Particle uptake by ex vivo activated human T lymphocytes 
was studied at 37 and 4 °C by flow cytometry. (C) Survival of particle-loaded T cells was determined using a WST-1 
colorimetric assay. Results represent the means of two independent experiments  SD. TX-100: Triton X-100 (posi-
tive control). 
 
3.4.5 Intracellular uptake of the polymer-photosensitizer complex PSS/mTHPP 
Given the strong toxic effect of polyester-IDA and AuSh-IDA nanoparticles on activated human 
T lymphocytes, a change in strategy was necessary to protect the cells more effectively against 
delivered anticancer drugs. In the treatment of many tumors light-inducible drugs such as Photo-
frin or Foscan have become an attractive alternative to conventional chemotherapeutic agents. 
While in the dark light-sensitive therapeutics do not affect cell viability, strong cytotoxic effects 
can be observed if treated cells are exposed to light [165]. Recently, preparation of a water-soluble 
poly(styrene sulfonate) (PSS)-complex of the hydrophobic photosensitizer 5,10,15,20-tetrakis(3-
hydroxyphenyl)porphyrin (mTHPP) was described [193]. Although red light-activated mTHPP is 
less cytotoxic than its approved derivative Foscan [192], the precursor has been frequently applied 
as model photosensitizer (PS) in basic research on photodynamic therapy (PDT) [153]. In the pre-
sent study, PSS/mTHPP was used exemplarily in order to evaluate whether polymeric photosen-
sitizer preparations are suitable drug formulations for cell-mediated drug delivery. 
For analysis of intracellular uptake, ex vivo activated human T lymphocytes were incubated in the 
dark for a total period of 8 h with 1 and 10 µg/mL PSS-complexed mTHPP. To distinguish spe-
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cific energy-dependent drug uptake from unspecific drug binding and diffusion processes, only 
half of the samples were kept at 37 °C, while the other part was incubated at 4 °C. The flow-
cytometer analysis shown in Figure 3.5A reveals a clear time- and concentration-dependent in-
crease of fluorescence intensities at both incubation temperatures. Moreover, the values measured 
at 4 °C were well below the values of the 37 °C samples strongly suggesting that activated T cells 
internalized the red fluorescent drug at elevated temperatures with energy-dependent processes 
being the basis of the uptake mechanism. To confirm drug incorporation, T cells incubated for 
2 h with 10 µg/mL complexed mTHPP were additionally studied by fluorescence microscopy 
(Fig. 3.5B). The strong photosensitizer signal detected in the cytoplasm of formaldehyde-fixed 
cells supports the findings of the flow cytometer analysis. Thus, intracellular photosensitizer up-
take by PSS/mTHPP-incubated T lymphocytes could be demonstrated. 
 
 
 
 
 
 
 
 
 
Fig. 3.5. Uptake studies with the water-soluble polymer-photosensitizer complex PSS/mTHPP. Internalization of 
mTHPP (red fluorescence) by ex vivo activated human T cells was detected using flow cytometry (A) and fluores-
cence microscopy (B). Nuclei were stained with DAPI (blue fluorescence). In the lower image a magnified area of 
the upper image is shown. (C) Survival of PSS/mTHPP-loaded T lymphocytes was analyzed using a WST-1 cell 
viability assay. Both, non-illuminated (- light) and illuminated cells (+ light) were examined. All viability data ob-
tained were normalized to the viability of non-illuminated, unloaded T cells. Data represent the means of at least two 
independent experiments  SD. TX-100: Triton X-100 (positive control). 
 
3.4.6 Viability of PSS/mTHPP-loaded T cells before and after illumination 
In the next experiment, both dark toxicity and phototoxic effect of the incorporated photosensi-
tizer were evaluated. To prepare PS-loaded cells, T lymphocytes were again incubated for 2 h in 
the dark with 10 µg/mL complexed mTHPP or treated with the appropriate amount of sterile pu-
rified water (control). Thereafter, T cells were transferred to fresh culture medium and further 
cultivated at 37 °C. At two different time points, either 2 or 72 h upon loading, the photosensitiz-
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er was stimulated in a portion of the cultures using a tungsten halogen light which was set to de-
liver a 2-minute light pulse of 2.8 J/cm2 (300-780 nm). 18-24 h upon illumination, the viability of 
irradiated and non-irradiated T cells was analyzed using a WST-1 assay. 
Although in the 72 h approach T lymphocytes were exposed to the photosensitizing agent for up 
to 96 h, no toxic effects could be detected if the loaded cells were kept in the dark (Fig. 3.5C). 
Thus, at a loading concentration of 10 µg/mL PSS-complexed mTHPP, no dark toxicity occurred 
during 4 days. However, upon irradiation, PS-loaded T lymphocytes were efficiently killed, irre-
spective of the time of light exposure. The irradiation itself had no negative effect on the lympho-
cytes, since illuminated, empty cells were not affected. Taken together, by loading T lymphocytes 
with a polymer formulation of a light-inducible anticancer agent, T cell survival and drug effect 
could be precisely controlled.  
 
3.4.7 Transfer and phototoxic effect of T cell-delivered mTHPP 
To characterize PSS/mTHPP-loaded T cells in more detail, first drug transfer from 
T lymphocytes to co-cultivated SKOV-3 ovary carcinoma cells was analyzed. In order to obtain 
strong fluorescence signals, the loading concentration was increased to 45 µg/mL. Furthermore, 
an incubation period of 3 h was chosen. Upon loading, T cells were washed three times with cul-
ture medium to remove non-internalized polymer-PS complex. Then, T lymphocytes were added 
to confluent SKOV-3 cells in a ratio of 4:1. After a co-cultivation period of 27.5 h, first the nu-
clear DNA was stained, before live cell microscopy was performed to visualize the distribution of 
the red fluorescent drug. Within the specified period of time, considerable amounts of mTHPP 
were transferred from loaded T lymphocytes to co-cultivated SKOV-3 cells as displayed in Fig-
ure 3.6A. Interestingly, the transferred photosensitizer was not equally distributed within tumor 
cells. As the images show, accumulation of the drug in the perinuclear region of SKOV-3 cells 
could be recognized. PS-uptake by tumor cells upon co-cultivation with PSS/mTHPP-loaded 
T lymphocytes was confirmed by flow cytometric analysis. In the 25-hour experiment shown in 
Figure S3.1 only SKOV-3 cells co-cultured with loaded T cells produced detectable fluorescence 
signals, whereas incubation with empty T lymphocytes did not result in an increase in fluores-
cence. 
Finally, co-cultures of complex-loaded T lymphocytes and SKOV-3 cells were utilized to evalu-
ate the phototoxic effect of T cell-delivered mTHPP on tumor cells. To prepare co-cultures, 
T lymphocytes were again loaded for 3 h with 45 µg/mL PSS-complexed mTHPP and, after ex-
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tensive washing, added in three different ratios (1:1, 2:1 and 4:1) to SKOV-3 ovary carcinoma 
cells. As a control, tumor cells were also incubated with unloaded T cells. Moreover, blanks con-
taining only loaded or unloaded T lymphocytes were prepared. To trigger the drug effect, a por-
tion of the cultures was exposed twice to a 2-minute light pulse (after 16 and 20 h), while the 
remaining samples were constantly kept in the dark. After a total co-cultivation period of 24 h, a 
WST-1 assay was performed. 
In the samples containing only T lymphocytes (= blanks), very low viability values were meas-
ured (compare Fig. S3.2). Thus, in the determination of cancer cell survival the T cell contribu-
tion to total viabilities could be neglected. However, in order to determine specifically SKOV-3 
survival, first T cell blanks were subtracted from the measured overall viabilities, before in a sec-
ond step all viability data obtained were related to the viability of untreated SKOV-3 cells which 
was set to 100%. Fig. 3.6B reveals that in co-cultures of SKOV-3 cells and PSS/mTHPP-loaded 
T lymphocytes cancer cell viability decreased significantly if samples were exposed to light. Fur-
thermore, the strength of the phototoxic effect was dependent on the amount of loaded T cells 
used. In contrast, the viability of non-illuminated, drug-containing cancer cells was not affected 
indicating that in the dark the transferred photosensitizer was not cytotoxic. Similarly, tumor cells 
co-cultivated with empty T cells (control) were not impaired by light. Thus, a specific phototoxic 
effect of T cell-delivered mTHPP on co-cultivated tumor cells could be demonstrated. 
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3.5 Discussion 
Living cells can be utilized to transport therapeutics to diseased sites as demonstrated in various 
pre-clinical studies [12, 13]. However, severe adverse effects of anticancer agents on carrier cells 
have prevented the use of cellular drug vehicles in cancer therapy until now. To preserve viability 
and physiological functions of carrier cells, several strategies including encapsulation of active 
drugs in protective nanoparticles or the use of inducible therapeutics have been proposed [12]. The 
present study aimed to identify anticancer drug formulations which do not impair the viability of 
human T lymphocytes thus allowing the use of drug-loaded T cells for treating cancer. To ensure 
T cell survival, novel polymeric nanoparticles (NPs) loaded with an active chemotherapeutic 
agent and a polymer-complex of a stimulus-sensitive drug were tested. 
For the first approach, a specific biocompatible polyester composed of diethylene glycol, dime-
thyl maleate and dimethyl sebacate monomers (maleate-based polyester, MPE) was synthesized 
to encapsulate the hydrophobic anthracycline idarubicin (IDA). In a physiological buffer MPE-
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Fig. 3.6. Photosensitizer transfer from loaded 
T lymphocytes to co-cultivated cancer cells and 
phototoxic effect of T cell-delivered mTHPP. (A) 
mTHPP-transfer (red fluorescence) from loaded 
T lymphocytes () to co-cultivated SKOV-3 ovary 
carcinoma cells () was visualized after 28 hours by 
live cell fluorescence microscopy. Nuclei were 
stained with Hoechst 33342 (in blue). Left panel: 
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16 and 20 h) or not illuminated at all (dark controls). 
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IDA nanoparticles displayed a minimal burst release of 15%, whereas reference NPs consisting 
of poly(lactic-co-glycolic-acid) (PLGA) and IDA lost half of the encapsulated drug, suggesting 
that MPE-IDA NPs were less leaky than PLGA-IDA NPs, and therefore, better suited to protect 
loaded T lymphocytes from the toxic effect of delivered IDA. 
For the examination of particle uptake ex vivo activated, polyclonal human donor T lymphocytes 
were incubated with different concentrations of PLGA- and MPE-encapsulated IDA and subse-
quently analyzed by flow cytometry and fluorescence microscopy. Both techniques revealed effi-
cient incorporation of the red fluorescent drug. However, irrespective of the particle type used the 
viability of loaded T cells substantially declined as determined by a standard cell viability assay. 
Thus, the polymeric drug encapsulations specifically prepared in this study did not exert a signif-
icant protective effect on loaded T lymphocytes. The observed decrease in T cell viability rather 
suggests that upon contact with T lymphocytes idarubicin was rapidly released from both nano-
particle preparations. Whether premature drug release from polyester-IDA NPs occurred early 
during the uptake process or after particle internalization cannot be decided on the basis of the 
experiments performed. 
In order to protect loaded T lymphocytes more effectively from the toxic effect of encapsulated 
idarubicin, MPE-IDA nanoparticles were subsequently coated with a gold shell (AuSh) using a 
simple one-step deposition method. As shown in a parallel study, AuSh-IDA NPs containing an 
additional magnetite core were internalized well by human CaCo-2 colon carcinoma cells. 
48 hours upon loading, only a slight cytotoxic effect (10%) was detected which was attributed to 
minor drug amounts released from a small fraction of non- or partially gold-coated nanoparticles 
(Schneider, personal communication). When in this study, activated human T lymphocytes were 
loaded with AuSh-IDA NPs without magnetite core, strong toxic effects were observed. Further-
more, the gold layer itself seemed to impair T cell viability. Thus, in contrast to CaCo-2 cells, 
which were only slightly affected by comparable particles, T cells did not tolerate the gold-coated 
MPE-IDA NPs specifically prepared for this work. Primary human T lymphocytes are, therefore, 
either more sensitive to idarubicin than CaCo-2 cells, or the proportion of non- and incompletely 
coated AuSh NPs was higher in this work than in the study conducted in parallel. 
In accordance with our results, the viability of Jurkat T cells loaded with magnetite-starch-
doxorubicin NPs was severely impaired [101]. Similarly, uptake of liposome-encapsulated doxoru-
bicin had a negative impact on the survival of murine peritoneal macrophages [74]. Others, who 
studied immune cell-mediated transport of liposomal drug formulations did not analyze cell via-
3. T CELL INTERACTIONS WITH POLYMERIC IDA-NPs AND PHOTOSENSITIZER 
 
74 
bility [72] or showed only short-term survival data [74]. Even though therapeutic effects of defense 
cells loaded with free or encapsulated anticancer drugs were detected in tumor-bearing mice [6, 72, 
74, 82], long-term survival of loaded carrier cells could not be demonstrated until now. Probably for 
this reason, clinical data are still missing. To test anticancer drug-loaded immune cells on human 
patients, cell viability and physiological functions need to be preserved. Research in this area, 
therefore, should focus on developing improved encapsulation strategies. Coating of polymeric 
NPs with a gold layer might help to reduce or even prevent premature drug release. Moreover, 
due to surface plasmon resonance in the near infrared AuSh NPs allow triggered release of en-
closed pharmaceuticals [254]. Therefore, the AuSh-IDA nanoparticles presented in this work 
should be specifically optimized for use on primary human T lymphocytes. 
In addition to improved encapsulation strategies for active drugs, stimulus-sensitive pharmaceuti-
cals could help to ensure survival of cellular drug vehicles. Therefore, a recently developed hy-
drophilic polymer-formulation of the model photosensitizer (PS) 5,10,15,20-tetrakis(3-
hydroxyphenyl)porphyrin (mTHPP) was included in the present study [193]. Like its clinically 
approved derivative 5,10,15,20-tetrakis(3-hydroxyphenyl) chlorin (mTHPC, the active pharma-
ceutical ingredient of Foscan), mTHPP shows virtually no dark toxicity. However, upon photo-
activation, the precursor generates reactive oxygen species (ROS) which can destroy cells and 
tissues [192]. While mTHPP has been used in many basic studies [153], mTHPC is clinically applied 
in photodynamic therapies (PDT) to treat malignancies such as head and neck, lung, and skin 
cancer [165]. 
In the present work, uptake of a water-soluble poly(styrene sulfonate) (PSS)-complex of mTHPP 
by activated polyclonal human T lymphocytes was demonstrated using flow cytometry and fluo-
rescence microscopy. In contrast to polyester-IDA NP-loaded T cells, lymphocytes incubated 
with PSS/mTHPP survived for at least 4 days if the cells were cultivated in the dark. However, 
immediate or time-delayed irradiation with a tungsten halogen light induced massive cell death. 
Thus, PSS/mTHPP-loaded T lymphocytes were protected against their toxic payload, until the 
drug effect was specifically activated. 
Using live cell fluorescence microscopy, PS-transfer from loaded T lymphocytes to co-cultivated 
SKOV-3 ovary carcinoma cells could be demonstrated. Upon transfer, the red fluorescent drug 
accumulated in the perinuclear region which is consistent with findings of Teiten and colleagues 
who localized Foscan specifically in the endoplasmic reticulum and Golgi apparatus of MCF-7 
breast cancer cells [255]. Furthermore, by illuminating co-cultures of complex-loaded T cells and 
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SKOV-3 cells, a specific phototoxic effect of T cell-delivered mTHPP on co-cultivated tumor 
cells could be detected. In view of these promising initial results, more detailed studies on 
PSS/mTHPP-loaded T lymphocytes need to follow. 
In 1994, a work about photosensitizer- and methotrexate-loaded rabbit erythrocytes was pub-
lished. Light-activated release of the chemotherapeutic agent as well as a combined chemo-
phototherapy effect on co-cultivated HeLa cells was observed [47]. Despite these promising in 
vitro results, the erythrocyte-based drug delivery system was not further developed, possibly be-
cause red blood cells do not possess any targeting capabilities. In contrast, polyclonal 
T lymphocytes can be redirected to various tumors either using a bispecific antibody (bsAb) as 
retargeting device or by genetic engineering yielding chimeric antigen receptor (CAR)-
expressing T cells [7, 256]. CAR- or bsAb-mediated binding of activated, polyclonal T cells to tar-
get cells stimulates the cytolytic activity of cytotoxic T lymphocytes. Consequently, in a cancer 
immunotherapy involving redirected, photosensitizer-loaded T cells the carrier cells would first 
exert their natural killing function, before the tumor is irradiated to activate the delivered drug. 
Thus, tumors would be eliminated through the consecutive action of redirected, cytotoxic 
T lymphocytes and a cell-delivered, light-activated photosensitizing agent. The cytotoxic T cell 
effect that can be exploited using a retargeting strategy makes polyclonal T lymphocytes superior 
to erythrocytes and other cells serving merely as drug carriers. Most importantly, by loading 
T cells with a light-inducible agent, we have found a way to preserve T cell viability. 
Hence, polymeric photosensitizer formulations such as PSS/mTHPP might help to overcome the 
drawbacks of existing cellular delivery systems for anticancer drugs. At the same time redirected, 
PS-loaded T lymphocytes open up new perspectives in the area of T cell therapy. Furthermore, 
the selectivity of photodynamic therapy (PDT) could be improved by using living cells as 
transport vehicles for photosensitizing agents. 
 
 
3.6 Conclusions 
Neither polyester-based polymeric drug encapsulations nor gold shell-coated polyester nanoparti-
cles were able to protect activated human T lymphocytes from the toxic effect of the active 
chemotherapeutic agent idarubicin. In contrast, uptake of the polymer-photosensitizer complex 
PSS/mTHPP did not impair T cell viability as long as the cells were kept in the dark. However, 
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upon exposure to light PSS/mTHPP-loaded T lymphocytes as well as co-cultivated cancer cells 
was efficiently killed. Thus, by loading living cells with a polymeric formulation of a light-
inducible anticancer drug, we provide a promising new way to prevent premature death of carrier 
cells, which has been a main drawback of cell-mediated drug delivery until now. 
 
 
3.7 Supplementary Information 
3.7.1 Analysis of PS-transfer from T cells to cancer cells by flow cytometry 
SKOV-3 ovary carcinoma cells resuspended in RPMI 1640 medium w/o phenol red supplement-
ed with 10% FBS and antibiotics were seeded in 24-well cell culture plates and allowed to adhere 
for at least 3 h. Then, SKOV-3 cells were treated in triplicate with PSS/mTHPP-loaded T cells 
(45 µg/mL, 3 h) at an T cell-to-cancer cell (T:C) ratio of 2:1 and 4:1. As control, cancer cells 
were also treated with medium and unloaded (empty) T cells (T:C = 4:1). Co-cultures were incu-
bated for 25 h at 37°C/5% CO2, before cells were rinsed three times with PBS. Subsequently, 
cells were detached using 0.05% trypsin/0.02% EDTA (PAN Biotech) and resuspended in ice-
cold FCM buffer (Miltenyi Biotec). To label the T cell population, a fluorescein-isothiocyanate 
(FITC)-conjugated anti-CD3 antibody (0.1 mg/ml, Bio-Rad AbD Serotec, Puchheim, Germany) 
was added to all samples. After 30 min at room temperature, cells were analyzed in a FACS Cali-
bur flow-cytometer (BD Biosciences). 10,000 events were acquired using the CellQuest Pro 
software (BD Biosciences). First, the bulk of T cells were excluded by gating SKOV-3 cells in a 
FSC-SSC dot plot. Then, remaining green fluorescent T lymphocytes were removed from analy-
sis by a second gating of only cancer cells in a FSC-FL1 dot plot, before fluorescence intensities 
of gated SKOV-3 cells were determined in the FL3 channel.  
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Fig. S3.1. Flow-cytometry analysis of photosensitizer uptake by SKOV-3 ovary carcinoma cells upon co-cultivation 
with PSS/mTHPP-loaded T lymphocytes. T cell-to-cancer cell ratios in the 25-hour co-culture experiment were 2:1 
and 4:1. Fluorescence intensities of gated cancer cell populations are expressed as GeoMean of fluorescence intensi-
ty (GMFI) values ± SD. One representative experiment is shown. 
 
3.7.2 Phototoxic effect of T cell-delivered mTHPP on cancer cells 
 
 
Fig. S3.2. The viabilities of PSS/mTHPP-loaded T cells prepared as blanks for dark controls (= non-illuminated 
SKOV-3 cells) were normalized to the calculated cancer cell viabilities (compare Fig. 3.6B). Data represent the 
means of three independently performed experiments  SD. T:C ratio = T cell-to-cancer cell ratio. 
 
3.7.3 Characterization of poly(diethylene glycol-maleate-co-sebacate)ester (MPE) 
The polymer was characterized by DSC, GPC and C/H-NMR. NMR results were: 1H-NMR 
(DMSO-d6, 400 MHz): δ = 1.23 (bs, CH2-Seb), 1.49 (bs, CH2-Seb), 2.24 (t, CH2-Seb), 3.58-3.67 
(m, CH2O-DEG, OMe), 4.10 (t, CH2OCO-DEG), 4.20 (CH2OH-DEG), 6.47 (bs, C=C, Mal); 13C-
NMR (DMSO-d6, 100 MHz): δ = 24.4, 28.4, 28.5, 33.2 (CH2-Seb), 51.0 (OMe), 60.2, 62.9, 63.8 
(CH2OCO-TEG), 67.9, 68.2, 69.7, 72.2 (CH2O-TEG,), 130.1 (C=C, Mal), 164.9, 172.7 (C=O). 
GPC for molecular weight and PDI measurement: Mn = 8000, Mw = 16000 Dalton. The polydis-
persity index (PDI) of MPE was 2.1. 
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4. Detailed analysis of interactions of PSS/mTHPP with human 
T lymphocytes and bispecific antibody mediated redirection of 
PSS/mTHPP-loaded T cells to carcinoma cells 
 
Parts of this chapter were published in: 
 
Blaudszun A.-R., Moldenhauer G., Schneider M., Philippi A. (2015) 
A photosensitizer delivered by bispecific antibody retargeted human T lymphocytes enhances 
cytotoxicity against carcinoma cells upon light irradiation 
Journal of Controlled Release; 197: 58-68 
 
 
4.1 Abstract 
Recently conducted clinical trials have provided impressive evidence that chemotherapy resistant 
metastatic melanoma and several hematological malignancies can be cured using adoptive T cell 
therapy or T cell-recruiting bispecific antibodies. However, a significant fraction of patients did 
not benefit from these treatments. Here we have evaluated the feasibility of a novel combination 
therapy which aims to further enhance the killing potential of bispecific antibody-redirected 
T lymphocytes by using these cells as targeted delivery system for photosensitizing agents. For a 
first in vitro proof-of-concept study, ex vivo activated human donor T cells were loaded with a 
poly(styrene sulfonate) (PSS)-complex of the model photosensitizer 5,10,15,20-tetrakis(3-
hydroxyphenyl)porphyrin (mTHPP). 
In the absence of light and when loading with the water-soluble PSS/mTHPP-complex occurred 
at a tolerable concentration, viability and cytotoxic function of loaded T lymphocytes were not 
impaired. When “drug-enhanced” T cells were co-cultivated with EpCAM-expressing human 
carcinoma cells, mTHPP was transferred to target cells. Notably, in the presence of a bispecific 
antibody, which cross-links effector and target cells thereby inducing the cytolytic activity of 
cytotoxic T lymphocytes, significantly more photosensitizer was transferred. Consequently, upon 
irradiation of co-cultures, redirected drug-loaded T cells were more effective in killing A549 lung 
and SKOV-3 ovarian carcinoma cells than retargeted unloaded T lymphocytes. Particularly, the 
additive approach using redirected unloaded T cells in combination with appropriate amounts of 
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separately applied PSS/mTHPP was less efficient, as well. Thus, by loading T lymphocytes with 
a stimulus-sensitive anticancer drug, we were able to enhance the cytotoxic capacity of carrier 
cells. Photosensitizer boosted T cells could open new perspectives for adoptive T cell therapy as 
well as targeted photodynamic therapy. 
 
 
4.2 Introduction 
Although chemotherapy, radiation therapy and surgery are the primary modalities to treat cancer, 
limitations such as systemic toxicity and drug resistance, limited repeatability of treatments and 
inoperable tumors, respectively, have motivated investigators to seek alternative therapies. Pho-
todynamic therapy (PDT) is such an emerging treatment, in which a light-sensitive photosensitiz-
er (PS) is either topically or systemically administered. After a latency period, the malignant le-
sions are selectively irradiated with light of a specific wavelength, thereby exciting the photosen-
sitizing agent. In the presence of oxygen, activated PS-molecules generate singlet oxygen (1O2) 
and reactive oxygen species (ROS), which provoke lethal oxidative damage in aberrant cells. In 
addition, PDT also causes damage to the tumor vasculature and evokes immune responses, which 
contribute to tumor destruction as well [165, 257, 258]. However, tumor selectivity after systemic ap-
plication of classical photosensitizers is limited and healthy tissues also accumulate PS [169]. The 
general distribution of PS leads to adverse effects, like prolonged eye and skin photosensitivity. 
To circumvent these obstacles, several tumor-targeting PDT strategies are under investigation 
[170]. 
Adoptive transfer of tumor-specific T lymphocytes (ACT) is another alternative for treatment of 
cancer and has shown curative potential [1]. It has been proven to be effective in clinical trials 
with hematological malignancies (complete remissions in two of three patients [21], remissions in 
six of eight patients [22]), metastatic melanoma (durable complete responses in 20 of 93 patients 
[2]) and other types of neoplastic diseases [23]. In these trials, tumor-reactive autologous tumor-
infiltrating lymphocytes (TILs) or patient-derived genetically engineered T cells were used for 
ACT. Transduced T lymphocytes have been redirected towards tumor-associated antigens 
(TAAs) through genetic modification with T cell receptor (TCR) or chimeric antigen receptor 
(CAR) genes [24]. A different option to guide T lymphocytes to sites of malignancies is the utiliza-
tion of bispecific antibodies (bsAb). These engineered molecules possess dual specificity for two 
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different antigens. One antigen-binding site of bsAb recognizes a surface marker, such as a TAA, 
on the target cell. In T lymphocyte-based therapies, the other moiety binds specifically to a com-
ponent of CD3, a signaling complex located on the plasma membrane of T cells. At the target 
site, bsAb-molecules cross-link effector to target cells thereby inducing the cytolytic activity of 
cytotoxic T lymphocytes (CTLs) in a non-major histocompatibility complex-restricted manner [7]. 
Adoptive cell therapy with TILs has been proven successful in treatment of metastatic melanoma. 
However, long-term follow-up data revealed that not all patients could benefit from ACT (5-year 
survival rate was 29% [2]). Moreover, not all tumors generate TILs which are appropriate for ACT 
[259]. Notably, even though transduced T cells have been shown very effective against hematolog-
ical malignancies, solid tumors represent a major obstacle for successful treatments [24]. Thus, 
further improvements are necessary to increase the curative potential of ACT. 
Since immune cells possess an intrinsic homing capability and are able to migrate to sites of in-
flammation initiated by injury, infection or neoplasms, cell-mediated drug delivery has emerged 
as an alternative to classical drug delivery strategies based on artificial drug carriers [12]. Consid-
ering the tumor-specificity of redirected T lymphocytes, we propose that a targeted PTD ap-
proach involving bsAb-guided T cells as a living drug delivery system to transport photosensitiz-
ing agents to tumor sites will be promising. The concept aims at enhancing the selectivity and 
efficacy of PDT for cancer, while simultaneously reducing adverse effects. Notably, the approach 
intends to combine the phototoxicity of PS-molecules delivered by redirected CD3+CD4+ helper 
T cells and CD3+CD8+ cytotoxic T lymphocytes (drug effect) with the cytotoxicity of retargeted 
CTLs (T cell effect) in a synergistic manner (compare Fig. 4.1). 
The photosensitizer 5,10,15,20-tetrakis(3-hydroxyphenyl)-porphyrin (mTHPP) is the parent por-
phyrin of the second-generation photosensitizer mTHPC (the active pharmaceutical ingredient of 
Foscan, approved for PDT in Europe) and is often used as model PS in basic research [153]. Re-
cently, preparation of a water-soluble complex (PSS/mTHPP) composed of hydrophobic mTHPP 
and poly(styrene sulfonate) sodium salt (PSS) was reported [193]. In a previous work, we have 
shown that PSS/mTHPP is internalized and tolerated by human T lymphocytes. In addition, un-
specific mTHPP transfer from loaded T cells to SKOV-3 ovarian carcinoma cells was observed, 
which impaired cancer cell proliferation after illumination in vitro [260]. In the present study, we 
demonstrate that a PSS/mTHPP payload did not impair the cytolytic function of T cells. Moreo-
ver, the bispecific antibody HEA125×OKT3 (EpCAM×CD3 [8, 10]) was used to redirect PS-loaded 
T lymphocytes to epithelial cell adhesion molecule (EpCAM, CD326) expressing carcinoma cells 
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in vitro. We show that these retargeted photosensitizer enhanced T cells were more efficient in 
killing tumor cells than non-redirected loaded and bsAb-guided unloaded T lymphocytes. Nota-
bly, the additive approach using redirected unloaded T cells in combination with separately ap-
plied PS-complex equal to the amount of mTHPP carried by T lymphocytes was less effective, as 
well. Thus, the combined cytotoxicity of transferred drug and T cells exhibited synergistic anti-
tumor effects. Our findings support the feasibility of the envisioned T cell-based targeted PDT 
approach. 
 
 
Fig. 4.1. Schematic illustration of the proposed mode of action of the T cell-based targeted PDT approach. 
 
 
4.3 Materials and methods 
4.3.1 T cell isolation, activation and expansion 
Human T lymphocytes were prepared as previously described [231]. In brief, CD3+, CD4+ and 
CD8+ T cells were isolated from buffy coat preparations by using the respective RosetteSep Kits 
(StemCell Technologies, Grenoble, France) according to the manufacturer’s instructions. In-
formed consent for the use of buffy coats was obtained from healthy donors. After isolation, re-
maining red blood cells were lysed with 3 mL of an ammonium chloride-based lysing buffer (BD 
Pharm Lyse, BD Biosciences, Heidelberg, Germany). Enriched T lymphocytes were resuspended 
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in cell culture medium (i.e., RPMI 1640 medium (PAN Biotech, Aidenbach, Germany) contain-
ing 10% (v/v) heat-inactivated FBS (PAN Biotech), 100 U/mL penicillin and 0.1 mg/mL strep-
tomycin (Sigma-Aldrich, Steinheim, Germany)). T cells were activated using MACSiBeads func-
tionalized with antibodies against human CD2, CD3, and CD28 (MACS T Cell Activa-
tion/Expansion Kit, Miltenyi Biotec, Bergisch Gladbach, Germany) at a density of 
2.5×106 cells/mL according to the manufacturer’s instructions. Expansion of T lymphocytes was 
achieved by suspending cells in fresh cell culture medium containing 20 U/mL of recombinant 
human Interleukin-2 (IL-2, PAN Biotech) at a density of 2.5×106 cells/mL 3 days after activation. 
Five to six days after stimulation, beads were removed from cultures by density gradient centrif-
ugation using Pancoll (human, PAN Biotech) as separating solution. T lymphocytes were resus-
pended in fresh cell culture medium with 20 U/mL of IL-2 at a density of 2.5×106 cells/mL. Puri-
ty of expanded CD4+ and CD8+ T lymphocytes was determined by flow cytometry (FACSCali-
bur, BD Biosciences) using 5 µg/mL FITC-conjugated antibodies against human CD4 or CD8 
(Bio-Rad AbD Serotec, Puchheim, Germany) (see Supplementary Information, Fig. S4.1). 
 
4.3.2 Tumor cell lines 
Cells of the human lung carcinoma cell line A549 (CCL-185, American Type Culture Collection 
(ATCC), Manassas, VA, USA) and of the human ovary adenocarcinoma cell line SKOV-3 
(HTB-77, ATCC) were maintained in cell culture medium (i.e., RPMI 1640 medium (PAN Bio-
tech) containing 10% (v/v) heat-inactivated FBS (PAN Biotech), 100 U/mL penicillin and 0.1 
mg/mL streptomycin (Sigma-Aldrich) at 37 °C in a humidified atmosphere with 5% CO2. 
 
4.3.3 Fluorimetric calibration of complexed mTHPP 
Biolitec AG (Jena, Germany) kindly supplied 5,10,15,20-tetrakis(3-hydroxyphenyl)-porphyrin 
(mTHPP, MW = 678.75 g/mol). To determine mTHPP content of different PS-complex prepara-
tions a mean calibration curve derived from solutions of pure mTHPP was used (Fig. S4.2A, see 
Supplementary Information, section 4.6). To this end, triplicate split samples of mTHPP were 
dissolved in ice-cold ethyl acetate (UV/IR-grade, Carl Roth, Karlsruhe, Germany) to produce 
stock solutions with a concentration of 1 mg/mL. Serial dilutions of each split sample were pre-
pared in duplicate in a cooled black 96-well polypropylene (PP) microplate with flat bottoms 
(Greiner Bio-One, Frickenhausen, Germany). Fluorescence of 100 µL aliquots of serial mTHPP-
solutions were measured in duplicate using a Modulus Microplate Multimode Reader (Promega, 
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Mannheim, Germany). Aliquots of pure ethyl acetate served as blanks. Fluorescence intensities of 
samples were measured (red optical kit: excitation wavelength λex = 625 nm; emission wave-
lengths λem = 660-720 nm) using a Modulus Microplate Multimode Reader (Promega). 
Complexed mTHPP was kindly provided by Hagar Ibrahim Labouta (Helmholtz Institute for 
Pharmaceutical Research Saarland (HIPS), Saarland University, Germany). Split samples of 
PSS/mTHPP lyophilizate preparations with defined masses of approximately 1 mg were dis-
solved in 500 µL of purified water obtained from an Elix3 (UV) water purification system 
(Merck Millipore, Darmstadt, Germany) in silanized glass vials (Medchrom, Flörsheim-
Dalsheim, Germany). The drug was extracted by adding 400 µL of ethyl acetate to the aqueous 
phase followed by vigorous mixing. The vials were placed in tubes (50 mL, Greiner Bio-One) 
and the biphasic organic-aqueous solvent system was briefly centrifuged (1000 × g for 0.5 min, 
5810, Eppendorf, Hamburg, Germany). Afterwards the organic solvent was aspirated and extrac-
tion procedure was repeated four times. All drug containing supernatants were pooled. Extracted 
mTHPP was dried in a desiccator attached to a diaphragm pump (MZ 2C, Vacuubrand, 
Wertheim, Germany) by solvent evaporation at 20 mbar for around 3 h. Each dried PS sample 
was dissolved in a defined volume of ice-cold ethyl acetate. For each extract 1:10-dilutions were 
prepared in triplicate and the fluorescence emissions of 100 µL aliquots of dilutions were meas-
ured in triplicate (= 9 measured values per extraction-sample). Pure ethyl acetate (also in tripli-
cate) served as blanks. To calculate the total mTHPP mass of PSS/mTHPP-complex samples the 
concentration of extracted and dissolved mTHPP was determined using the calibration curve. The 
ratio of PSS/mTHPP mass per mTHPP mass obtained from two PS-complex preparations is 
shown in Fig. S4.2B & S4.2C. All PS-complex stock solutions could now be adjusted to 1 mg 
mTHPP per mL. For all experiments the concentration of mTHPP and not of PSS/mTHPP is in-
dicated. 
 
4.3.4 Preparation and handling of PSS/mTHPP-complex 
Poly(styrene sulfonate) sodium salt (PSS, MW = 4.23 kDa) was purchased from Sigma-Aldrich. 
PSS/mTHPP-complex was kindly provided by Hagar Ibrahim Labouta (Helmholtz Institute for 
Pharmaceutical Research Saarland (HIPS), Saarland University, Germany) and prepared as de-
scribed before [193]. After calibration of complex preparations, lyophilized PSS/mTHPP-complex 
was dissolved in purified water as stock solution containing 1 mg mTHPP per mL. Specified 
concentrations refer to pure mTHPP. Experiments involving PS-complex were prepared using an 
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LED light source (SBAR I, TPL Vision, La Chevrolière, France) with a peak wavelength of 
588 nm. (UV/Vis spectra of PSS/mTHPP are provided in the Supplementary Information, 
Fig. S4.3). Direct exposure to LED light was avoided. Incubations were performed protected 
from light to prevent premature activation of mTHPP at 37 °C in a humidified atmosphere con-
taining 5% CO2. 
 
4.3.5 Loading of peripheral blood CD3+, CD4+ and CD8+ T lymphocytes 
T cells were loaded with PSS/mTHPP in cell culture medium (compare section 4.3.2) at a density 
of 2.5 × 106 cells/mL. If not otherwise indicated, T lymphocytes were treated with 25 µg/mL of 
complexed mTHPP for 2 h at 37 °C/5% CO2. Cells were sedimented (300 × g and 4 °C for 10 
min, centrifuge 5810 R, Eppendorf, Germany) and washed three times with ice-cold supplement-
ed RPMI 1640 to remove non-internalized drug. T lymphocytes not immediately processed were 
stored on ice protected from light. 
 
4.3.6 Fluorimetric quantitative determination of mTHPP mass in CD3+ T lymphocytes 
2 × 107 CD3+ T cells were loaded in duplicate with PSS/mTHPP. As control 
2 × 107 T lymphocytes were also incubated in cell culture medium. Afterwards, T lymphocytes 
were washed three times as described before. Cell sediments were resuspended in 400 µl of PBS 
and cell concentration was determined using an automated cell counter (CASY Model TT, OMNI 
Life Science, Bremen, Germany). Moreover, to calculate the precise number of loaded 
T lymphocytes, the suspension volume was determined by weighing a reference sample with a 
defined volume of cell suspension. After adding 100 µL of cell culture lysis reagent (Promega) 
T cells were lysed for 30 min. Then, 400 µL of ethyl acetate was added to extract mTHPP and 
samples were vigorously mixed. The biphasic organic-aqueous solvent system was centrifuged at 
16100×g for 5 min (5415 R, Eppendorf). The ethyl actetate phase was aspirated and collected. 
Extraction procedure was repeated three times and pooled samples were vacuum dried. Extracts 
were resuspended in 1 mL of ice-cold ethyl acetate. Fluorescence intensities of samples were 
measured (red optical kit: excitation wavelength λex = 625 nm; emission wavelengths λem = 660-
720 nm) in triplicate using a Modulus Microplate Multimode Reader (Promega). Extracts ob-
tained from unloaded T lymphocytes served as blanks. A calibration curve of pure mTHPP 
(Fig. S1A, see Supplementary Information, section 4.6) was used to determine the total mass of 
PS. This value was also used to calculate the uptake efficiency. It should be noted that mTHPP of 
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T cells which had been used to determine the cell concentration after the loading process, were 
lost prior to the ethyl acetate extraction. Hence, all respective values were corrected accordingly. 
The average mass of mTHPP, taken up by a single T cell, was calculated by dividing the total 
mTHPP mass by the number of extracted cells. 
 
4.3.7 Flow cytometric analysis of mTHPP uptake by CD3+ T lymphocytes 
CD3+ T cells were loaded in duplicate for different periods with indicated concentrations of 
PSS/mTHPP at 4 °C or at 37 °C. As control, T lymphocytes were treated with an appropriate but 
small aliquot of purified water. Prior to treatment, cells were either pre-chilled or pre-warmed at 
4 °C or at 37 °C, respectively. After washing, T cells were resuspended in ice-cold flow cytome-
ter (FCM) buffer (MACS Buffer containing 2 mM EDTA and 0.5% BSA (Miltenyi Biotec) sup-
plemented with 0.1% NaN3 (Sigma-Aldrich)). Fluorescence intensities (λex = 488 nm, 
λem > 670nm) of 10,000 events were measured using a FACSCalibur cytometer (BD Biosciences, 
Heidelberg, Germany) controlled by CellQuest Pro software (BD Biosciences). Geometric means 
(GeoMean) of fluorescence intensities (GMFI) derived from gated populations were calculated 
with FlowJo software (Tree Star, Ashland, OR, USA) and normalized to the maximum GMFI. 
 
4.3.8 Fluorescence microscopy of loaded CD3+ T cells 
Nuclei of CD3+ T lymphocytes were stained in supplemented RPMI 1640 (w/o phenol red (PR), 
PAN Biotech) containing 10 µg/mL of Hoechst dye (Hoechst 33342, trihydrochloride, trihydrate, 
Life Technologies, Darmstadt, Germany) at 37 °C in the dark for 30 min. After washing, cell 
membranes were stained with fluorescein-isothiocyanate (FITC)-labeled anti-CD3-mAb 
(0.1 mg/mL, Bio-Rad AbD Serotec, Puchheim, Germany) in FCM buffer at room temperature for 
30 min. Washed T lymphocytes were resuspended in ice-cold FCM buffer. Around 3×105 cells 
per well were seeded onto black µClear 96-well microplates (Greiner Bio-One) and sedimented 
(300×g, 4 °C for 5 min) again. T cells were imaged using a digital camera (F-View II, Olympus, 
Hamburg, Germany) controlled by cellp imaging software (Olympus) and attached to an IX71 
inverted microscope (Olympus) equipped with a 60× PlanApo N oil-immersion objective (Olym-
pus; NA of 1.42). Immersion oil Immersol 518N (Carl Zeiss Microscopy GmbH, Göttingen, 
Germany) was used. Image overlays illustrating blue (Hoechst dye; λex = 360-370 nm; 
λem > 420 nm), green (anti-CD3-mAb; λex = 460-490 nm; λem = 510-550 nm), and red fluores-
cence (mTHPP; λex = 510-550 nm; λem > 590 nm) were generated via cellp imaging software. 
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4.3.9 Bispecific antibody EpCAM×CD3 
BsAb was kindly provided by Gerhard Moldenhauer (Department of Translational Immunology, 
German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany) 
and was produced as previously described [10]. A concentration of 0.1 µg bsAb/mL was used in 
all experiments. 
 
4.3.10 Flow cytometric analysis of drug transfer 
2 × 105 A549 cells resuspended in 400 µl of supplemented RPMI 1640 (w/o PR) were seeded 
onto wells of 24-well cell culture plates (Greiner Bio-One) and were allowed to adhere for at 
least 3 h. CD3+ T cells were labeled with 0.2 µM CFSE (5-(and-6)-carboxyfluorescein diacetate, 
succinimidyl ester, mixed isoforms (Life Technologies); 10 mM in DMSO (Hybri-Max grade, 
Sigma-Aldrich)). To this end, sedimented T lymphocytes were resuspended in pre-warmed phos-
phate buffered saline (PBS, Life Technologies) containing 0.2 µM CFSE and were incubated in 
the dark at 37 °C for 15 min. Afterwards, cells were centrifuged again and supernatant was dis-
carded. Then, cells were resuspended in pre-warmed supplemented RPMI 1640, incubated pro-
tected from light at 37 °C for another 30 min and washed. A549 cells were treated in duplicate 
with CFSE-labeled and loaded T cells at an effector to target cell ratio (E:T ratio) of 2:1 either 
with or without bsAb. Co-cultures were incubated for increasing periods as indicated. After each 
time point, cells were rinsed with PBS. Subsequently, cells were trypsinized (0.05% tryp-
sin/0.02% EDTA (PAN Biotech)) and after washing resuspended in ice-cold FCM buffer. Ten 
thousand events were accumulated via live gating in a predefined cancer cell gate. The bulk of 
T cells were excluded by gating A549 cells in an FSC-SSC dot plot. Remaining green fluorescent 
T lymphocytes were removed from analysis by a second gating of only cancer cells in an FSC-
FL1 dot plot. GeoMean of red fluorescence intensities (λex = 488 nm, λem > 670nm) derived from 
successively gated A549 cell populations were determined and normalized to the maximum 
GMFI. 
 
4.3.11 Fluorescence microscopic analysis of drug transfer 
Co-cultures were prepared as described in the previous section but incubated in black µClear 96-
well microplates for either 2 h or 22 h. A549 cells were also rinsed but not trypsinized. Imaging 
of cells was conducted as already described in section 4.3.8, but with one different dye (CFSE: 
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λex = 460-490 nm; λem = 510-550 nm). To compare mTHPP fluorescence intensities, cells were 
imaged using the same conditions (automatic gain disabled, exposure time = 50 ms). 
 
4.3.12 Viability assay 
CD3+ T lymphocytes were loaded with different concentrations of PSS/mTHPP up to 45 µg/mL 
for 2 h. Cells were also incubated with 0.2 mg/mL of PSS (MW = 4.23 kDa, Sigma-Aldrich). 
Upon loading and washing, cell concentration was determined and T lymphocytes were adjusted 
to a density of 2.5×106 cells/mL. Subsequently, 100 µL of cell suspensions was transferred in 
triplicate into wells of 96-well microplates (for suspension cells, Greiner Bio-One). As negative 
control or as positive control cell culture medium or a detergent (Triton X-100, 1% (v/v), Merck 
Millipore, Darmstadt, Germany) was used, respectively. To determine the bioreductive activity 
[238] of cells, WST-1 colorimetric assays (Roche, Mannheim, Germany) were performed accord-
ing to the manufacturer’s instructions. In brief, 10 µL of WST-1 reagent was added to samples 
2 h before the end of the incubation period. Background controls contained the corresponding 
medium and WST-1 reagent. Absorbance of samples was measured against background controls 
at a wavelength of 450 nm (reference: 690 nm) using an absorbance reader (Spectra Rainbow 
Thermo, Tecan, Crailsheim, Germany). Values of mean absorbance derived from negative con-
trol samples represented 100% bioreductive activity denoted as viability. 
 
4.3.13 Cytotoxicity assay 
SKOV-3 cells suspended in 50 µl of supplemented RPMI 1640 (w/o phenol red) were seeded 
onto 96-well cell culture plates (Greiner Bio-One) at a density of 40,000 cells per well. After 3 h, 
80,000 unloaded or PSS/mTHPP loaded CD3+ T lymphocytes also suspended in 50 µl of cell 
culture medium containing bsAb but devoid of PR were added in triplicate. To remove the con-
tribution of effector cells to the absorbance measured in co-cultures, wells containing only loaded 
or unloaded T cells and bsAb served as blanks (similar as shown in [261]). As positive control or as 
negative control, tumor cells were treated in triplicate with Triton X-100 (2% (v/v)) or with sup-
plemented RPMI 1640 (w/o PR), respectively. WST-1 assays were started 30 min before the end 
of indicated incubation periods. The percentage of cancer cell viability for each time point was 
calculated via the following equation: 
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   
 alone  targetsofA 
alone effectors ofA cultures-co ofA 100 viability%   
 
Where A represents the mean absorbance of samples minus the mean absorbance of background 
controls. 
 
4.3.14 Cytotoxicity assay after light irradiation 
Tumor cells were prepared as aforementioned and were treated in triplicate with bsAb and either 
unloaded CD3+ T cells, PSS/mTHPP loaded CD3+ T cells or unloaded CD3+ T cells plus sepa-
rately applied PSS/mTHPP (final concentration = 0.23 µg/mL) at an E:T ratio of 2 to 1. The con-
centration of added PS was deduced from the greatest determined value for the internalized mass 
of mTHPP per T cell (0.29 pg, Fig. 4.2D, donor 2). As control, tumor cells were co-incubated 
with unloaded or loaded CD3+ T lymphocytes. Appropriate background controls were prepared 
as well. WST-1 assays were performed 20 min (for A549 cells) or 30 min (for SKOV-3 cells) 
before the end of indicated incubation periods. To activate the photosensitizer, co-cultures were 
exposed to a fluence of 8.3 J/cm2 applied over a period of 15 min using a tungsten halogen light 
source (Haloline Eco, 400 W, 9000 lm, Osram, München, Germany) 2 hours before absorbance 
measurements. Co-cultures which were measured after one hour had not been irradiated. Percent-
ages of cancer cell viability were determined using the aforementioned equation (section 4.3.13). 
Absorbance of mTHPP internalized by CD3+ T cells and of separately applied mTHPP and was 
negligible (see Supplementary Information, Fig. S4.4A & B). Cytotoxicity assay was repeated 
with A549 cells co-cultured either with loaded CD4+ or loaded CD8+ T lymphocytes. 
 
4.3.15  Viability assay after incubation with supernatants obtained from loaded CD3+ 
T cells 
After loading and washing of CD3+ T cells, cell density was adjusted to 1.6×106 cells/mL using 
ice-cold medium (w/o PR). Cell suspensions were divided into several aliquots, which were 
transferred into wells of 24-well microplates for suspension cells (Nunc, Thermo Fisher Scien-
tific, Roskilde, Denmark). Samples were collected after culturing for 0 h, 2 h, 6 h, 14 h, 22 h and 
46 h at 37 °C / 5% CO2 protected from light. Cells were sedimented and aspirated supernatants 
were stored at 4 °C. Unloaded T cells were used as control. Solutions composed of supplemented 
RPMI 1640 (w/o PR) containing either 0.46 µg/mL or 2 µg/mL of complexed mTHPP were also 
prepared. Aliquots of these solutions were collected and stored at 4 °C after the same incubation 
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periods. 40,000 A549 cells were prepared as described before and treated in triplicate with 50 µl 
of supernatants and of PSS/mTHPP-solutions. Background controls were prepared accordingly. 
The experiment was exactly carried out like the cytotoxicity assay described in the previous sec-
tion including a corresponding illumination schedule. For instance, samples which had been 
treated with supernatants collected after 6 h were also irradiated after an incubation period of 6 h. 
 
4.3.16 Fluorimetric detection of mTHPP 
Supernatants were transferred in duplicate into wells of a black 96-well microplate with flat bot-
toms (Greiner Bio-One). In an additional experiment, solutions composed of supplemented 
RPMI 1640 (w/o PR) containing either 0.2 µg/mL or 0.46 µg/mL of complexed mTHPP were 
prepared and aliquots of these solutions were collected and stored at 4 °C after the same incuba-
tion periods indicated in the previous section. Aliquots of cell culture medium were processed in 
the same way. Fluorescence emissions of samples were detected using the red optical kit of the 
Modulus Microplate Multimode Reader. 
 
4.3.17 Statistical analysis 
Significant differences between tested groups were calculated with a two-tailed unpaired Student 
t test using GraphPad Prism for Windows (GraphPad Software, La Jolla, CA, USA). P values of 
< 0.05 were considered as significant and are indicated with star or plus symbols as follows: */+ 
P < 0.05, **/++ P < 0.01 and ***/+++ P < 0.001. 
 
 
4.4 Results 
4.4.1 Qualitative and quantitative analysis of mTHPP uptake 
Recently, uptake of PSS/mTHPP by peripheral blood CD3+ T cells has been demonstrated for 
low loading concentrations (1 and 10 µg/ mL [260]). In the present study, uptake experiments with 
the maximum tolerable loading concentration (see next section) of PSS/mTHPP were carried out. 
To this end, CD3+ T lymphocytes were incubated with 12.5 and 25 µg/mL of PSS/mTHPP at 
37 °C and 4 °C. Reducing the incubation temperature is a simple method to gather preliminary 
information about a possible internalization mechanism. After the indicated incubation periods, 
cells were washed to remove excess drug and then analyzed by flow cytometry (Fig. 4.2A). 
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Complexed mTHPP was internalized by T lymphocytes at 37 °C in a concentration and time-
dependent manner, whereas drug uptake was strongly impaired at 4 °C. Obviously, the process 
was energy dependent indicating drug uptake via endocytosis [237]. Furthermore, the capacity for 
PS-uptake was not reached within 8 h of incubation suggesting the potential to improve the load-
ing process. 
Live cell fluorescence microscopy was performed to illustrate a more realistic intracellular distri-
bution of mTHPP in T cells compared to formaldehyde fixed and mounting medium embedded 
T lymphocytes (compare [260]). In contrast to unloaded T lymphocytes, loaded T cells emitted an 
intense red fluorescence (Fig. 4.2B). Merged fluorescence images clearly show that red fluores-
cent cell compartments are encircled by green stained cell membranes, which do not contain 
mTHPP in observable amounts. Hence, the sites of red fluorescence emission were mainly locat-
ed within T cells. This is supported by the red stained structures of yet to be determined cell 
compartments in the perinuclear area of the cytoplasm, which resemble intracellular located en-
doplasmic reticulum and Golgi apparatus (Fig. 4.2C, middle panels) and could not be distin-
guished in fixed cells. 
Subsequently, the amount of mTHPP incorporated by T cells was quantitatively determined. 
From the mass of mTHPP determined after ethyl acetate extraction by fluorescence spectrometry, 
the drug payload transported by a single carrier cell was calculated. As shown in Fig. 4.2D on 
average 0.24 ± 0.03 pg of mTHPP were internalized by a single T cell. However, the overall up-
take efficiency was low (Fig. 4.2E). On average only 2.3% of the mTHPP used was taken up. 
 
4. BISPECIFIC ANTIBODY MEDIATED REDIRECTION OF PSS/mTHPP-LOADED T CELLS  
 
91 
 
 
Fig. 4.2. Qualitative and quantitative determination of PSS/mTHPP internalization by ex vivo activated human CD3+ 
T lymphocytes. (A) Flow cytometric analysis of T cells upon incubation in medium as control or in medium contain-
ing indicated concentrations of PSS/mTHPP at 4°C versus 37°C. Fluorescence intensities of gated populations are 
expressed as normalized GMFI values ± SD of 2 independent experiments using 2 different donors (n = 2). (B) Rep-
resentative fluorescence images of unloaded (upper panel) and loaded (lower panel & C) T lymphocytes. Nuclei and 
membranes of live cells are blue and green fluorescent, respectively. T lymphocytes showing red fluorescence con-
tain mTHPP (C) The photosensitizer is located within the lymphocytes and is not observable in cell membranes as 
shown in the merged image (lower left panel) composed of the green (upper left panel) and the red fluorescence 
picture (middle left panel). Locations of blue stained cell nuclei are shown in right hand panels. (D) Mass means ± 
SD derived from T cell-loadings each conducted in duplicate after ethyl acetate extraction are shown for 4 donors 
(D1-D4). The overall mean ± SD for the internalized mTHPP mass per cell is also shown (n = 4). (E) Illustration of 
uptake efficiency of loading procedures conducted with 4 different donors (mean ± SD, n = 4). The black bar repre-
sents the total mass of complexed mTHPP (200 µg) used for T cell loading. The gray bar shows the mass of PS ex-
tracted from cells (4.6 ± 0.4 µg). 
 
4.4.2 Viability and cytotoxic function of loaded peripheral blood CD3+ T lymphocytes 
To determine a safe maximum loading concentration of complexed mTHPP, CD3+ T cells were 
incubated with indicated amounts of PS-complex for 2 h. Bioreductive activity (i.e. viability) of 
loaded T cells was analyzed at indicated time points (Fig. 4.3A). Incubation with poly(styrene 
sulfonate) sodium salt, used in the same concentration equal to 45 µg/mL of complexed mTHPP, 
did not affect T cell viability. Thus, at this concentration the complexing agent itself can be con-
sidered as non-toxic. T lymphocytes which had been incubated only with 20 or 25 µg/mL of 
PSS/mTHPP tolerated the payload well. Even after 48 h, cell viability was still not impaired 
compared to the viability of untreated control group. However, dark toxicity was observed at 
loading concentrations greater than 25 µg/mL and bioreductive activity was decreasing in a con-
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centration-dependent manner. Therefore, a loading concentration of 25 µg/mL of complexed 
mTHPP was fixed for later experiments. 
To analyze whether loaded T cells have the same capacity to kill tumor cells as unloaded 
T lymphocytes, EpCAM-positive SKOV-3 ovarian adenocarcinoma cells were treated with 
T cells in combination with bispecific antibody (bsAb) EpCAM×CD3, which induces cytolytic 
activity of cytotoxic T lymphocytes against EpCAM-expressing target cells. After addition of 
immune cells the viability of tumor cells was analyzed at indicated time points (Fig. 4.3B). No 
significant difference in redirected lysis of SKOV-3 cells was observed. Over the course of time, 
the progression of both viability curves is nearly identical. In conclusion, mTHPP-loaded T cells 
were as lethal as unloaded T lymphocytes. Obviously, the drug payload did not impair the natural 
cytotoxicity of T cells towards target cells. 
 
 
 
 
 
 
Fig. 4.3. Maximal tolerable mTHPP payload and cytolytic 
capacity of loaded CD3+ T cells were assessed using WST-1 
colorimetric assays. (A) T cells were incubated for 2 h with 
indicated concentrations of complexed mTHPP and the great-
est respective concentration of the complexing agent PSS. The 
bioreductive activity expressed as percentage of viable cells 
normalized to untreated control cells was determined 4 h, 24 h 
and 48 h after transfer of washed T cells into PS-complex and 
PSS free cell culture medium. (B) Cytolytic function of un-
loaded and loaded T lymphocytes (loading concentration = 
25 µg/mL of complexed mTHPP), in the presence of bsAb 
was compared for up to 48 h in co-cultures with SKOV-3 
cells as target cells. The effector to target cell ratio was 2:1. 
(A, B) All cells were kept protected from light during the 
experimental period. Mean values ± SD of 2 representative 
experiments with 2 different donors are shown (n = 2). 
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4.4.3 Photosensitizer transfer from loaded peripheral blood CD3+ T lymphocytes to co-
cultivated carcinoma cells 
It was shown that unspecific transfer of mTHPP from CD3+ T cells to target cells is possible [260]. 
In the present study, drug transfer was characterized in more detail. To this end, EpCAM-
expressing A549 lung carcinoma cells were co-incubated with unloaded or PS-complex-loaded 
T cells in the presence or absence of bsAb over a total period of 22 h. The transfer of mTHPP 
was visualized by live cell fluorescence microscopy (Fig. 4.4A, C). After 2 h and 22 h of co-
cultivation, A549 cells treated with CFSE-labeled, loaded T lymphocytes plus bsAb showed a 
more intense red fluorescence than lung carcinoma cells, which had been co-incubated with 
CFSE-labeled, non-redirected loaded T cells (Fig. 4.4A). In either case, the emission of fluores-
cence observed after 22 h (Fig. 4.4A, lower panels) was more intense than after 2 h (Fig. 4.4A, 
upper panels) of co-cultivation. The photosensitizer was accumulated in specific compartments of 
A549 cells, which are likely to be the endoplasmic reticulum and the Golgi apparatus (Fig. 4.4C). 
Although we have used PSS-complexed mTHPP, those findings are consistent with the observa-
tions of Teiten and colleagues, which had used mTHPC [255]. 
Fluorescence microscopy images suggest that the presence of bsAb increases drug transfer in co-
cultures. To confirm this effect, mTHPP transfer was further evaluated via flow cytometry 
(Fig. 4.4B). As expected, the GMFI derived from A549 cells, which had been co-incubated with 
loaded T lymphocytes, increased constantly. The longer the co-cultivation lasted, the more 
mTHPP was transferred and the greater were the determined GMFI of analyzed tumor cells. 
However, when incubated with bsAb-retargeted loaded T cells, A549 cells showed much stronger 
fluorescence signals than upon co-cultivation with non-redirected loaded T lymphocytes. Thus, 
drug transfer was more efficient when T cells and tumor cells were cross-linked through bsAb. 
Fig. 4.4D shows some of the data used to calculate GMFI values for cancer cells which had been 
co-cultivated with loaded carrier cells plus bsAb. Notably, the PS transfer is also illustrated by a 
population shift of A549 cells and drug loaded T lymphocytes along the logarithmic x-axis repre-
senting mTHPP fluorescence intensity over the course of time. While the drug is transferred, the 
red fluorescence intensity of the loaded T cells population is shifting to smaller values. In con-
trast, the fluorescence intensity of the A549 cell population is increasing, indicating an internali-
zation of transferred mTHPP by cancer cells. 
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Fig. 4.4. Assessing mTHPP transfer from carrier CD3+ T cells to target carcinoma cells. For all experiments the E:T 
ratio was 2:1. (A) Representative merged fluorescence images of rinsed and live A549 cells 2 h and 22 h after co-
incubation with loaded T lymphocytes either in the presence or absence of bsAb. Cell nuclei were stained with 
Hoechst dye and are blue fluorescent. Areas mostly devoid of CFSE-T cells (white arrows) are shown. Cell com-
partments containing mTHPP are red fluorescent. (B) A549 lung carcinoma cells were co-cultivated with unloaded 
and loaded T cells in combination with bsAb as well as with loaded T lymphocytes without bsAb for up to 22 h at 
37°C. Fluorescence intensities of gated cancer cells populations are expressed as normalized GMFI values ± SD 
(n = 3). Statistically significant differences in drug transfer are indicated by P-values represented by star symbols (* 
P < 0.05, ** P < 0.01 and *** P < 0.001, ns = not significant). (C) A very bright red fluorescent mTHPP loaded 
T lymphocyte (white arrow) attached to two A549 cells after 22 h of co-cultivation in combination with bsAb is 
shown. The sample had been rinsed before imaging. Cancer cells have internalized a considerable amount of mTHPP 
(upper panel). Sites with accumulated photosensitizer are mainly located around the cell nuclei (upper panel and 
middle panel). In the lower panel, the combined fluorescence images were merged with the corresponding bright 
field image. White lines highlight the estimated location of tumor cell membranes. (D) Contour plots, obtained from 
one of the experiments shown in B, of A549 cells and CFSE-labeled loaded T cells (LTc) for indicated co-incubation 
periods are illustrated. Black orientation lines are laid over the center of populations measured after 2 h of co-
cultivation in the presence of bsAb. 
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4.4.4 Enhanced cytotoxicity of bsAb-redirected, photosensitizer-loaded CD3+ 
T lymphocytes 
We addressed the crucial question of whether redirected mTHPP-loaded CD3+ T lymphocytes 
are more efficient in killing EpCAM-expressing carcinoma cells than unloaded T cells after irra-
diation. As shown in Fig. 4.5A and B, co-incubation with unloaded T lymphocytes had no signif-
icant effect on the viability of ovarian and lung carcinoma cells. In contrast, cancer cell viability 
considerably decreased to less than 60% following treatment with loaded T lymphocytes and ex-
posure to light after 24 h. This result is owed to the fact that loaded T cells are able to transfer 
mTHPP to cancer cells as shown in the previous section. Since loaded T lymphocytes were killed 
upon exposure to light [260] and viability measurements were carried out 2 h after irradiation of 
co-incubation, redirected unloaded T cells had more time to kill target cells than retargeted carrier 
cells. However, in irradiated co-cultures, redirected loaded T lymphocytes inhibited tumor cell 
growth more efficiently than bsAb-guided T cells. For instance, after 8 h and 24 h of co-
cultivation, retargeted loaded T lymphocytes had killed 39% and 21%, respectively, more SKOV-
3 cells than redirected unloaded T cells. The treatment with redirected loaded T cells was even 
more effective in experiments with A549 cells (Fig. 4.5B). In comparison to retargeted unloaded 
T cells, the viability of A549 cells was significantly reduced by 52% and by 31% after 8 h and 
24 h, respectively. Importantly, we could also demonstrate, that drug effect and T cell effect syn-
ergistically act together. The combination of retargeted T lymphocytes, separately applied 
PSS/mTHPP (0.23 µg/mL) and light was less effective in killing cancer cells than PS-complex-
loaded, redirected T cells after illumination. Only when the tumor cells had enough time to ac-
cumulate the dissolved PS-complex were comparable killing percentages observed after 24 h. 
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Fig. 4.5. Evaluation of killing potential of bispecific antibody-redirected, photosensitizer-loaded T cells by WST-1 
assays and fluorimetric detection of mTHPP in supernatants (SN) harvested from loaded carrier cells. Time-
dependent redirected killing of SKOV-3 ovarian carcinoma cells (A) and of A549 lung carcinoma cells (B) by un-
loaded and loaded T cells is shown. The mass of separately applied complexed mTHPP was equal to the greatest 
mass, which had been internalized by 80,000 T cells. Thus, the final concentration of free PSS/mTHPP in WST-1 
assays was 0.23 µg/mL. The effector to target cell ratio in all experiments was 2:1. Statistically significant differ-
ences (P-values) between the viability of cancer cells co-cultivated with loaded T cells + bsAb and cancer cell viabil-
ity after treatment with T cells + bsAb or with T cells + bsAb + free PSS/mTHPP for each incubation period are 
indicated with star or plus symbols, respectively (*/+ P < 0.05, **/++ P < 0.01 and ***/+++ P < 0.001; ns = not 
significant). Mean values ± SD of 2 representative experiments with 2 different donors (n = 2) for each carcinoma 
cell line are shown. (C) WST-1 assay conducted with supernatants obtained from unloaded and loaded T cell cultures 
analogous to the experiment presented in (B). Mean values ± SD of 4 different donors (n = 4) are shown. For free 
complexed drug controls (0.23 & 1 µg/mL) and detergent control, n was equal to 2. (A, B, C) Samples were exposed 
to light 2 h before determination of cell viability. Co-cultures measured after 1 h of incubation were not irradiated. 
(D, lower panel) Detection of mTHPP in aliquots of the same supernatants obtained from loaded T cells tested in the 
experiment shown in (C). Mean values ± SD of 4 different donors (n = 4) are shown. For drug controls n was equal 
to 2 (upper panel). 
 
4.4.5 Cytotoxicity of supernatants obtained from loaded CD3+ T lymphocyte cultures 
Subsequently, we examined whether PSS/mTHPP, which could have been released by loaded 
CD3+ T cells into cell culture medium, has an impairing effect on cancer cell viability. However, 
A549 cells, which had been incubated with supernatants, either collected from cultures of loaded 
T lymphocytes or as control from unloaded T cells, showed no reduced viability upon exposure 
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to light (Fig. 4.5C). Cancer cells were also treated with 0.23 µg/mL of PSS/mTHPP, which is 
equal to the concentration that would have been achieved had 80,000 carrier cells released their 
entire drug payload into the co-culture medium. After 22 h of incubation and subsequent irradia-
tion, A549 cells were clearly affected by PSS/mTHPP mediated phototoxicity. Fluorescence 
spectrometry measurements support that supernatants obtained from loaded T cells did not con-
tain the pharmaceutical in cytotoxic doses. As shown in Fig. 4.5D, there is no difference in fluo-
rescence emissions detectable when supernatants harvested from unloaded T cell cultures are 
compared to those of loaded carrier cells (lower panel). In contrast, mTHPP at concentrations of 
0.2 µg/mL and 0.46 µg/mL is actually measurable (Fig. 4.5D, upper panel). The former value 
corresponds to one-tenth of the undiluted concentration of PSS/mTHPP used as positive control 
in the experiment shown in Fig. 4.5C, whereas latter value matches the concentration which 
could have been theoretically achieved by a complete release of drug by loaded T cells. 
 
4.4.6 Boosted cytotoxicity of bsAb-redirected, photosensitizer-loaded CD4+ and CD8+ 
T lymphocytes 
In the presence of the bispecific antibody HEA125×OKT3, CD4+ T cells can exhibit a cytotoxic 
effect against EpCAM-expressing target cells [10]. Therefore, we analyzed whether PSS/mTHPP-
loaded CD4+ T cells would be suitable as carrier cells as well. In addition, we were interested 
whether we could increase the synergistic effect demonstrated for drug-loaded CD3+ T cells 
(Fig. 4.5A & B) by using only loaded CD8+ T lymphocytes. The results shown in Fig. 4.6A and 
4.6B confirm both assumptions. The purity of both T cell subsets was consistently greater than 
96% (Supplementary Information, Fig. S4.1.). 
Co-incubation with unloaded CD4+ T lymphocytes had no significant effect on the viability of 
A549 cells. Likewise, background lysis of unloaded CD8+ T lymphocytes was insignificant. As 
expected, cancer cell viability was considerably decreased following treatment with both subsets 
of loaded T lymphocytes and exposure to light. After 24 h bsAb-retargeted CD4+ T cells had 
killed 47% of lung carcinoma cells. At that time point, cytotoxic CD8+ T cells had already elimi-
nated 66% of target cells. In irradiated co-cultures, redirected loaded CD4+ T lymphocytes inhib-
ited tumor cell growth more efficiently than bsAb-guided CD4+ T cells and non-redirected load-
ed cells. Therefore, CD4+ T lymphocytes could be of use as carrier cells. Within the first 8 h of 
co-incubation, bsAb-mediated cytolytic activity of CD3+ (Fig. 4.5B), CD4+ (Fig. 4.6A) or CD8+ 
T cells (Fig. 4.6B) was comparable. In contrast, retargeted loaded CD8+ T lymphocytes had erad-
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icated 85% of target cells, while CD3+ and CD4+ loaded T cells had only killed 64% and 59%, 
respectively, of cancer cells after illumination. Thus, loaded CD8+ T lymphocytes were the most 
effective subset in killing A549 cells, which was still the case after 24 h of co-cultivation. 
We have not investigated whether there is a difference in drug uptake by different subsets of 
T cells. However, had the CD4+ and CD8+ T cells internalized significant different amounts of 
PSS/mTHPP, two distinguishable populations should have appeared in flow cytometry drug load-
ing experiments with CD3+ T lymphocytes (Fig. 4.2A). However, that was not the case. Hence, 
we tested the additional approach using free PSS/mTHPP as well. Again, we could demonstrate, 
that drug effect and T cell effect act synergistically. The combination of bsAb-redirected CD4+ 
or CD8+ T lymphocytes, separately applied PSS/mTHPP and light was less effective in killing 
A549 cells than drug-loaded, redirected T cells of both subsets after illumination. Interestingly, 
the synergistic effect demonstrated for loaded CD3+ (Fig. 4.5B) and CD4+ T lymphocytes was 
less pronounced, especially within the first 8 h, than the synergy shown for drug-loaded CD8+ 
T cells. 
 
 
 
Fig. 4.6. Determination of the killing potential of bsAb-redirected, PS-loaded subsets of T lymphocytes by WST-1 
assays. Time-dependent redirected killing of A549 lung carcinoma cells by unloaded and loaded CD4+ (A) and 
CD8+ (B) T cells is shown. The concentration of separately applied complexed mTHPP was 0.23 µg/mL. The effec-
tor to target cell ratio was 2:1 in all experiments. Statistically significant differences (P values) between the viability 
of cancer cells co-cultivated with loaded T cells + bsAb and cancer cell viability after treatment with T cells + bsAb 
or with T cells + bsAb + free PSS/mTHPP for each incubation period are indicated with star or plus symbols, respec-
tively (*/+ P < 0.05, **/++ P < 0.01 and ***/+++ P < 0.001; ns = not significant). Mean values ± SD of 3 experi-
ments with 3 different donors (n = 3) are shown.  
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4.5 Discussion 
In the present work, we have demonstrated the feasibility of a novel T cell-based targeted PDT 
approach in vitro. To this end, we have used a water-soluble formulation of the model photosen-
sitizer mTHPP complexed with poly(styrene sulfonate) sodium salt (PSS). The photosensitizer 
itself is practically insoluble in water. In preliminary experiments, we could confirm that free 
mTHPP is also taken up by T lymphocytes (Supplementary Information, Fig. S4.5). Additional 
data imply that concentrations up to 10 µg/mL of mTHPP are non-toxic for T cells (Supplemen-
tary Information, Fig. S4.6). However, while loading T cells with PSS/mTHPP was very repro-
ducible, loading with free mTHPP was obviously not. This is indicated by huge standard devia-
tions shown in Fig. S4.7 (Supplementary Information). Adding an organic mTHPP solution to an 
aqueous cell-suspension seems to generate inhomogeneous loading conditions. This was not the 
case when PSS/mTHPP was used. Therefore, we decided to use the water-soluble drug formula-
tion throughout the present study. 
An important part of our approach is to exploit the natural cytotoxic potential of drug-loaded 
T lymphocytes against malignant neoplasms in the context of adoptive T cell therapy. Therefore, 
it is essential that loaded T cells survive the drug payload until their arrival at tumor sites. Addi-
tionally, the internalized pharmaceutical must not impair the intrinsic cytotoxicity of 
T lymphocytes. It has been demonstrated that CTLs can be detected at neoplastic sites within 
48 h to 72 h after reinfusion into patients [262, 263]. Here, we have shown that CD3+ T cells tolerat-
ed loading concentrations of up to 25 µg/mL of complexed mTHPP for at least 48 h after the end 
of the loading procedure. In particular, loaded CD3+ T lymphocytes exhibited the same killing 
capacity as unloaded CD3+ T cells when kept protected from light. Therefore, the obtained data 
supports the hypothesis that loaded T cells could be functional for ACT and following PDT in 
patients.  
Although we have demonstrated that, of the tested T cells, bsAb-guided drug-loaded CD8+ 
T lymphocytes were most effective in killing cancer cells in vitro, we aim to use all peripheral 
blood T cells in vivo. The rationale behind this is the specificity of the bispecific antibody, which 
cross-links all CD3+ T cells to target cells. Thus, all these cells could be exploited as drug carrier 
cells. This includes CD4+ T cells, which exert a cytotoxic phenotype in combination with bsAb 
(Fig. 4.6A) [10]. Furthermore, cells of the CD4+ subset could augment the response to adoptive 
T cell transfer when co-administered with CD8+ T cells in vivo [122, 123]. 
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After intravenous injection, T lymphocytes reside for several hours in the lungs of humans and 
mice. Thereafter, the bulk of T cells redistributes to liver, spleen and secondary lymphoid organs 
[262, 264-266]. Furthermore, on the way to tumor sites drug-loaded T cells will interact with other 
cells. For instance, when circulating T lymphocytes extravasate through endothelial barriers [267], 
a part of the pharmaceutical payload will probably be transferred to these endothelial cells. How-
ever, off-target toxicity to the mentioned tissues is not to be expected, as long as no light activa-
tion occurs in that area. Presumably, not all carrier cells will be able to deliver the drug to target-
ed sites. Nevertheless, Cerundolo and co-workers demonstrated that adoptively transferred tu-
mor-specific cytotoxic T lymphocytes, loaded with the plant toxin ricin, had a greater therapeutic 
effect on peripherally localized tumors than unloaded CTL [84]. It remains to be seen if the 
amount of delivered photosensitizer will also be sufficient for an efficient PDT. On the other 
hand, a variety of experimental strategies are under investigation to improve the trafficking of 
adoptively transferred T lymphocytes to malignant tissues [268-270]. Thus, there is potential that the 
T cell-based targeted PDT approach may lead to a better photosensitizer biodistribution toward 
the tumor sites than systemically administered drug.  
We have demonstrated that drug transfer is directly dependent on a proximity effect and/or cell-
cell interaction. When non-redirected mTHPP-loaded human T lymphocytes were co-incubated 
with human allogenic cancer cells, the transferred dose of mTHPP was sufficient to kill a consid-
erable amount of cancer cells upon exposure to light. In contrast, when loaded T lymphocytes 
were substituted for supernatants obtained from drug-loaded T cells, tumor cells were not affect-
ed after irradiation. We conclude that mTHPP transfer is primarily not mediated via the cell cul-
ture medium. After addition, loaded T cells, representing spots of high PS-concentration, will 
settle on top of or between cancer cells. All eukaryotic cells have constitutive exocytic pathways 
to the cell surface and for secretion of molecules like proteins [271]. Along these secretory routes 
complexed mTHPP could be released by loaded T cells and endocytosed by tumor cells located 
in close proximity. Besides, T cells are also able to migrate from tumor cell to tumor cell in vitro 
[272]. As a consequence, bsAb-independent contacts are presumably established between the two 
cell types and the photosensitizer can be passed from loaded T lymphocytes to tumor cells. These 
interactions are probably induced by adhesion molecules and mediated for instance via LFA-
1/ICAM-1 or CD2/CD58-complexes [273]. Most notably, when carcinoma cells were co-cultivated 
with loaded T cells in combination with bsAb EpCAM×CD3, even more photosensitizer was 
transferred, emphasizing the importance of cell-cell contacts for a more efficient drug transfer. 
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Salnikov and colleagues have demonstrated that the duration of contacts between T lymphocytes 
and pancreatic cancer cells mediated by EpCAM×CD3 was substantially longer compared to a 
control antibody [9]. It is conceivable that bsAb-mediated increase of drug transfer is caused by 
prolonged cell-cell interactions. In addition, bispecific antibodies bind to the ε-chain of the CD3 
molecule [10], which is a component of the T cell receptor (TCR) complex. Upon restimulation of 
TCRs of activated T cells regulated exocytic processes occur, in which immunological mediators 
are secreted into the intercellular lumen. While CD4+ T cells mainly release different kinds of 
chemokines and cytokines, CD8+ T cells predominantly secret cytokines and degranulate their 
lytic granules to exert their intrinsic cytotoxic function [274]. Thus, additionally to constitutive 
exocytic pathways, PSS/mTHPP could be released by those regulated secretory processes as well. 
Therefore, the bsAb does not only provide tumor cell specificity but also indirectly enhances 
“drug selectivity”. This explains why in irradiated co-cultures and in the presence of bsAb, 
PSS/mTHPP-loaded carrier cells inhibited tumor cell growth more efficiently than unloaded 
T lymphocytes. Most importantly, the combination of freely applied drug and bsAb-retargeted 
immune cells was less effective in killing cancer cells than PS-loaded redirected T cells indicat-
ing that drug effect and T cell effect act together in a synergistic manner. 
Assessment of the feasibility of lymphocyte-based drug delivery started 31 years ago, when it 
was shown that ricin carrying spleen cells could transfer the toxin to recipient spleen cells in vitro 
[97]. In following studies ricin-loaded T cells [84] as well as lymphokine-activated killer (LAK) 
cells [82] were used to treat tumor bearing mice. Although these studies provided a proof of con-
cept for the T cell-based drug delivery approach, the selection of ricin as payload for carrier cells 
had several drawbacks. The major one was that after ricin loading the cytolytic activity of lym-
phocytes was seriously impaired [82, 84, 99]. Due to high systemic toxicity in mice, Mandruzzato 
and colleagues substituted ricin for an anthracycline [6]. The authors achieved a reduction of lung 
metastases. However, since loaded LAK cells had redistributed to liver and spleen, considerable 
and presumably harmful drug levels were found in these organs of mice. Above all, cytotoxic 
activity of carrier cells was gravely inhibited again. Obviously, active agents exerting immediate 
cytotoxicity prevent exploitation of the natural T cell cytotoxicity. To overcome this obstacle, we 
have encapsulated the chemotherapeutic agent idarubicin in polyester-based and gold-shell-
coated polyester nanoparticles. The rationale was to protect T lymphocytes against drug toxicity 
upon loading. However, these drug encapsulations were not able to prevent premature death of 
carrier cells [260]. As a consequence, we deem those respective active drugs not appropriate for 
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T cell-based drug delivery. Thus, by using a photosensitizer, the mode of action of which can be 
specifically triggered in a time-dependent manner at the diseased site, we provide a clear im-
provement to the cell-mediated drug delivery approach. Other investigators have also pursued 
similar strategies but did not yet demonstrate any therapeutic effects in vitro as well as in vivo 
[102-104]. To our best knowledge, only Stephan and colleagues were able to augment the therapeu-
tic potential of T cells without impairing cell functions, so far. By covalent coupling of cytokine 
or small-molecule drug containing nanoparticles onto the plasma membrane surface, they provid-
ed a sustained “pseudoautocrine” stimulation to carrier cells, which caused an increased T cell 
expansion, longevity and an enhanced tumor elimination after in vivo transfer [90, 91]. However, 
the approach of Stephan and co-workers differs from ours in that the payload is attached to the 
outside of carrier cells. Furthermore, non-cytotoxic drugs were used, which acted on carrier cells 
and not directly on target cells. 
Using drug-loaded cytotoxic T cells seems to be counterintuitive as the target cell to which 
mTHPP is transferred will already be killed by the attacking CTL. However, we have clearly 
demonstrated that using bsAb-retargeted loaded CD8+ T lymphocyte was the most effective ap-
proach in elimination target cancer cells (Fig. 4.6B). The reason for this in vitro efficiency could 
be the mentioned proximity effect. One CTL is attached to a target cell and kills it. In the mean-
time the same CTL releases drug molecules via exocytic pathways or degranulation of lytic gran-
ules is accompanied by drug “secretion”. The photosensitizer is then taken up by bystander cells. 
In case those cells are not immediately attacked by the same or other CTLs light irradiation will 
eradicate them. This could happen all over the cell monolayer. Furthermore, while receiving the 
“lethal hit” by loaded CTLs, target cells could internalize the drug. After cell death, drug contain-
ing remains of eliminated target cells could be endocytosed by neighboring cells. This could also 
destroy those cells after irradiation. 
 
 
4.6 Conclusions 
We have shown that PS-loaded ex vivo activated human T lymphocytes survive the drug payload 
and do not show impaired natural cytolytic function. When retargeted through a bispecific anti-
body, the resulting living drug delivery system is able to transfer the photosensitizer to carcinoma 
cells more efficiently. Redirected loaded T cells of all tested populations (CD3+, CD4+ or CD8+) 
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are superior to redirected unloaded T lymphocytes in killing tumor cells after irradiation. The 
T cell-drug effect is synergistic rather than additive supporting the selectivity of bsAb-mediated 
mTHPP transfer, which, to our knowledge, was not demonstrated yet. The combination of cell-
mediated drug delivery, cellular immunotherapy and photodynamic therapy could significantly 
increase selectivity and effectiveness of PDT. In addition, “super-killer T cells” [84] with drug 
boosted cytotoxicity could be beneficial for adoptive cell therapies. Our in vitro proof of concept 
study is the first step to establish the T lymphocyte-based photosensitizer delivery approach for in 
vivo studies. 
 
 
4.7 Supplementary Information 
4.7.1 Purity of isolated, activated and expanded CD4+ or CD8+ T lymphocytes 
 
 
 
Fig. S4.1. Purity of isolated, activated and then expanded CD4+ (A) or CD8+ T cells (B) determined by flow cytom-
etry. To assess the purity of T lymphocyte populations of healthy donors (3 per cell subset), cells were labeled in 
duplicate with either 5 µg/mL of FITC-conjugated anti-human-CD4 or anti-human-CD8 monoclonal antibodies. As 
negative control, T cells were labeled with 5 µg/mL of FITC-conjugated monoclonal antibodies of the same isotype 
as well (Bio-Rad AbD Serotec, Puchheim, Germany). One representative sample of each donor and subset is shown 
in the histograms. The illustrated markers within the overlays were used to calculate the purity of T cell populations: 
purity (CD4+ T cells) = 97.6 % ± 1.3 %; purity (CD8+ T cells) = 97.5 % ± 1.4 %; (mean ± SD; n = 3 per cell subset). 
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4.7.2 Calibration of PSS/mTHPP preparations 
 
 
 
Fig. S4.2. Calibration of PSS/mTHPP by fluorescence spectrometry. (A) Calibration curve for pure mTHPP. Means 
± SD are shown (each data point is based on 12 measurements, n = 3, for fluorescence intensity arbitrary units were 
used). (B, C) Mass ratios of two PSS/mTHPP preparations are illustrated. The mass value of each extracted mTHPP 
is based on 9 fluorescence measurements. On average 5.67 mg and 5.43 mg of the first and the second complex 
preparation, respectively, contain 1 mg of pure mTHPP (Error bars represent ± SD, n = 6 per preparation). 
 
 
4.7.3 UV/Vis spectra of PSS/mTHPP 
 
 
 
Fig. S4.3. UV/Vis spectra of complexed mTHPP dissolved in purified water or RPMI 1640 medium containing 10% 
(v/v) heat-inactivated FBS, 100 U/mL penicillin and 0.1 mg/mL streptomycin. As reference the respective solvent 
without PSS/mTHPP was used. The pH value of both solvents was adjusted to 7.4. Spectra were determined using an 
Ultrospec 3300 pro UV/Visible Spectrophotometer (Amersham pharmacia biotech, Cambridge, England). 
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4.7.4 Contribution of mTHPP to absorbance in WST-1 assays 
 
 
 
Fig. S4.4. Contribution of mTHPP to absorbance. In the present study, WST-1 assays were adjusted so that controls 
of untreated cancer cells would yield an absorbance of approximately A = 1. (A) Absorbance of non-irradiated blank 
controls of one of the experiments shown in Fig. 4B (Tc = T cells) after an incubation period of 1 h is illustrated. A 
contribution of mTHPP in loaded T cells (LTc) to the total absorbance is not detectable. The concentration of sepa-
rately applied complexed mTHPP was 0.23 µg/mL. Absorbance of PSS/mTHPP (PS) at this concentration is also 
negligible (A (bright grey bars), B). (A, B) Means and SD of triplicate samples are shown (n = 1). 
 
 
4.7.5 Qualitative analysis of mTHPP uptake by fluorescence microscopy 
 
 
 
Fig. S4.5. Fluorescence images of formaldehyde-fixed and FluorSave (Merck Millipore, Darmstadt, Germany) 
mounting medium embedded T cells (principle of staining procedure is described in section 3.3.8). 
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4.7.6 Viability of T cells after loading with free or complexed mTHPP 
 
 
 
Fig. S4.6. Viability of T cells after loading with 10 µg/mL of free mTHPP and approximately (see caption of Fig. 
S4.7) 10 µg/mL of complexed mTHPP for 2 h. Cell survival was determined using a colorimetric XTT assay as de-
scribed in section 3.3.9. After loading, cells were washed to remove non-internalized drug (mean values ± SD of 
quadruplets, n = 1). 
 
4.7.7 Qualitative analysis of mTHPP uptake by flow cytometry 
 
 
 
Fig. S4.7. T lymphocytes were loaded with 10 µg/mL of free mTHPP and approximately (see below) 10 µg/mL of 
complexed mTHPP for indicated incubation periods. After loading, cells were washed to remove non-internalized 
drug and fluorescence intensities of T cell populations were determined via flow cytometry (GMFI ± SD values of 2 
loadings of T cells obtained from the same donor, n = 1).  
The data implies that the amount of internalized complexed mTHPP is smaller than the amount of free drug. Howev-
er, at the time the experiments were conducted, PSS/mTHPP had not been calibrated so far. The concentration of 
complexed mTHPP was theoretically deduced based on the findings of Reum and colleagues [193]. In retrospect, it is 
likely that the actual concentration used for loading of T cells was well below 10 µg/mL. 
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5. Overall Conclusion and Outlook 
Living T cells can be exploited as pharmacytes to transport therapeutics to diseased sites as 
demonstrated in various pre-clinical studies. However, most of these studies showed that physio-
logical and immunological functions such as migration, circulation, and cytolytic activity of hu-
man T lymphocytes were impaired after loading them with cytotoxic anticancer compounds. In 
addition, premature death of carrier cells has been a major drawback of cell-based approaches to 
transport cytotoxic payloads, probably hampering clinical trials up to now. One purpose of the 
presented work was to identify anticancer drug formulations that preserve drug loaded 
T lymphocytes from cell death and ideally do not reduce the cytolytic function of CTLs. The lat-
ter requirement is essential because the other main objective of this thesis was to combine the 
cytotoxicity of cell-delivered pharmaceuticals with cell-mediated cytotoxicity. Particularly, the 
question was addressed whether this combination acts in an additive or synergistic manner. 
One strategy to overcome the aforementioned obstacles could be the encapsulation of cytotoxic 
therapeutics into protective nanoparticulate systems for cellular uptake. These materials for drug 
encapsulation must have some basic characteristics such as non-toxicity for carrier cells and bio-
degradability to ensure sustained release of enclosed pharmaceuticals inside the carrier cells as 
well as exocytosis of payload at the diseased site. Furthermore, ligands attached to the respective 
material that facilitate increased drug loading would be favorable. 
In the first part of this thesis, interactions between lysine-based statistical glycosylated copoly-
peptides and human T lymphocytes were investigated for the first time. These biodegradable pol-
ymers, kindly provided by Thomas Stöhr (Organic Macromolecular Chemistry, Saarland Univer-
sity, Germany), could serve as an encapsulation material for pharmaceuticals. A standard XTT-
based colorimetric viability assay confirmed that these glycopolypeptides were well tolerated by 
T cells, fulfilling a basic requirement. In addition, flow cytometric and fluorescence microscopic 
analysis demonstrated that galactosylated and mannosylated polymers were readily taken up by 
ex vivo activated T lymphocytes. This occurred in a temperature-dependent manner, suggesting 
an energy-dependent uptake mechanism such as endocytosis. In contrast, internalization of gluco-
sylated polypeptides was significantly reduced and uptake of unsubstituted polypeptides was 
even lesser pronounced. This result indicates that attached galactose as well as attached mannose 
could indeed facilitate an increased cellular uptake of polylysine-based nanoscale particles. Pre-
liminary experiments conducted by Thomas Stöhr demonstrated that the generation of these par-
ticles is feasible [224]. However, suboptimal size distribution of nanoparticles indicated that the 
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process for NP generation needs to be optimized. In addition, drug encapsulation was not real-
ized. Nevertheless, these results highlights the potential use of statistical glycosylated copolypep-
tides in biomedical applications. 
Instead of investigating polypeptide-based nanoscale systems, idarubicin (IDA) enclosing 
poly(lactic-co-glycolic-acid) (PLGA) nanoparticles and NPs based on newly synthesized 
poly(diethylene glycol-maleate-co-sebacate)ester (MPE) were tested in the second part of this 
thesis. The polyester-based NPs were kindly provided by Qiong Lian (Biopharmaceutics and 
Pharmaceutical Technology, Saarland University, Germany). Using flow cytometry and fluores-
cence microscopy the fluorescent drug was detected within cells. NPs devoid of IDA were non-
toxic, thereby showing their biocompatibility. However, nanoparticulate drug formulations were 
not able to protect activated human T lymphocytes from the toxic effect of the active chemother-
apeutic agent idarubicin as determined by XTT assay. Following, Qiong Lian coated MPE-IDA 
NPs with a gold layer to reduce premature drug release. However, this measure did not improve 
the viability of T cells either. On the contrary, gold-coated MPE-based NPs, even without drug 
content, already exhibited significant cytotoxicity in themselves. The observed decrease in T cell 
viability suggests that upon contact of IDA-NPs with T lymphocytes idarubicin was rapidly re-
leased. This could be due to the high lipophilicity of IDA, which could have facilitated immediate 
transfer from nanoparticles to hydrophobic areas such as lipid membranes of T cells. A “simple” 
solution to this problem could be the substitution of IDA for a less lipophilic anthracycline such 
as doxorubicin. However, this would probably require the development of a new nanoparticulate 
system including its characterization. The maleate part of MPE-NPs contains a double bond, 
which is accessible for cross-linking of polyesters within these NPs. Cross-linking could probably 
cause better entrapment of IDA within nanoparticles. Again, this approach would require more 
research, before cellular tests would be feasible. Another idea could be a replacement of the gold 
shell. Indeed, Lian and colleagues have already developed IDA-NPs coated with the polysaccha-
ride chitosan. However, the development of these NPs was coincident with the pursuit of a new 
strategy for the T cell-mediated drug delivery approach. 
This new strategy was the third part of this thesis and encompassed the replacement of the active 
anthracycline (IDA) by a stimulus-sensitive photosensitizer (mTHPP), the mode of action of 
which is only triggered by light irradiation in the presence of oxygen. The PS was kindly provid-
ed by Hagar Ibrahim Labouta (HIPS, Saarland University, Germany) in a water-soluble formula-
tion (PSS/mTHPP). Cellular incorporation of the PS was confirmed by flow cytometriy and fluo-
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rescence microscopy. Uptake was temperature-dependent, suggesting an energy-dependent inter-
nalization by endocytosis. PS-loaded ex vivo activated human T lymphocytes survived the drug 
payload and did not show impaired natural cytolytic function when kept in the dark as assessed 
with WST-1 viability assay. When retargeted through a bispecific antibody, drug-loaded T cells 
were able to transfer the photosensitizer to carcinoma cells more efficiently. Redirected loaded 
T lymphocytes of all tested cell subsets were superior to redirected unloaded T lymphocytes in 
killing tumor cells after irradiation. The T cell-drug effect is synergistic rather than additive sup-
porting the selectivity of bsAb-mediated mTHPP transfer, which was not demonstrated yet. 
These results are promising and justify testing the approach in vivo. However, the model photo-
sensitizer mTHPP is not an ideal compound for the application in animal experiments and should 
be replaced by mTHPC. In contrast to mTHPP, its derivative is far more sensitive for activation 
with red light, which penetrates living tissue more deeply. Since both compounds have very simi-
lar chemical structures, results obtained in experiments with mTHPC are expected to be similar to 
those gained in this thesis. Furthermore, it was revealed that the uptake efficiency of PSS/mTHPP 
was rather poor. It remains to be seen whether ligands targeting receptors on the surface of 
T cells could achieve a greater drug uptake. A possible ligand, for instance, could be transferrin, 
which binds to the transferrin-receptor expressed by activated T cells. 
In this thesis, all peripheral T cells were loaded with drugs. However, as noted in the introduc-
tion, while certain subsets of T lymphocytes can promote tumor regression other populations are 
responsible for tumor progression. It remains to be elucidated which composition of T cell sub-
sets represents the best pharmacyte mixture. On the other hand, this concern could be irrelevant, 
because T lymphocytes will die due to the drug effect. This poses a major drawback of the ap-
proach, because adoptive T cell therapies regularly rely on the generation of memory 
T lymphocytes to provide long-term tumor control. However, it does not necessarily mean that 
the drug delivery concept is not reasonable. Solid tumors often represent a major obstacle for 
successful ACT. It is imaginable that a first attack with pharmacytes could render the cancer vul-
nerable for subsequent adoptive T cell therapy. For instance, although T lymphocytes can accu-
mulate in the tumor stroma, the tumor vasculature can be a barrier that prevents deep tumor infil-
tration. The drug effect could damage this barrier and pave the way for later administered T cells. 
Generally, it is advantageous that carriers survive as long as possible to ensure maximal drug 
release and exploitation of the T cell effect. Engineering T lymphocytes with a resistance for the 
delivered drug could be the subject of further research. In the context of photosensitizers, this 
5. OVERALL CONCLUSION AND OUTLOOK 
 
110 
resistance could be provided, to speculate, by scavengers of reactive oxygen species. These 
should remain within the carrier cells, while the PS is released and activated. Moreover, the con-
cept is not restricted to bispecific antibody redirected polyclonal ex vivo activated T cells. In the-
ory, it could be transferred to other types of ACT. For instance, tumor-infiltrating lymphocytes as 
well as tumor specific CAR T cells, both frequently used in clinical trials, could be loaded with 
pharmaceuticals. 
To conclude, the work presented here provides substantial new insights indicating the feasibility 
of the envisioned T cell-mediated drug delivery approach, which have implications for three re-
search areas: The use of “drug-enhanced super-killer” T lymphocytes could improve the clinical 
outcome of adoptive T cell therapies. Furthermore, the approach opens new perspectives in the 
area of cell-mediated drug delivery, since it prevents premature death of carrier cells that has 
been a major drawback of cell-based transport of anti-cancer drugs until now. Finally, the selec-
tivity of photodynamic therapy could be significantly improved. Therefore, the combination of 
T lymphocyte-mediated drug delivery, adoptive T cell transfer and PDT could become a potent 
modality for the treatment of cancer. However, it is obvious that more research, particularly in 
vivo, is needed to further determine important parameters, which require optimization for maxi-
mal efficacy of this concept. 
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6. List of Abbreviations 
ACT: Adoptive cell transfer/therapy 
ADME: Absorption, distribution, metabolism, and excretion 
Ag: Antigen 
APC(s): Antigen-presenting cell(s) 
AuSh: Gold shell-coated 
BSA: Bovine serum albumin 
BsAb(s): Bispecific antibody(ies) 
CAR: Chimeric antigen receptor 
CD: Cluster of differentiation 
CFSE: 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
CLSM: Confocal laser scanning microscopy 
CTL(s): Cytotoxic T lymphocyte(s) 
DABCO: 1,4-diazabicyclo-[2,2,2]-octane 
DAMPs: Damage-associated molecular patterns 
DAPI: 4’,6-diamidino-2-phenylindole dihydrochloride 
DAU: Daunorubicin 
DC(s): Dendritic cells 
DDS: Drug delivery systems 
DiD: 1,1'-dioctadecyl-3,3,3',3'- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt 
DiO: 3,3'-dioctadecyloxacarbocyanine, perchlorate 
DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
DOX: Doxorubicin 
DSC: Differential scanning calorimetry 
EA: Ethyl acetate 
EDTA: Ethylenediaminetetraacetic acid 
EE: Encapsulation efficiency 
EpCAM: Epithelial cell adhesion molecule 
EPI: Epirubicin 
FACS: Fluorescence-activated cell sorting 
FBS: Fetal bovine serum 
FCM: Flow cytometry 
FI: Fluorescence intensity 
FITC: Fluorescein isothiocyanate 
FM: Fluorescence microscopy 
GA: Golgi apparatus 
CG: Cytotoxic granules 
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GeoMean: Geometric mean 
GMFI: Geometric mean of fluorescence intensity 
GPC: Gel permeation chromatography 
HOMO: Highest occupied molecular orbital 
HpD: Hematoporphyrin derivatives 
HPLC: High-performance liquid chromatography 
IS: Immunological synapse 
ICD: Immunogenic cell death 
IDA: Idarubicin 
IDA-NP(s): Idarubicin encapsulating nanoparticle(s) 
IDOL: Idarubicinol 
IDX: 4’-deoxy-4’-iododoxorubicin 
IL: Interleukin 
ISC: Intersystem crossing 
LAK cell: Lymphokine-activated killer cell 
LED: Light-emitting diode 
LTc: Loaded T cell 
LUMO: Lowest unoccupied molecular orbital 
mAb: Monoclonal antibody 
MAIT: Mucosa-associated invariant T cells 
MHC: Major histocompatibility complex 
MPE: Maleate-polyester 
mTHPC: 5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin 
mTHPP: 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin 
MW: Molecular weight 
MTOC: Microtubule-organizing center 
NADPH: Nicotinamide adenine dinucleotide phosphate 
NCA: N-carboxyanhydride 
NIR: Near infrared 
NK cell: Natural killer cell 
NMR: Nuclear magnetic resonance 
NP(s): Nanoparticle(s) 
PBS: Phosphate buffered saline 
PD: Polylysinderivate 
PDI: Polydispersity index 
PDT: Photodynamic therapy 
PHA: Phytohaemagglutinin 
PL: Polylysine 
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PLGA: Poly(lactic-co-glycolic-acid) 
PL-Gal: Galactosylated polysine 
PL-Glu: Glucosylated polylysine 
PL-Man: Mannosylated polylysine 
PP: Polypropylene 
PMS: Phenazine methosulfate 
PR: Phenol red 
PS: Photosensitizer/Photosensibilisator 
PSS: Poly(styrene sulfonate) sodium salt 
PVA: Polyvinyl alcohol 
RES: Reticuloendothelial system 
RNA: Ribonucleic acid 
ROS: Reactive oxygen species 
SMT: Somatic mutation theory 
SD: Standard deviation 
SPM: Scanning probe microscopy 
TAA(s): Tumor-associated antigen(s) 
TCR(s): T cells receptor(s) 
TDL(s): Thoracic duct lymphocyte(s) 
Th: T helper (cell) 
Thf: T helper follicular (cell) 
TIL: Tumor-infiltrating lymphocyte 
Top: Topoisomerase 
Treg: Regulatory T cell 
TZ: T-Zellen 
UV/Vis: Ultraviolet/Visible 
WST-1: 5-(2,4-disulfophenyl)-2-(4-iodophenyl)-3-(4-nitrophenyl)-2H-tetrazolium 
XTT: 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium 
ZS: Zytostatika 
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